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The Centers for Medicare and Medicaid Services (CMS) instituted the Hospital Readmission 
Reduction Program (HRRP) to reduce the frequency of heart failure (HF) 30-day hospital 
readmissions. To meet the needs of patients with end-stage HF, palliative care (PC) is promoted 
to provide additional support to patients and reduce unnecessary hospital readmission. While PC 
is a plausible and logical intervention, effectiveness in achieving a reduction in readmissions has 
not been assessed in an HF population with adequate controls to assess confounding. The goal of 
this research was to assess the effectiveness of palliative care for HF (HFPC) consult to effect 
change in 90-day hospital readmissions in a propensity-matched model that adequately controls 
for mortality at a single-site 526-bed tertiary-care facility. Index hospitalization for live HF 
discharges: Oct 1 - Dec. 31, 2019, n =250. Propensity matching aided in achieving a more 
homogeneous population with less variability and ensured a greater likelihood of observing an 
accurate and valid assessment of the outcome of interest. Results were statistically significant, 
demonstrating a strong association between HFPC consult and 90-day hospital readmission in a 
propensity-matched population. Logistic regression showed a statistically significant association 
between HFPC and 90-day hospital readmission, p < .001. The logit transformation of the HFPC 
factor, OR 4.3, 95% CI [1.8 - 10.6]. Survival analysis demonstrated that time to readmission 
happens more frequently in patients who have an HFPC consult; readmissions occur earlier in 
the post-discharge period and are strongly skewed to the immediate 30-day post-discharge 
period. Further, more than 50% of HF patients who have an HFPC consult experience a hospital 
readmission within 30 days of discharge, and more than 75% of HF patients who have an HFPC 
consult will have a hospital readmission within 90 days of discharge. This dissertation study 





planning for HF patients, it has a strong negative association with the objective of reducing 
hospital readmissions. HFPC consult predicted earlier hospital readmissions in this HF 
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Chapter 1: Introduction 
Introduction 
The Centers for Medicare and Medicaid Services (CMS) instituted the Hospital 
Readmission Reduction Program (HRRP) to reduce the frequency of heart failure (HF) 30-day 
hospital readmissions. To fill the health care needs of patients with end-stage heart failure, 
palliative care (HFPC) and hospice referrals are promoted to provide additional support to 
patients, in addition to their primary care and specialist physicians, and reduce unnecessary 
hospital readmission. While HFPC is a plausible and logical intervention, effectiveness in 
achieving a reduction in readmissions has not been assessed in a heart failure population with 
adequate controls to assess potential sources of confounding and interaction. This dissertation 
study demonstrated the error of this assumption. 
Patients must have a diagnosis of end-stage heart failure to be eligible for referral to 
palliative care (PC). Patients with end-stage heart failure are intuitively expected to have a higher 
rate of mortality compared to patients without a diagnosis of end-stage heart failure. These 
factors suggest that patients eligible for HFPC would be at higher risk for increased mortality 
events than patients not eligible for HFPC services; thus, any evidence supporting HFPC as an 
intervention to reduce hospital readmission should control mortality. However, most 
administrative datasets used for health services research do not capture mortality. 
Currently, hospital-readmission metrics include all patients diagnosed with HF who are 
readmitted within a 30-day time period in their numerator, with the denominator including all 
patients discharged with a diagnosis of HF. If the patient experiences a mortality event in the 30-
day period after hospital discharge, there is no opportunity for readmission, and the mortality 





date, have evaluated the efficacy of palliative care to achieve a reduction in hospital 
readmissions but have not evaluated this potential for significant differential mortality. Thus, not 
accounting for mortality in follow-up studies evaluating the effectiveness of HFPC (Palliative 
Care for Heart Failure) may result in significant ascertainment bias. If differential mortality is 
present but unquantified and mortality is more prevalent in the HFPC group, a Type I error will 
occur, or a significant intervention effect will be found when, in truth, there is no intervention 
effect.  
This investigation evaluated the potential for differential mortality in the relationship 
between 90-day HF hospital readmission and eligibility for referral to HFPC with a thorough 
mortality follow-up of all patients admitted for HF. This investigation assessed the mortality-
adjusted, propensity-matched (severity-adjusted) relationship between HFPC consult and 90-day 
hospital readmission in patients with a diagnosis of end-stage heart failure (HF) in the current 
context of administrative mandates that aim to reduce the frequency of HF hospital readmissions.  
Problem Statement 
Heart failure is the most common discharge diagnosis in the United States, affecting 5.1 
million people annually (Arora et al., 2017; Fasolino & Phillips, 2016). Of the estimated 900,000 
COVID-19 hospitalizations that occurred through November 2020, 12% of hospitalizations were 
attributable to heart failure (O’Hearn et al., 2021). The Centers for Medicare and Medicaid 
Services (CMS) implemented components of the 2010 Affordable Care Act with the introduction 
of the Hospital Readmission Reduction Program (HRRP) and publicly reported hospital 30-day 
all-cause risk-standardized mortality rates and 30-day all-cause risk-standardized readmission 
rates for acute myocardial infarction (AMI), heart failure (HF), and pneumonia (Krumholz et al., 





readmissions in a broad array of inpatient hospitalizations, specifically HF, based on a ratio of 
predicted versus expected 30-day readmissions (Medicare, 2017). According to Davis et al. 
(2017), a higher than expected rate of 30-day readmissions following HF hospitalization can 
negatively impact hospital performance measures and incur reimbursement penalties. A myriad 
of interventions has since been proposed to decrease the number of HF readmissions (Bradley et 
al., 2013). The introduction of palliative care to end-stage organ failure patients is new and has 
received increasing attention worldwide in the last decade (Ng et al., 2016).  
Research evaluating the effectiveness of a PC consult in the setting of acute 
hospitalization for HF as an intervention to decrease 30-day hospital readmission has shown 
mixed results and methodological limitations. A broad array of guidelines promote its adoption, 
while the literature has demonstrated poor reproducibility of the reliability of an HFPC consult to 
effectively reduce hospital readmissions (Chuang & Fausto, 2014; Chuang et al., 2017; Nelson et 
al., 2011; O’Connor et al., 2015; Wiskar et al., 2017). Retrospective studies have been limited by 
a lack of validation studies assessing sensitivity and specificity of the PC consultation coding 
(ICD9-V66.7) and ascertainment bias with an inability to measure differential mortality (Hua et 
al., 2017; Wiskar et al., 2017). Prospective studies have been limited by low enrollment and loss 
to follow-up, leading to the study being underpowered, with unintended crossover and limited 
PC staffing resources to sustain the intervention (Sidebottom et al., 2015; Szekendi et al., 2016). 
The goal of this dissertation study was to assess the effectiveness of HFPC consult to effect 
change in 90-day hospital readmissions in a propensity-matched model that adequately controls 
for mortality at a single-site 526-bed tertiary-care facility. 
Heart Failure 
The impetus for HFPC arises from issues pertaining to the incidence, prevalence, and 





than five million patients annually (Arora et al., 2017; Fasolino & Phillips, 2016). By 2030, with 
prevalence remaining stable, more than eight million patients in the United States will have HF, 
with expected three-year mortality rates as high as 50% among Medicare beneficiaries after an 
HF admission (Heidenreich et al., 2013). Even if prevalence remains constant for age, sex, race, 
or ethnicity, rising costs and technological innovation are expected to increase the total direct 
medical costs of HF from $21 billion to $53 billion. Inclusive of indirect costs, total expenditure 
is projected to increase from $31 billion to $70 billion in 2030 (Heidenreich et al., 2013).  
Readmissions 
 The impetus for HFPC arises out of issues relating to hospital readmission rates. 
Readmission rates were first introduced in 1953 to characterize risk among neuropsychiatric 
patients discharged from the Department of Veterans Affairs (VA) hospitals (Jenkins et al., 
1953). In 2009, CMS began to publicly report hospital 30-day all-cause risk-standardized 
mortality rates and 30-day all-cause risk-standardized readmission rates for AMI, HF, and 
pneumonia (Centers for Medicare and Medicaid Services, 2015; Krumholz et al., 2013). The 
2010 Affordable Care Act implemented the HRRP on the premise that a hospital’s scope of 
responsibility should include post-discharge care coordination (Centers for Medicare and 
Medicaid Services; Chin et al., 2016).  
In October 2012, CMS began reducing Medicare payments for inpatient hospitalizations 
based on a ratio of predicted versus expected 30-day readmissions for AMI, HF, pneumonia, 
Chronic Obstructive Pulmonary Disease(COPD), hip or knee replacement, and CABG surgery 
(Centers for Medicare and Medicaid Services, 2015). More than the expected 30-day 
readmissions following HF hospitalization negatively impacts hospital performance measures 
and reimbursement (Davis et al., 2017). A myriad of interventions have since been proposed to 





strategies to achieve a reduction in readmission rates (Bradley et al., 2013; Woolhandler & 
Himmelstein, 2016). However, whether HFPC is an appropriate care strategy to achieve these 
aims has not been fully evaluated. 
CMS implemented thirty-day readmission rates despite limited evidence supporting 30-
day readmission rates as an indicator of between-hospital variation in the quality of care (Chin et 
al., 2016; National Quality Forum, 2016). The team that developed the metrics noted low 
intracluster correlation coefficients (ICC) of 4.8-5.3% for mortality measures and 1.5-2.6% for 
readmission measures (Chin et al., 2016). ICCs represent the proportion of risk explained by 
hospitals (between-hospital variation) compared to the total risk in the population (all variation; 
Chin et al., 2016). This poor correlation was further evaluated by Chin et al. (2016), who found a 
sharp and consistent reduction in the readmission ICC after the seventh-day post-discharge, 
suggesting that a significant proportion of the presumed hospital quality signal at 30 days may be 
attributed to other characteristics of the individual and community setting of care. These 
characteristics include the socioeconomic and demographic profile of the hospital’s patient 
population, the hospital’s resource availability, and patient social support or mental health issues 
(Chin et al., 2016; Pandey et al., 2017).  
Other HF studies have likewise failed to demonstrate a strong association between in-
hospital quality of care and 30-day readmission rates (Fischer et al., 2015). The goal of the 
selection of 30-day readmission rates as an indicator of quality relates more to encouraging 
hospitals to assume responsibility for post-discharge adherence and primary care follow-up 
rather than hospital quality of care. In addition, it is to represent a public policy intended to shift 





continuity of care (Chin et al., 2016). Time to readmission intervals was an important 
consideration for this investigation and the determination of HFPC effectiveness. 
Hospitals with the greatest burden of readmissions are more likely to be penalized for 
higher readmission rates, raising questions of whether CMS readmissions penalties are equitably 
and justly applied for hospitals with a high prevalence of socially or medically complex patients 
(Pandey et al., 2017). A recent evaluation of readmissions for AMI, a condition related to HF, 
found an inequitable burden of readmission among hospitals serving patient populations with 
higher levels of social disadvantage and higher illness acuity (Pandey et al., 2017). Inequity is an 
important consideration in the evaluation of HFPC, which is also prone to similar inequities. 
AdventHealth Tampa was chosen as the site for this investigation primarily because of its 
advocacy of PC services to the HF population.  
Studies have established a temporal decline in HF readmissions but have been criticized 
as confounded by changes in coding rather than improvements in care (Desai et al., 2016; Jha, 
2015; Zuckerman et al., 2016). Emerging evidence has also demonstrated the potentially harmful 
effects of the HRRP with increased mortality associated with continuing implementation 
(Dharmarajan et al., 2017; Fonarow et al., 2017; Gupta et al., 2017; Krumholz et al., 2013). 
There are emerging calls for HRRP outcome metrics to be reevaluated to align with evidence 
that acute care and discharge quality metrics do not appear to influence readmissions. Hospital 
readmissions are often attributable to individual and community aspects of care, indicating the 
need to identify better quantified strategies that can reliably meet patients’ needs and effectively 
manage morbidity, leading to unnecessary hospital readmission. Alternative explanations of 
decreasing HF readmission trends are an important consideration of efficacy in evaluating HFPC 





assessed the differential time to readmission for patients who have an HFPC consult compared to 
those who do not. The study will contribute to the evidence on the effectiveness of palliative care 
to meet these diverse patient needs and reduce hospital readmission. Specifically, this research 
assessed the effectiveness of palliative care for HF (HFPC) consult to effect change in 90-day 
hospital readmissions in a propensity-matched model that adequately controls for mortality.  
Palliative Care 
The expansion of palliative care programs beyond cancer to end-stage organ failure 
patients is new and has received increasing widespread attention worldwide in the last decade 
(Ng et al., 2016). A key element of hospital interest in palliative care is the risk adjustment it 
affords, the presence of a coded palliative care consult (V667) or hospice referral on the 
electronic medical record of the patient admitted with HF increases the expected count of HF 
readmissions in CMS quality calculations and creates a greater opportunity for the hospital to 
have a less than the expected count of HF readmissions, which translates into a higher quality 
score for the admitting hospital (Trivette, 2017). 
 PC has shown an ability to reduce readmission rates in mixed patient populations (Nelson 
et al., 2011; O’Connor et al., 2015). Preceding implementation of HRRP, Kaiser Permanente 
researchers conducted a prospective pre versus post-intervention with a fully constituted PC 
team. They found a statistically significant2 reduction in six-month readmissions from 1.15 to 0.7 
readmissions per patient (Nelson et al., 2011). After implementing HRRP, University of 
Pennsylvania researchers conducted a retrospective review of PC consults and reported a 
protective effect3 for 30-day hospital readmission (O’Connor et al., 2015). Both studies were 
limited by a study population that relied on the presence of a PC consult request, creating a 
 
2 p =.025 





significant risk of selection bias, in that patients most likely to adhere to PC guidance were 
selected and therefore likely to bias the observed results. 
 Furthermore, mortality was not assessed; this added an ascertainment bias. Ascertainment 
bias and the significant potential for confounding by mortality were important elements 
controlled for in this investigation in establishing the effectiveness of HFPC to reduce 90-day 
hospital readmissions. A broad array of stakeholders have also produced consensus statements 
that support the introduction of palliative care for HF (American Academy of Hospice Palliative 
Medicine, Center to Advance Palliative Care, Hospice Palliative Nurses Association, Last Acts 
Partnership & National Hospice Palliative Care Organization, 2004; Davies & Higginson, 2004; 
Goodlin et al., 2004; Jaarsma et al., 2009; Yancy et al., 2013). These guidelines also identify 
several challenges, including defining criteria for appropriateness for HFPC consultation, 
barriers to referral, consistency of service delivery, and HFPC team resources. 
Another factor that influences the consistent adoption of palliative care in the acute care 
environment is the broad variability in the hospital-level perceived appropriateness for an HFPC 
consult. Even though overall eligibility for an HFPC consult is consistently high, with 18.8% of 
the total inpatient population determined to be eligible, HFPC consult rates for eligible patients 
varied widely from 12.5% - 58.8%, but not achieving 100% referral of eligible patients 
(Szekendi et al., 2016). Evaluating variation in appropriateness by diagnosis, Szekendi et al. 
(2016) found that patients with poor prognosis cancer were appropriate for a PC consult 100% of 
the time, while patients with advanced HF (Class IV, LVAD, or EF <35%) were appropriate just 
33% of the time. Demonstrating similar challenges to appropriately identify patients for a PC 
consult in the setting of a complex chronic condition, patients with a diagnosis of COPD 





variation in appropriateness for PC consultation by diagnostic criteria demonstrates the 
confusion of non-PC clinicians who are primarily familiar with the system of palliative care that 
focuses on cancer end-of-life care. The hospital site for this investigation was specifically chosen 
because it has been a consistent, strong proponent of PC services to the HF population.  
Another important factor is the consistency of delivery of PC services. Of those 
appropriate for referral, a minority (31.6%) received a referral and actual delivery of any PC 
services (Szekendi et al., 2016). A further 29.8% received a referral but no PC services, and the 
remaining 60.9% of those appropriate for a referral received neither a referral nor services 
(Szekendi et al., 2016). A physician order is often necessary to operationalize PC or hospice 
referral but is not sufficient to ensure completed service delivery. AdventHealth Tampa has 
eliminated this barrier by implementing a site policy enabling activation of a nurse-initiated 
HFPC consult request. There is also considerable variation in the definition of what services are 
included in a palliative care consult for HF (Szekendi et al., 2016). Other work has suggested 
that HFPC focused primarily on symptom control did not decrease readmissions4 compared to 
HFPC focused on advanced care planning and goals5 (O’Connor et al., 2015). Poor consistency 
of service delivery complicates the ability of the non-PC clinician to be confident in the services 
that may be provided if an HFPC consult is requested and likewise for researchers determining 
effectiveness (Szekendi et al., 2016). The consistency of service delivery at AdventHealth 
Tampa via a site policy enabling nurse-activated HFPC consult requests minimizes the potential 
bias of this issue. The resources available on the HFPC team are also variable and may include a 
PC physician, an inpatient PC RN, a social worker, a bioethicist, and hospital chaplain; 
 
4 OR 1.05, p =0.684, 95% CI [0.82 - 1.35] 





alternatively, it may comprise a palliative care RN only, or there may be no team available 
(Nelson et al., 2011).  
Lastly, validating completed service delivery is complicated by variable hospital coding 
practices, defined as documentation of an ICD-9 V66.7 palliative care encounter, ranging from 
0-100%, limiting the accuracy and reliability of administrative data (Szekendi et al., 2016). This 
evidence demonstrates important methodological issues: (a) consistency of referral to PC 
services, (b) consistency of availability of PC services, (c) reliability of completed service 
delivery, (d) consistency and reproducibility of PC services provided, and (e) reliability of 
accurately assessing the delivery of PC services. AdventHealth Tampa minimizes these 
methodological issues respectively by (a) enabling nurse-activated HFPC consult requests, (b) 
partnerships that ensure consistency of availability of PC services, (c) reliability of completed 
consult on the medical record, (d) consistency and reproducibility of PC services provided, albeit 
limited to this single site which may not be generalizable to the broader population of hospitals, 
and (e) reliability of the completed consult is verifiable within the body of the medical record. 
While the reliability of the model of services for HFPC is an important aspect of HFPC service 
delivery, the scope of services provided is beyond the scope of this investigation. 
A third factor is the reliability of the model of services for HFPC that is significantly 
different from cancer-focused end-of-life care compared to an end-organ failure trajectory of 
decline (Jaarsma et al., 2009). The trajectory of decline associated with end-organ dysfunction, 
such as HF, demonstrates a more gradual loss of function interrupted by acute exacerbations that 
cause sudden precipitous losses in function without a full return to baseline over time; this 
indicates a need to reevaluate the underlying assumptions that have been developed from a 





readmissions (Jaarsma et al., 2009). The scope of services provided for cancer-focused PC would 
be expected to be substantively different than the scope of services for HFPC. In addition, PC 
efficacy based on previously mixed patient populations cannot be reliably generalized to the 
population of patients with HF demonstrating different trajectories of decline. While the model 
of services for HFPC is important, it is beyond the defined scope of this investigation.  
A fourth factor is the major barriers that exist in initiating a physician-ordered referral for 
palliative care: (a) there is typically no standard definition of palliative care within the 
organization, resulting in subjective criteria and wide variation amongst clinicians; (b) HFPC is 
erroneously associated with end of life care and life expectancy of two weeks or less; (c) 
educational opportunities for non-PC clinicians to gain skills in primary palliative care are 
infrequent and rarely mandatory; (d) subspecialist physicians with longstanding patient 
relationships retain a desire to maintain that relationship and provide subspecialist management 
that may not be met by a HFPC clinician; and (e) an internal psychological conflict that exists for 
both patients and clinicians in the perception of referral to HFPC indicates a choice for end of 
life care and the seemingly competing interest to seek advanced specialty care and pursue access 
to advanced cutting edge therapies, for example, “giving up” versus “doing everything” 
(Szekendi et al., 2016). While these human factors issues are important, they are beyond the 
scope of this investigation.  
Despite these challenges, several recent studies have sought to establish the effectiveness 
of HFPC to reduce hospital readmission. A large post-HRRP longitudinal analysis using the 
Agency for Healthcare Quality and Research (AHRQ) Nationwide Readmission Database (NRD) 
that compiles all hospital admissions for patients from 22 states and tracks patients throughout 





428.xx) who received an HFPC consult were 58% less likely to be readmitted for HF,6 and 54% 
were less likely to be readmitted for any cause7 during the nine-month follow-up period (Wiskar 
et al., 2017). Noting the inherent susceptibility of administrative datasets to diagnostic and 
procedure coding errors, the authors noted a limitation for this study was the absence of 
validation in an HF population that coding of a PC visit actually occurred and relied on previous 
validation of PC coding in a stroke population with a sensitivity of 81% and specificity of 97% 
(Wiskar et al., 2017). A second validation study in a mixed patient population at a single center 
noted problems assessing the validity of the V66.7 code for documentation of PC consultation 
with a poor sensitivity of 53.9% and specificity of 75.1% (Hua et al., 2017).  
Montefiore Medical Center researchers further evaluated the effectiveness of HFPC with 
a retrospective cohort study and, in a reversal of their findings from an earlier 2014 study, found 
that while fewer patients with a completed palliative care consult were readmitted, compared to 
those with a consult ordered but not completed, the difference was not statistically significant8 
(Chuang & Fausto, 2014; Chuang et al., 2017). The researchers noted an important limitation in 
their studies was an inability to control for mortality that may produce a differential assessment 
of the readmission outcome; patients with HFPC consultation or hospice referral may die, 
resulting in fewer readmissions in the HFPC cohort. Allina Health investigators executed a 
randomized intervention for patients appropriate for HFPC but noted no statistically significant 
change in readmission within 30 days9 (Sidebottom et al., 2015). Interpretation of results was 
limited by an underpowered sample size, crossover, and losses to follow-up if readmission 
occurred outside of the hospital system (Sidebottom et al., 2015). While not reflective of a US 
 
6 9.3% versus 22.4%, p < 0.01 
7 29.0% versus 63.2%, p < 0.01 
8 43% and 53%, respectively, x2 =1.9, p =0.171 





health care system or population, the challenge of reducing HF readmissions with HFPC has also 
been evaluated in international settings in Hong Kong with a randomized intervention that noted 
the absence of a statistically significant difference10 (Wong et al., 2016). These studies reflect the 
limitations found in previous studies that showed important confounders that were controlled for 
in this investigation of HFPC and its effectiveness at decreasing 90-day hospital readmission. 
Relevance and Significance 
This dissertation study is relevant to the development of evidence in several key health 
care areas of interest, including heart failure, hospital readmissions, and palliative care. Heart 
failure prevalence is increasing; administrative pressures to reduce hospital readmissions show 
no sign of weakening, and alternative strategies like palliative care require an evidence-based 
and methodologically rigorous evaluation of outcomes. This study assessed whether a hospital-
generated referral to palliative care services could reduce 90-day hospital readmissions for heart 
failure in a propensity-matched model after controlling for mortality.  
Research Question and Hypotheses 
 This dissertation study addressed the following research questions and hypotheses: 
RQ1: Will a hospital-generated referral to palliative care services reduce 90-day hospital 
readmissions for heart failure in a propensity-matched model after controlling for mortality?  
H0: There is no significant difference in 90-day readmissions in HF patients receiving 
HFPC consultation versus patients not receiving HFPC consultation after controlling for 
mortality and severity. 
H1: The increased level of resources, education, facilitated decision-making, and future 
health planning would enable patients to better understand their symptoms and improve health 
 





behaviors through a better understanding of the health system that will allow them to seek health 
care services in less hospital-oriented settings and ultimately decrease hospital readmissions. 
H1a: There is a statistically significant difference in 90-day readmissions in HF patients 
receiving HFPC consultation versus patients not receiving HFPC consultation after controlling 
for mortality and severity. 
To answer the research question, appropriate measures were abstracted to assess the 
impact of previously unaddressed confounders that carry a significant risk of ascertainment bias 
(e.g., mortality). The research question also ensured the comparison of similar risk characteristics 
by using a propensity-matched model (e.g., comparing hospital readmissions of patients with HF 
with similar acuity). This investigator assumes that a better understanding of the health system 
will enable patients to seek health care services in less hospital-oriented settings and ultimately 
decrease hospital readmissions.  
Definition of Terms 
AMI   





 CMS   
COPD   
CRT 
EF% 
Acute myocardial infarction 
Affordable Care Act 
Angiotensin Converting Enzyme inhibitors 
Against Medical Advice 
Angiotensin Receptor Blocker 
Coronary artery bypass graft surgery 
Centers for Medicare and Medicaid Services 
Chronic Obstructive Pulmonary Disease 
Cardiac Resynchronization Therapy device 













PC   
PMHx   
SNF   
SPSS 
Heart Failure 
Heart Failure Palliative Care 
Hospital readmission rates 
Hospital Readmission Reduction Program 
Intra-Aortic Balloon Pump 
Implantable Cardiac Defibrillator 
International Statistical Classification of Diseases and 
Related Health Problems, 10th revision 
Palliative Care 
Past Medical History 
Skilled Nursing Facility 
Statistical Package for the Social Sciences 
Summary 
Recent administrative mandates from the Centers for Medicare and Medicaid Services 
embodied in the Hospital Readmission Reduction Program aim to reduce the frequency of heart 
failure 30-day hospital readmissions. To fill the health care needs of patients with end-stage heart 
failure, palliative care referrals are promoted to provide additional support to patients in addition 
to their primary care and specialist physicians. As a result, patients have an improved 
understanding of their disease, improving disease management and thereby decreasing hospital 
utilization, thus reducing hospital 30-day readmissions after an index HF hospitalization.  
Heart failure is the most common discharge diagnosis in the United States, affecting 5.1 
million annually (Arora et al., 2017; Fasolino & Phillips, 2016). CMS implemented components 





of key hospital metrics for mortality and readmission rates for AMI, HF, and pneumonia 
(Krumholz et al., 2013). In October 2012, penalties were introduced, and Medicare payments for 
inpatient hospitalizations were reduced based on a ratio of predicted versus expected 30-day 
readmissions (Medicare, 2017). HFPC for end-stage organ failure patients is widely promoted as 
an effective intervention and has received increasing attention worldwide in the last decade (Ng 
et al., 2016). As noted, research evaluating the effectiveness of HFPC consultation or hospice 
referral in the setting of acute hospitalization for HF as an intervention to decrease 30-day 
hospital readmission has yielded mixed results and methodological limitations (Chuang & 
Fausto, 2014; Chuang et al., 2017; Hua et al., 2017; Nelson et al., 2011; O’Connor et al., 2015; 
Sidebottom et al., 2015; Szekendi et al., 2016; Wiskar et al., 2017).  
The hypothesis of this investigation was that the increased level of resources, education, 
facilitated decision-making, and future health planning would enable patients to better 
understand their symptoms and improve health behaviors through a better understanding of the 
health system that will allow them to seek health care services in less hospital-oriented settings 
and ultimately decrease hospital readmissions. This investigation assessed the effectiveness of 
palliative care referral to reduce 90-day hospital readmissions for heart failure. The research 
question measured the impact of potentially important mortality confounding, and it used a 
propensity-matched model to ensure comparison of similar risk characteristics. This research 
also assessed the mortality-adjusted relationship between HF propensity-matched cohorts and 
90-day hospital readmission in the current context of administrative mandates that aim to reduce 







Chapter 2: Review of the Literature 
Historical Review of the Literature Contributing to the Topic 
A comprehensive historical review of the literature pertaining to this investigation of 
HFPC and 90-day hospital readmission requires an in-depth understanding of the literature 
associated with heart failure, hospital readmissions, and palliative care. It also requires an 
understanding of the factors that contribute to the societal and individual burden of heart failure, 
including (a) an assessment of the literature pertaining to the incidence, prevalence, 
pathogenesis, and disease progression of heart failure, (b) a review of the development and 
evolution of the hospital readmission metric and associated administrative mandates, (c) an 
understanding of the symptomatic burden of disease for patients. Moreover, a complete historical 
review of the literature for this investigation requires an understanding of the factors that 
contribute to the issues pertaining to HF readmissions, including (a) an appreciation of the 
economic burden for hospitals related to HF hospital readmission, (b) a recognition of the 
posited emergence of increased mortality associated with downward trends of HF readmission 
subsequent to initiation of the administrative mandates, (c) the challenges involved with 
identifying effective alternative strategies to reduce HF readmissions, and (d) an understanding 
of the complexities of medical management when implementing a comprehensive strategy to 
reduce HF readmission. Lastly, a full review of the literature pertaining to this investigation 
requires an understanding of the definition and evolution of palliative care, including (a) the 
variation in the trajectory of disease that requires careful consideration when applying a service 
traditionally developed to provide care for terminal cancer patients, (b) the breadth of 
recommendations and position statements that advocate for the use of palliative care in patients 





Historical Review of the Literature Relating to HF 
A comprehensive historical review of the literature pertaining to the investigation of 
HFPC and 90-day hospital readmission requires an understanding of the factors that contribute to 
the societal and individual burden of heart failure, including (a) an assessment of the literature 
pertaining to the incidence, prevalence, pathogenesis and disease progression of heart failure, (b) 
a review of the development and evolution of the hospital readmission metric and associated 
administrative mandates, and (c) an understanding of the symptomatic burden of disease for 
patients. The sustained incidence, increasing prevalence, and significant lifetime risk create the 
strong imperative to improve all aspects of care associated with the diagnosis of HF. The 
prevalence of risk factors in the US population, the increasing prevalence of obesity and 
diabetes, the associated cost for care, and potentially significant increases in the future cost of 
care for patients with HF indicate a significant imperative to improve the care and management 
of individuals with HF. The challenges of a clinical syndrome with high mortality, complex 
medical management of multiple comorbidities, and challenges with identifying interventions 
with associated mortality benefit create the imperative for identifying new strategies for 
improved management of patients with HF. 
Diagnosis and Case Definition of HF  
HF is a complex clinical syndrome comprised of cardiac and pulmonary signs and 
symptoms, including paroxysmal nocturnal dyspnea, orthopnea, neck vein distension, rales, 
cardiomegaly, jugular venous pressure elevation, ankle edema, dyspnea on exertion, and pleural 
effusion (Dunlay & Roger, 2014).  
Incidence and Prevalence of HF 
 The current incidence of HF is based on data from 2005 to 2014 from the National Heart, 





community surveillance and demonstrates 1,000,000 incident cases annually in individuals > 55 
years of age (Huffman et al., 2013). Incident cases are also highly skewed towards older adults, 
with rates for White males per 1,000 person-years estimated at 32 cases over the age of 75, 11 
for ages 65 -74, and 3.9 for ages 55-64 (Benjamin et al., 2018). Temporal trends in incidence 
suggested an overall decline in HF incidence between 2000 and 2010, while earlier studies 
indicated that the incidence of HF has remained largely stable over time (Barker et al., 2006; 
Gerber et al., 2015; Levy et al., 2002; McCullough et al., 2002).  
In 2018, 6.5 million (2.5%) Americans >20 years of age were estimated to have a 
diagnosis of HF based on 2011 to 2014 National Health and Nutrition Examination Survey 
(NHANES) data, representing a 12% increase in prevalence from 2012, and consistent with the 
model projecting a prevalence of 8.5 million (3%) of Americans by 2030 (Benjamin et al., 2018; 
Heidenreich et al., 2013). Projections estimate a 46% increase in the prevalence of HF from 2012 
to 2030 due to the aging of the population and improvements in the delivery of care that improve 
survival (Benjamin et al., 2018; Heidenreich et al., 2013). Prevalence is highly skewed towards 
older adults, with 14.1% of men over the age of 80, 6.2% of men 60-79, 1.4% of men age 40-59, 
and just 3% of men age 20-39 identified as cases. Prevalence data is based on self-report, 
calculated based upon a response of “yes” to the question of ever having congestive heart failure 
during the NHANES data collection (Benjamin et al., 2018). NHANES data are likely to 
underestimate actual prevalence as found in even a small sample. When asked to self-report “Do 
you have HF?” eight of 94 (8.5%) responded “no” (Gilotra et al., 2017). 
Temporal trends in incidence and prevalence may be affected by variability in the 
reliability of diagnostic criteria used to diagnose HF, the reliability of other methodologies that 





occurrence of a hospitalization event to identify a quantifiable case of HF (Dunlay & Roger, 
2014). Incidence and prevalence estimates are also affected by the population examined, with 
Medicare beneficiaries demonstrating higher incidence rates compared to young populations. 
Moreover, lifetime risk is high, with 20-45% of individuals age 45 to 95 estimated to acquire a 
diagnosis of HF. Lifetime risk of HF was similar amongst White (32-39%) and Black (24-36%) 
females. Disparate lifetime risk of HF was estimated in White men (30-42%) versus Black men 
(20-29%) due to competing mortality risks for Black men (Huffman et al., 2013). The sustained 
incidence, increasing prevalence, and significant lifetime risk create the strong imperative to 
improve all aspects of care, including effective measures to prevent excess hospital readmission 
associated with the diagnosis of HF. 
Risk Factor Prevalence and Cost of HF 
 Risk factors for HF are common, with at least one risk factor present in up to 33% of the 
US adult population (Benjamin et al., 2018). Coronary artery disease, hypertension, diabetes 
mellitus, obesity, and smoking are responsible for 52% of incident HF cases (Heidenreich et al., 
2013). Lack of optimal control of blood pressure, cholesterol, diabetes, smoking, and body mass 
is estimated to account for 88.8% of incident HF events (Dunlay & Roger, 2014). Racial 
disparities and dietary and lifestyle factors are also significant contributors to HF risk 
(Heidenreich et al., 2013). Demographic risk factors include older age, male sex, ethnicity, and 
low socioeconomic status (Heidenreich et al., 2013). Dunlay and Roger (2014) reported that the 
risk factor prevalence of hypertension, hyperlipidemia, and smoking has declined, while the 
prevalence of obesity and diabetes has risen. 
Associated total cost for HF in 2012 was estimated to be $30.7 billion, of which 68% was 
attributable to direct medical costs. Heidenreich’s model also projects a 127% increase in total 





much as $160 billion in direct cost alone by 2030 (Heidenreich et al., 2013). Hospitalizations  
(including readmissions) are prevalent after an HF diagnosis, with 83% of patients hospitalized 
at least once and 43% hospitalized at least four times, and represent a substantial portion (75%) 
of the cost of HF care (Dunlay & Roger, 2014; Heidenreich et al., 2013). Total individual 
lifetime costs were $109,541,11 with the majority accumulated during hospitalizations (mean 
$83,980 per person; Dunlay et al., 2011). 
Other factors that affect cost include the use of long-term care facilities and the impact of 
advanced heart failure therapies. Discharges to a skilled nursing facility (SNF) increased among 
Medicare beneficiaries from 6.8% in 1980-84 to 13.4% between 2000-2004 (Dunlay & Roger, 
2014). Further, 24.1% of Medicare beneficiaries in an evidence-based prevention program were 
discharged to an SNF after an HF hospitalization (Dunlay & Roger, 2014). More than 50% of HF 
hospitalizations to SNF expire within one year (Dunlay & Roger, 2014). Advanced heart failure 
therapies such as organ transplants and left ventricular assist devices (LVAD) are costly, and 
eligible patients represent only a small fraction of all US cases of those living with HF (Dunlay 
& Roger, 2014). The prevalence of risk factors in the US population, the increasing prevalence 
of obesity and diabetes, the associated cost for care, and potentially significant increases in the 
future cost of care for patients with HF indicate a significant imperative to improve the care and 
management of individuals with HF. Interventions such as HFPC may address the burden of 
disease and decrease costs predominantly by decreasing hospital readmissions. 
Mortality and Comorbidity 
After the initial diagnosis of HF, survival is 72-75% at one year and 35-52% at five years, 
which has significantly improved in recent decades, nonetheless indicating a diagnosis with 
 





substantially high mortality rates (Dunlay & Roger, 2014). While efficacious for symptom 
management, established HF treatment alternatives such as diuretics, ultrafiltration, vasodilators, 
inotropes, and spironolactone have demonstrated no mortality benefit in large, well-conducted 
clinical trials (Rayner-Hartley et al., 2018). Multiple comorbidities in HF constitute a significant 
burden of medical complexity in HF populations: renal insufficiency, atrial fibrillation, and 
COPD or asthma, and increase the complexity of medical management (Rayner-Hartley et al., 
2018).  
A recent review of characteristics of patients attending the ED for HF noted an increased 
prevalence of previous coronary artery bypass graft (CABG) or percutaneous coronary 
intervention (PCI), hypertension, peripheral vascular disease (PVD), stroke, and diabetes in 
patients less than 80 years compared to those older than 80 (Claret et al., 2016). Older patients 
were more likely to present with additional comorbidities such as atrial fibrillation, dementia, 
and chronic renal failure (Claret et al., 2016). The challenges of a clinical syndrome with high 
mortality, complex medical management of multiple comorbidities, and challenges with 
identifying interventions with associated mortality benefit create the imperative for identifying 
new strategies, such as HFPC, for improved management of patients with HF. 
Summary  
 The sustained incidence, increasing prevalence, and significant lifetime risk of HF create 
the strong imperative to improve all aspects of care associated with the diagnosis of HF. The 
prevalence of risk factors in the US population, the increasing prevalence of obesity and 
diabetes, the associated cost for care, and potentially significant increases in the future cost of 
care for patients with HF indicate a significant imperative to improve the care and management 





medical management of multiple comorbidities, and challenges with identifying interventions 
with associated mortality benefit create the imperative for identifying new strategies, such as 
palliative care to prevent HF hospital readmission, to improve management of patients with HF. 
Historical Review of the Literature Relating to Hospital Readmission for HF 
A complete historical review of the literature for this investigation of whether HFPC is an 
effective intervention to reduce 90-day hospital readmissions requires an in-depth understanding 
of the numerous factors that contribute to the issues pertaining to HF readmissions, including (a) 
the emergence of the hospital readmission metric, (b) the economic burden of readmission for 
hospitals, (c) risk factors associated with hospital readmission, (d) the burden of symptoms for 
HF patients, (e) HF readmission rate trends since the implementation of HRRP, (f) mortality 
trends associated with hospital readmission initiatives, and (g) an understanding of the 
complexities of HF medical management that must be considered when identifying an effective 
strategy to reduce HF readmissions. These factors create the impetus for developing innovative 
approaches to manage the HF patient population with HFPC consults that may serve as an 
effective method to reduce 90-day HF hospital readmissions.  
The Hospital Readmission Metric 
 The earliest published literature on HF recognized the elements of the process of care, 
adequate patient education during discharge instructions, and prompt follow-up (Lewis, 1978). In 
the mid-1980s, the prevalence of HF was identified as a significant cause of hospital 
readmission; within a 6-month period after index hospitalization, 36% of patients with a primary 
diagnosis of HF experienced a hospital readmission (Gooding & Jette, 1985). Dunlay and Roger 
(2014) reported that heart failure is the leading cause of hospitalization among Medicare 
beneficiaries and has the highest 30-day readmission rate (~25%) of any diagnosis. Greater than 





with high mortality (Dunlay & Roger, 2014). To create new strategies, CMS implemented 
incentives to encourage hospitals to address the issue.  
 Readmission rates were first introduced in 1953 to characterize risk among 
neuropsychiatric patients discharged from the Department of Veterans Affairs (VA) hospital 
(Jenkins et al., 1953). In 2005, to promote quality and manage costs, the Hospital Compare 
website was launched, introducing the metrics and proposed methodology for public reporting of 
hospital quality metrics (DeVore et al., 2016). In 2009, the American College of Cardiology 
(ACC) and the Institute for Healthcare Improvement (IHI) launched the Hospital to Home (H2H) 
initiative targeting a goal of reducing 30-day hospital readmission by 20% by December 2012 
(American College of Cardiology & Institute for Healthcare Improvement, 2009). On July 9, 
2009, CMS began to publicly report hospital 30-day all-cause risk-standardized mortality rates 
and 30-day all-cause risk-standardized readmission rates for AMI, HF, and pneumonia (Centers 
for Medicare and Medicaid Services, 2015; Krumholz et al., 2013). The 2010 Affordable Care 
Act implemented the HRRP on the premise that a hospitals’ scope of responsibility should 
include post-discharge care coordination (Centers for Medicare and Medicaid Services, 2015; 
Chin et al., 2016). On October 1, 2012, CMS Medicare introduced penalties and started to reduce 
payments for inpatient hospitalizations if a hospital demonstrated a higher than expected versus 
predicted 30-day readmissions for multiple diagnoses, specifically identifying HF readmissions 
(Centers for Medicare and Medicaid Services, 2015; Davis et al., 2017).  
The CMS implemented 30-day readmission rates based on hierarchical logistic regression 
models that were derived from Medicare claims data and adjusted for variation in hospital 
volume and case mix (McIlvennan et al., 2015). The metric was implemented despite limited 





quality of care (Chin et al., 2016; National Quality Forum, 2016). Intracluster correlation 
coefficients (ICC) represent the proportion of risk explained by hospitals (between-hospital 
variation) compared to the total risk in the population (all variation). Poor 30-day readmission 
correlation was noted with ICC values of 4.8-5.3% for mortality measures and 1.5-2.6% for 
readmission measures. Further time-dependent analysis demonstrated a sharp reduction in the 
readmission ICC after the seventh day post-discharge,12 suggesting that a significant proportion 
of the presumed hospital quality signal at 30 days may be attributed to characteristics of the 
individual or community setting of care such as the socioeconomic and demographic profile of 
the hospital’s patient population, the hospital’s resource availability, patient social support, or 
mental health issues (Chin et al., 2016; Pandey et al., 2017).  
Similar findings were noted in a longitudinal review of index HF admissions from 2006 
to 2009 in Australia with non-statistically significant interhospital ICC for 30-day unplanned 
readmission of 0.0125,13 and statistically significant patient-level factors of age and comorbidity 
were more predictive of unplanned 30-day hospital readmission (Korda et al., 2017). In a large 
meta-analysis of hospital process indicators, 30-day readmissions were not associated with 
adherence to any of the CMS required hospital process indicators, indicating that the causation of 
readmissions lies outside of the purview of the acute hospital admission (Fischer et al., 2015; 
Pandey et al., 2017). Thus, it follows that selection of 30-day readmission rates as an indicator of 
quality is to encourage hospitals to assume responsibility for post-discharge adherence and 
primary care follow-up and likely represents a public policy intended to shift responsibility from 
individual care providers to systems of care, such as that embodied by multidisciplinary HFPC, 
to promote a more cohesive shared responsibility for continuity of care (Chin et al., 2016). 
 
12 78%, 49% and 76% among patients admitted with AMI, HF and pneumonia respectively  





The development of readmission metrics is flawed as a measure of hospital quality of 
care. These metrics are more likely to represent administrative priorities to promote improved 
systems of care that include both individual and community aspects of care. HFPC may 
contribute to improved continuity of care and thereby result in fewer unplanned hospital 
readmissions. 
Burden of Readmission for Hospitals 
 A recent evaluation of adherence to AMI acute and discharge performance measures 
showed an inequitable burden of readmission among hospitals serving patient populations with 
higher levels of social disadvantage and higher illness acuity (Pandey et al., 2017). Compared to 
White patients and non-minority serving hospitals, Black patients and minority-serving hospitals 
demonstrated an increased risk of all-cause readmission for HF14 in a large analysis of more than 
three million Medicare recipients, notably prior to initiation of HRRP (Joynt et al., 2011). 
Consequently, hospitals with a high prevalence of socially or medically complex patients carry 
the greatest burden of readmissions and are more likely to be penalized, raising questions of 
whether CMS readmissions penalties are equitably and justly applied (Joynt & Jha, 2013; Pandey 
et al., 2017).  
 Hospitals with the highest readmission rates are more likely than hospitals with lower 
readmission rates to care for patients who are (1) younger, Black, not married, less educated, 
retired, (2) have fewer total assets, lower household income, and a Medicare disability, (3) are 
Medicaid enrolled, (4) have an absence of supplemental health insurance, a current smoking 
status, multiple comorbidities, depression, lower cognition, lower self-rated health, fewer 
household residents, and multiple difficulties with activities of daily living (ADLs), mobility and 
 





agility (Barnett et al., 2015; Freedland et al., 2016). Hospitals that serve a higher percentage of 
patients enrolled in both Medicare and Medicaid (dual-enrolled) were 20% more likely to have 
excess readmissions using the CMS methodology than hospitals that served a lower percentage 
of patients with dual-enrolled statuses, indicating that hospitals that serve a more disadvantaged 
population are disproportionately subject to payment reduction penalties under HRRP; this 
difference was reduced to 0 by adjusting for individual dual eligibility status and hospital share 
of patients with dual eligibility (Gu et al., 2014). The equity issues described herein are the 
subject of broad debate and represent issues beyond the defined scope of this investigation but 
are nonetheless a necessary background to understand the complications associated with 
emerging HFPC initiatives. 
Previous studies among patients with HF have likewise failed to demonstrate a strong 
association between in-hospital quality of care and 30-day readmission rates (Fischer et al., 
2015). Studies have established a temporal decline in HF readmissions but may be confounded 
by changes in coding rather than improvements in care (Desai et al., 2016; Jha, 2015; Zuckerman 
et al., 2016). The evidence suggests there is an emerging imperative for HRRP outcome metrics 
to be reevaluated to align with the evidence that acute care and discharge quality metrics do not 
appear to influence readmissions, and hospital readmissions are often attributable to individual 
and community aspects of care. The hospital burden of care is disproportionately distributed. 
Hospitals with the highest readmission rates tend to bear the responsibility for sicker, poorer, less 
educated patients with fewer social supports. These hospitals are also more likely to incur 
payment reduction penalties for excess 30-day HF readmissions. These issues are relevant to this 
investigation in that if health systems are encouraged to divert resources to ensure HFPC referral 





hospital readmissions, especially for health systems that already struggle with caring for the 
highest risk patients in a situation of limited resources. 
Trends in HF Readmissions Since HRRP  
 An annotated detailed summary of findings pertaining to HF readmission rates is 
included in Appendix A1. In summary, initial support for the introduction of the HRRP was 
strong, identifying multiple reasons for excessive 30-day readmission rates that, if properly 
managed during the inpatient admission, may reduce readmission rates15 (Berenson et al., 2012). 
The HRRP also embeds accountability in the system, as hospitals are no longer able to abdicate 
responsibility for patients after they leave but instead remain accountable for what happens to 
patients in the post-discharge period, resulting in improved discharge planning and care 
coordination (Jha, 2015). However, caution was also advised that the implementation of the 
HRRP may have unintended consequences for the care of vulnerable populations and older 
adults (Gu et al., 2014; Naylor et al., 2012). Ultimately, HFPC may bridge the gaps between 
hospital discharge and primary care physician follow-up. 
A 2000-2011 community study of Olmsted County, MN residents, identified rates of 
readmission that were highest during the first 30 days then decreased precipitously after. A 
minority were readmission for heart failure (17%). More often, the reason for hospitalization was 
another cardiovascular (32%) or non-cardiovascular (51%) cause (Chamberlain et al., 2017). The 
authors noted that in order to reduce hospitalizations in patients with HF, an integrated approach 
focusing on comorbidities is required (Chamberlain et al., 2017). HFPC may be the modality to 
achieve this integration. 
 
15 hospital-acquired infections and other complications, premature discharge, failure to 
coordinate and reconcile medication, inadequate communication among hospital personnel, 





 HF Mortality Trends 
 HF mortality trends are an important aspect of this study because the dependent variable, 
HFPC consult, seeks to impact the post-discharge period, and differential mortality may affect 
the assessment of the outcome of interest—90-day hospital readmission. The causes attributable 
to mortality surrounding HF hospitalization are not well understood. One hypothesis is that 
hospitalization events are uniquely followed by a time-dependent, transient, biologic vulnerable 
state for all patients, characterized by hemodynamic and neurohormonal abnormalities and end-
organ damage (Dunlay et al., 2010; Gheorghiade et al., 2012). Temporal changes in mortality 
risk before and after HF readmission demonstrate a net increase in predicted mortality risk16 after 
readmission with a nadir at 90 days, demonstrating a persistent mortality risk that never returns 
to pre-readmission levels (Cook et al., 2016). 
A single state review of readmissions between 1998-2001 found a 12-month mortality 
rate of 41% with a 30-day readmission versus a mortality rate of 27% amongst propensity-
matched patients without a 30-day readmission (Arundel et al., 2016). Evaluating patient 
characteristics and a marked 37% net increase in mortality post HF readmission in a global, 
randomized clinical trial identified characteristics associated more often with a patient’s 
individual clinical risk profile rather than risk relative to hospitalization itself (Cook et al., 2016). 
Korda et al. (2017) observed statistically significant associations with patient-level 
characteristics of age and severe comorbidities for 30-day hospital readmission versus hospital-
level characteristics. Simply put, 30-day readmission captures the patient with worsening clinical 
symptoms requiring admission rather than the hospitalization itself being causative to the 
resulting mortality risk (Cook et al., 2016). Palliative care may provide the needed transition and 
 





continuity of care to address the observed increase in mortality risk associated with 
hospitalization. 
Readmission Trends and Associated Mortality 
 Results are mixed with regard to readmission trends and associated mortality and 
annotated results; an annotated summary can be found in Appendix A2. Early evidence assessing 
mortality outcomes since the implementation of HRRP showed absent or non-statistically 
significant trends (Bergethon et al., 2016; DeVore et al., 2016). However, early caution was 
raised about the potential consequences of the HRRP with concerns about the metric itself, 
suggesting a risk of shifting hospital expenditures to focus on reducing readmissions at the 
expense of more urgent quality improvement efforts and introducing punitive measures for 
readmission in hospitals that have achieved low mortality rates with higher readmission rates 
(Joynt & Jha, 2012). In a comprehensive review of the HRRP program, 30-day readmission rates 
for HF were unchanged over time while noting a statistically significant increase in mortality 
after implementation of public reporting (DeVore et al., 2016).  
Emerging evidence has demonstrated the potentially harmful if unintended effects of the 
HRRP, with emerging evidence of increased mortality associated with continuing 
implementation (Bueno et al., 2010; Dharmarajan et al., 2017; Fonarow et al., 2017; Gupta et al., 
2017; Krumholz et al., 2013). In a secondary analysis of previously published results on 
readmission and mortality, researchers identified a statistically significant negative correlation 
between the longitudinal trend in mortality rates and readmission rate17 (Krumholz et al., 2009; 
Krumholz et al., 2013). The caution offered by the authors that the “relationship was only modest 
and not throughout the entire range of performance” (p. 590) is of interest; however, stratified 
 





analysis revealed consistent statistically significant inverse correlations regardless of key hospital 
characteristics of teaching status, ownership status, safety net status, or geographic location 
(Krumholz et al., 2013). A comparison of mortality trends pre- and post-intervention identified 
no statistically significant differences between hospitals participating in the Premier Hospital 
Quality Incentive Demonstration (HVBP hospitals) and hospitals not participating (non-HVBP 
hospitals), which were more likely to include small, private, non-teaching critical access 
hospitals in the South and Midwest exempt from CMS penalties (Figueroa et al., 2016). While 
there was no statistically significant difference in mortality trend between HVBP and non-HVBP 
hospitals, both categories witnessed a reversal in the observed mortality trend for HF with rates 
declining in the pre-intervention period18 and statistically significant increases of 0.02 and 0.03, 
respectively, in the post-intervention period (Figueroa et al., 2016). If findings of increased 
mortality in the post-discharge period are accurate, HFPC may provide the needed transition and 
continuity of care to minimize mortality differences. 
Controversy continues on the validity of the association of the HRRP with mortality 
evaluated in a cross-sectional study with poor baseline performers in HF quality metrics 
demonstrating a decrease in mortality19 while all other hospitals demonstrated an increase in 
mortality20 (Chatterjee & Joynt Maddox, 2018). A large retrospective cohort study inclusive of 
3.2 million HF hospitalizations evaluating the four periods of HRRP implementation identified 
consistent increases in 30-day post-discharge mortality21 (Wadhera et al., 2018). A second large 
retrospective cohort study using similar sampling methodology and time period identified four 
 
18 -0.7 for HVBP hospitals and -0.11 for non-HVBP hospitals  
19 13.5 to 13.0% 
20 10.9 to 12.0% 
21 0.27%, 0.49% and 0.52% for the respective intervals of baseline change prior to HRRP 






million HF hospitalizations. A key difference was the inclusion of inpatient mortality events, 
which included an additional 800,000 cases accounted for by a calculated 2% mortality rate of 
cases not included in the study population of Wadhera et al.’s (2018) research (Khera et al., 
2018). Thirty-day post-discharge mortality increased between 2006 and 2014; however, the 
researchers qualified that finding with the observation that 30-day post-discharge mortality also 
increased prior to the announcement of the HRRP, which suggests that observed increases are 
expected (Khera et al., 2018).  
In addition, in their final presentation of results, the authors combined the decreasing 
trend of in-hospital mortality with the increasing trend of 30-day post-discharge mortality to 
illustrate their conclusion that there was no statistically significant overall change in HF 
mortality as measured by the composite of post-admission mortality (Khera et al., 2018). In 
summary, the authors make a dualistic argument that there are no statistically significant 
increases in overall post-admission mortality. If that argument is not sufficient, the observed 
increases are wholly attributable to the natural and expected increases in overall HF mortality. 
Mortality remained a significant source of variability and was an important confounder for this 
evaluation of the impact of HFPC on 90-day hospital readmissions.  
HRRP has been moderately successful at reducing hospital readmissions after an index 
HF admission. It is also likely that the reduction in HF hospital readmissions is associated with 
an increase in HF mortality. Studies to date have not stratified the HF population to determine 
what subgroups are at the highest risk for increased mortality, but it is intuitive to propose that 
those with Stage III, IV HF or meeting eligibility criteria for a palliative care referral would be 
most likely to be at highest risk. An annotated summary of studies pertaining to HF readmission 





Risk Factors for Readmission 
 Risk factors for readmission identified in previous studies include:  
 comorbidities of diabetes, chronic lung disease, renal failure, or electrolyte 
imbalance. Fifty percent of readmissions were due to a cardiac cause, pulmonary 
causes (13%), renal causes (9%), smoking status, alcohol intake, depression, and 
lower cognition score. 
 characteristics of the hospital stay and disposition, including patients with a 
prolonged hospital admission greater than one week and patients discharged to an 
SNF or home with a nurse 
 interventions during the acute hospitalization, including transfusion during the index 
admission 
 demographic characteristics of older age, less education 
 economic characteristics of fewer total assets, lower household income, Medicare 
primary insurance or Medicaid enrollment, absence of supplemental health insurance, 
and absence of prescription drug coverage. 
 social isolation, including no living children, no living siblings, no friends living 
nearby and infrequent contact with friends, poor self-rated health, difficulties with 
activities of daily living (ADLs), decreased mobility and decreased agility (Arora, 
Patel, et al., 2017; Barnett et al., 2015; Freedland et al., 2016; Mirkin et al., 2017). 
These studies demonstrate the scope required of a program to effectively reduce hospital 
readmissions and reflect the necessary scope of socioeconomic, health literacy, and psychosocial 
considerations that need to be considered in efforts to successfully address hospital readmissions 





interventions like palliative care offer a broader scope to address the highly variable patient 
circumstances that need to be addressed. These elements represent important co-factors for this 
investigation and are represented within the demographic and severity characteristics included in 
this investigation. 
Patient Drivers of HF Hospital Readmission 
 Patient perception of symptoms and the reasons for hospital readmission are important to 
understanding the issues that improve the self-management of HF and decrease unnecessary 
hospital readmission. HFPC may directly affect patient perception of symptoms to seek hospital 
readmission. Hospital admission for HF is associated with fatigue, drowsiness, dyspnea, anxiety, 
decreased well-being, and edema. In one review, up to 58% of patients reported that symptoms 
had not improved an average of four days after hospital discharge compared to admission (Khan 
et al., 2015).  
Patient-identified reasons for HF admission include worsening heart failure, dietary 
nonadherence, or other worsening medical condition; only a small proportion (4%) did not know, 
had no access to a provider, or reported a medication issue (Gilotra et al., 2017). Physician 
perspective agreed with patient perceptions on issues of dietary nonadherence, but physicians 
were much more likely to identify a medication issue as a major reason for HF admission. 
Patients identified three major themes relating to reasons for hospital readmission: a lack of 
caregiver support and personal motivation to provide self-care: “I can’t take care of myself, and I 
can’t find anybody who can provide care” (p. 539), acceptance of condition and desire for 
aggressive care: “I ain’t going nowhere, and I’m fighting” (p. 539), and access to care and poor 
quality of care: “I have problems, medical, psychological, financial and every day I’m out, it gets 





Perception of illness related to personal control and treatment beliefs about the necessity 
of medications versus adverse effects have been noted to be significantly associated with 
medication adherence, which is a critical aspect of care for the success of interventions that aim 
to reduce hospital readmissions (Turrise, 2016). In the Journal of the American Medical 
Association (JAMA) forum, Jha (2015) eloquently advocated that “during an acute illness, 
patients prioritize survival, maintaining functional status, cognitive clarity, being treated with 
dignity, and reducing pain. Reducing hospital readmission, while important, is likely a lower 
priority for patients” (p. 1681).  
Perception of symptoms, medication and dietary adherence, perceived social support, 
cognitive and economic capabilities to provide self-care, perception of illness, and access to care 
influence an individual’s ability to provide self-care sufficient to appropriately reduce 
unnecessary hospital readmission. HFPC may directly affect patient perceptions of these co-
factors and influence subsequent health-seeking behaviors, giving patients the confidence to 
accurately interpret their symptoms and thereby avoid unnecessary hospital readmissions. 
Strategies for Reducing HF Readmissions  
 Interventions that have demonstrated the potential to decrease hospital readmissions 
include (a) the development of risk prediction models, (b) optimizing medical therapy, and (c) 
health system strategies (Ziaeian & Fonarow, 2016). A myriad of interventions have since been 
proposed to decrease the number of HF readmissions and may encourage inappropriate care 
strategies to achieve a reduction in readmission rates (Bradley et al., 2013; Woolhandler & 
Himmelstein, 2016). HFPC is typically considered a health system strategy that may provide the 
needed transition and continuity of care to optimize compliance with medical therapy.  
Validated risk prediction models have shown poor discrimination in their ability to 





2011; Krumholz et al., 2016). Cognitive testing as a part of routine clinical care during 
hospitalization has shown greater predictive performance of hospital readmission, and inclusion 
of cognitive testing in other models improved predictive accuracy (Patel et al., 2015). Inclusion 
of measures of health literacy and functional and cognitive status may improve predictive 
models, but further validation is required (Ziaeian & Fonarow, 2016). 
Optimizing medical therapy may include advanced heart failure interventions such as 
cardiac resynchronization therapy, ultrafiltration, and left ventricular assist devices; however, 
they are costly, and eligible patients represent only a small fraction of all US cases living with 
HF (Al-Khazaali et al., 2016; Dunlay & Roger, 2014). Cost-effective medication management 
may include digoxin, beta-blockers, aldosterone inhibitors, angiotensin-converting enzyme 
(ACE) inhibitors, angiotensin receptor blockers (ARB), or a new combination product Sacubitril 
or Valsartan that has shown efficacy in managing HF (Khder et al., 2017; Ziaeian & Fonarow, 
2016). Remote monitoring, whether by telephone or via embedded impedance technology in ICD 
or CRT devices, did not improve outcomes or reduce readmissions but increased admissions due 
to increased monitoring (Chaudhry et al., 2010; Jayaram et al., 2017; Krumholz et al., 2016). 
Implantable pulmonary artery sensors that wirelessly transmit pulmonary artery pressure 
measurements offer the potential to reduce HF readmissions up to 58% in a single-blind trial but 
are reliant on the fidelity of data and timely response to information (Abraham et al., 2011). 
Statistically significant health system strategies to reduce hospital readmissions include 
partnering with community physicians, local hospitals, nursing responsibility for medication 
reconciliation, arranging follow-up appointments before discharge, a process to send discharge 
summaries directly to the patient’s primary physician, and assigning staff to follow-up on test 





intervention contributed statistically significant reductions to HRR, the effect size was limited, 
ranging from -0.18% to -0.34% (Bradley et al., 2013). 
Effective interventions to reduce HF readmissions must include medical management, 
early reassessment, health literacy, assessment of neuropsychological status, financial means, 
and assessment of functional status (Sperry et al., 2015). Current fragmented strategies cannot 
deliver a comprehensive scope of services required to decrease hospital readmissions and 
improve patient outcomes. HFPC may be a plausible and feasible health system strategy to 
improve compliance with treatment interventions and thereby decrease 90-day hospital 
readmissions. 
Summary 
 The development of readmission metrics is flawed as a measure of hospital quality of 
care. Readmission metrics are more likely to reflect administrative priorities to promote the 
development of improved systems of care that incorporate individual and community aspects of 
care more likely to contribute to improved continuity of care and result in fewer unplanned 
hospital readmissions. HFPC may be a plausible and feasible modality of care delivery to 
achieve the objective of reduced HF hospital readmission. The hospital burden of care is 
disproportionately distributed, and hospitals with the highest readmission rates carry the 
responsibility for sicker, poorer, less educated patients who have fewer social supports. These 
hospitals are also more likely to incur payment reduction penalties for excess 30-day HF 
readmissions. 
Mortality risk increases after hospital readmission and never returns to pre-admission 
levels. Palliative care may provide the needed transition and continuity of care to address the 





successful at reducing hospital readmissions after an index HF admission. It is also likely that the 
reduction in HF hospital readmissions is also associated with an increase in HF mortality. 
Studies to date have not stratified the HF population to determine what subgroups are at the 
highest risk for increased mortality, but it is intuitive to propose that those with Stage III, IV HF 
or meeting eligibility criteria for a palliative care referral would be most likely to be at highest 
risk. Assessment of mortality is a previously unassessed and yet high-risk source of confounding 
and is a key aspect of this investigation. 
The scope required of a program to effectively reduce hospital readmissions should 
include components that address socioeconomic, health literacy, and psychosocial 
considerations. Perception of symptoms, medication and dietary adherence, perceived social 
support, cognitive and economic capabilities to provide self-care, perception of illness, and 
access to care influence an individual’s ability to provide self-care sufficient to appropriately 
reduce unnecessary hospital readmission. Effective interventions should include medical 
management, early reassessment, health literacy, assessment of neuropsychological status, 
financial means, and assessment of functional status. Current fragmented strategies cannot 
deliver a comprehensive scope of services required to decrease hospital readmissions and 
improve patient outcomes. Hospital-focused interventions alone can contribute little, while 
interventions like palliative care offer a broader scope to address the highly variable patient 
circumstances that need to be addressed.  
This study assessed the effectiveness of the entry point of access to palliative care 
services, the initial palliative care consult. Whether palliative care consultation resulted in the 
delivery of a sufficiently broad scope of interventions to meet palliative care standard of practice 





interventions are delivered at the discretion of the PC provider individualized to the needs of 
each patient. Future research efforts on service delivery of palliative care should assess the 
elements that are evidenced-based and consistently delivered, how they are documented as 
complete, how progress is measured and the ideal timeline for service delivery. This study 
focused on the entry point to service delivery to determine whether the presence of a single PC 
consult alone, as defined and required by CMS, could result in a reduction in hospital 
readmissions. 
Historical Review of the Literature Relating to HFPC 
Lastly, a full review of the literature pertaining to this investigation requires an 
understanding of the definition and evolution of palliative care, including (a) the variation in the 
trajectory of disease that requires careful consideration when applying a service traditionally 
developed to provide care for terminal cancer patients, (b) the breadth of recommendations and 
position statements that advocate for the use of palliative care in patients with HF, and (c) trends 
and barriers for implementation of HFPC consistently and reliably. 
Definition of Palliative Care 
 Palliative care is defined by the US Department of Health and Human Service (HHS), 
Centers for Medicare & Medicaid Services (CMS) and the National Quality Forum (NQF) as   
“patient and family-centered care that optimizes quality of life by anticipating, preventing, and 
treating suffering” (Braun et al., 2016). A comprehensive palliative care intervention includes 
assessment and management of physical symptoms, psychosocial and spiritual concerns, and 
advance care planning (National Consensus Project, 2018). Palliative care throughout the 
continuum of illness involves addressing physical, intellectual, emotional, social, and spiritual 





simplified definition proposed in the 4th Edition of the National Consensus Project (NCP) 
clinical practice guideline for quality palliative care embodies three elements: (a) comprehensive 
physical, emotional, spiritual, and social assessment, (b) skilled management of pain and other 
distressing symptoms, and (c) expert communication about what is most important to patients 
and families and implementing care plans to achieve those goals (National Consensus Project, 
2018). Unlike hospice, palliative care is offered simultaneously with medical treatment (Gelfman 
et al., 2017).  
The palliative care movement began in the 1970s as a grassroots community hospice 
movement aimed at caring for cancer patients in their homes (Adler et al., 2009). Medicare 
added hospice services to its benefits in 1982 (Connor, 2007). The trajectory of declining health 
in HF is very different from the trajectory of declining health associated with cancer. As such, 
the model of palliative care services that has been developed to meet the needs of patients with 
cancer may not translate well to meet the needs of patients with HF (Murray & Sheikh, 2008). 
Unlike cancer, HF exacerbations are unpredictable, advanced therapies are expensive and limited 
in their availability, and outcomes remain uncertain (Gelfman et al., 2017). Palliative care 
treatment models for HF have vastly improved in specificity and complexity and recognize the 
specific pathophysiologic changes and variable trajectory of declining physical function unique 
to HF (Goodlin, 1997, 2005, 2009; Morrison & Meier, 2004). In 2005, the American College of 
Cardiology and American Heart Association guidelines for the first time included 
recommendations that included discussion with patients and families about prognosis for 
functional capacity and survival, advance directives, palliative care and hospice care (Hunt, 





This perspective on a new approach to HFPC is seen in the earliest investigations 
evaluating PC, suggesting a broader approach to chronic illnesses, noting that “the transition 
model of hospice care does not serve HF patients well, as most do not want to choose between 
curative treatment and symptom relief. A broader model of palliative medicine would offer 
aggressive symptom management and comprehensive care to the large percentage of outpatients 
with advanced illness who are still pursuing aggressive management or cure of their disease” 
(Rabow et al., 2004, p. 83). 
Hospice Care. Palliative care and hospice care are separate and distinct concepts that are 
often mistakenly used interchangeably but have important differences. Palliative care is a 
broadly inclusive term describing all aspects of care that focus on improving quality of life and 
symptom control over curative therapy. Hospice is a defined subset of palliative care patients 
with an imminently life-limiting illness and has important implications for health insurance 
benefits (McIlvennan & Allen, 2016). This distinction is important, as bias persists among 
patients and providers that palliative care referral is equivalent to hospice care and is a major 
barrier to provider referrals and patient uptake of referral (Kavalieratos et al., 2014). This 
perception has driven efforts to rebrand HFPC as an intervention for patients with ‘advanced’ HF 
versus ‘end-stage’ HF and attempts to reduce the pernicious stereotype that palliative care is an 
option only of last resort (Kavalieratos et al., 2016).  
Guidelines. The advocacy for palliative care to be made available to advanced HF 
patients is broadly advocated and embodied in numerous guidelines and consensus statements 
from: 





 American Academy of Hospice Palliative Care Medicine (American Academy of 
Hospice Palliative Medicine, 2004) 
 Consensus statement on palliative and supportive care in advanced heart failure 
(Goodlin et al., 2004) 
 European Society of Cardiology (Jaarsma et al., 2009) 
 Canadian Cardiovascular Society (McKelvie et al., 2011) 
 Centers for Medicare & Medicaid Services (Centers for Medicare & Medicaid 
Services) 
 American Heart Association scientific statement (Allen et al., 2012) 
 International Society for Heart and Lung Transplantation (Feldman et al., 2013) 
 Centers for Medicare & Medicaid Services decision memo for ventricular assist 
devices (Centers for Medicare & Medicaid Services, 2013) 
 Joint Commission for the Accreditation of Hospital Organizations ("Modified: 
Ventricular assist device destination therapy requirements, 2014") 
 Heart Failure Society of America (Fang et al., 2015) 
 American Heart Association and Heart Failure Society of America: HF in Skilled 
Nursing Facilities (Jurgens et al., 2015) 
 Geriatrics Section of the American College of Cardiology (Kirkpatrick et al., 2016) 
 American Heart Association (Braun et al., 2016; Heidenreich et al., 2013) 
 American Stroke Association (Braun et al., 2016) 
 American College of Cardiology (Yancy et al., 2017; Yancy et al., 2013) 





Despite the prevalence of guidelines and consensus statements, the evidence to establish 
the efficacy and effectiveness of palliative care to improve outcomes in HF is preliminary; a US 
national strategy for palliative care does not exist and remains an unrealized opportunity to 
improve value in health care (Meier, 2011; Meier et al., 2017). Highlighting the paucity of 
literature available to cardiologists, a review of the literature from 2009-2013 quantifying 
publications on HFPC found only 11 (0.1%) articles in the predominant cardiology journals on 
the topic of HF with PC as the main topic and an additional six (0.0%) with palliative care as a 
specific mention (Xie et al., 2017). Palliative care journals performed marginally better, with 47 
(1.2%) of PC articles listing HF as a main topic and another 17 articles (0.4%) listing HF as a 
significant mention (Xie et al., 2017). Representation of the topic in cardiology conference 
proceedings demonstrated similar poor performance, with only 21 (1.2%) HF seminar sessions 
and 17 (0.4%) poster presentations listing PC as a main topic (Xie et al., 2017). This 
performance is largely driven by the absence of funding for HFPC, with <0.1% of federal 
funding for HF allocated to research on PC, only 21 (0.7%) grants funded with HFPC as a main 
topic, and another 13 (0.4%) with PC as a significant mention from the 2,921 HF grants funded 
by federal sources from 2009-2013, despite its prevalence and emphasis in a broad array of 
guidelines and consensus statement (Xie et al., 2017).  
 In 2017, only one paper evaluating HFPC was selected for presentation at the annual 
assembly of the American Association of Palliative and Hospice Medicine (AAHPM) and the 
Hospice and Palliative Nurses Association (HPNA) as a study with significant potential for 
impact on hospice and palliative care practice. The study was subsequently evaluated as having a 
high risk of bias. Additionally, it was conducted in a very different health care setting in Hong 





Institutes of Health, National Palliative Care Research Center sponsored workshop was convened 
to outline the current research base, identify knowledge gaps and research priorities (Gelfman et 
al., 2017). The summary statement of the current evidence from the newly formed Improve 
Palliative Care Therapies for Patients with Heart Failure and Their Families (IMPACT-HF2) 
workgroup concluded that the current state of the science for palliative care in HF is limited, and 
further evidence is required to: (1) better understand advanced HF patients’ limiting symptoms 
and focus treatment on their relief, (2) better characterize and address the needs of the caregivers 
of advanced HF patients, (3) improve patient and family understanding of HF disease trajectory 
and importance of advance care planning, and (4) determine the best models of palliative care, 
including models for those who want to continue life-prolonging therapies (Gelfman et al., 
2017). This research proposal addressed research priority #2 of the NIH, NPCRC to better 
characterize and address the needs of the caregivers of advanced HF patients by evaluating an 
area of key interest to caregivers regarding whether palliative care consultation in a general 
medical population can reduce 90-day hospital HF readmission without increasing mortality. 
Trends of Palliative Care Utilization 
 There has been a significant trend of increased HFPC over time, with utilization trends in 
veterans with severe heart failure increasing from 6% to 10% from 2007 to 2013. Overall, 51% 
of patients with HF died within one year of hospitalization. Patients seen by PC had a 1-year 
mortality of 72.8% compared to 49.5% among those who were not seen by PC22 (Mandawat et 
al., 2016). Fromme et al. (2006) emphasized that the observed reduction in hospital readmission 
rates was undoubtedly lower because of the differential mortality that occurred within the 
 





palliative care consultation group. Outcomes demonstrating the benefit of PC utilization should 
consider this differential mortality; however, studies to date have failed to do so.  
Access to PC programs is variable across the United States, with the lowest prevalence of 
PC programs found in the South-Central regions. Even among hospitals with 300 or more beds, 
12% of hospitals in the South did not have a current palliative care program (Dumanovsky et al., 
2016). The resulting unmet need for palliative care in US hospitals was quantified with an 
observed extreme hospital-level variation from 12% to more than 90% of eligible patients 
receiving palliative care referral or services (Szekendi et al., 2016). 
Enrollment in PC programs has also demonstrated marked variability. Patients enrolled in 
PC are more likely to be White, older, female, exhibit multiple comorbidities, access acute care 
services such as ER visits, hospitalizations, and ICU admission, and be receiving services in a 
long-term care setting than patients with cancer (Bain et al., 2009; Cheung et al., 2013; 
Setoguchi et al., 2010). A more in-depth evaluation of racial differences noted a persistent 
disparity over time, with non-White individuals eligible for hospice services 20% less likely to 
enroll and more likely to disenroll23 in services compared to Whites (Unroe et al., 2012). Non-
Whites accessing PC services were more likely than Whites to be younger, exhibit a higher 
frequency of comorbidity, reside in a state with Medicaid buy-in, and live in a non-rural location 
(Unroe et al., 2012). The perceptions associated with PC among patients self-described as 
familiar with PC services include many negative perceptions about it being a service to provide 
“comfort to dying patient and family,” “for dying patients,” or “comfort care.” Increasingly 
positive perceptions include “team effort towards the patient to provide everything the patient 
needs,” “semi holistic approach to care,” or “pain relief, patient comfort, support for family.” 
 





Others have perceived PC as an assistive service described as “help with day-to-day activities, 
not in a hospital setting,” “visiting nurse who gives medications,” or “home care for elderly and 
sick” (Khan et al., 2015, p. 1713-1714). Among patients eligible for PC services, only 22% 
reported familiarity; however, 68% were interested in receiving PC services, which indicates that 
there is potential to address unmet needs associated with HF that is not being effectively 
managed by existing patient management systems (Khan et al., 2015). 
Barriers and Supports for implementation of HFPC 
 In a recent multisite, retrospective, point prevalence study, the majority of patients 
appropriate for referral (60.9%) received neither referral nor services and identified barriers to 
referral, including (a) no standard definition of palliative care, even within organizations 
resulting in subjective referral criteria and variation in clinical practice patterns, (b) specialist 
reluctance to refer because of long-standing patient relationships and desire to retain patient 
management, (c) variable educational opportunities available to clinicians to acquire skills in 
primary palliative care, and (d) a perceived conflict that has the provider motivated to provide 
advanced specialty care and patient acceptance of not “doing everything” (Szekendi et al., 2016, 
p. 363). This variation in referral patterns has remained consistent over time, as demonstrated in 
a 2007 benchmarking study that assessed adherence to quality improvement metrics for palliative 
care and found wide variability in the provision of key performance measures that varied from 
0% to 100% (Twaddle et al., 2007). 
Factors propelling the adoption of HFPC services include (a) increasing referrals over 
time as HFPC teams develop relationships with frontline physicians and caregivers become 
aware of the value of HFPC services, (b) impression that HFPC teams should be reserved for the 
management of complex symptom management and when difficult patient and family dynamics 





strategic goals to reduce readmissions, (d) increasing public awareness among patients and 
providers, and (e) increased focus on the hospital mission to provide patient-centered care 
(Szekendi et al., 2016). Of note is the paucity of research demonstrating efficacy or effectiveness 
as a factor promoting the adoption of HFPC services. Several studies have focused on 
demonstrating the benefit of HFPC for the hospital system and reductions in hospital 
readmissions, length of stay, and overall cost reduction (Bharadwaj et al., 2016; Lukas et al., 
2013). 
HFPC has been advocated to alleviate the symptom and psycho-social burden associated 
with advanced HF (Alpert et al., 2017; Dahlin, 2013). Compared to patients receiving cancer PC, 
HFPC patients experience a similar panel of symptoms, including (in declining rate of 
frequency) fatigue, anorexia, dyspnea, pain, insomnia, depression, anxiety, constipation, 
agitation, diarrhea, and nausea (Kavalieratos et al., 2014). Symptoms that were improved by HF 
hospitalization include nausea, anorexia, dyspnea, depression, edema, and decreased well-being; 
symptoms unmet by the hospitalization included pain, fatigue, drowsiness, and anxiety and may 
represent an opportunity to improve patient outcomes with services that are available and fall 
within the purview of HFPC services (Khan et al., 2015). While many symptoms improved 
during hospitalization—fatigue (60%), anorexia (28%), dyspnea (25%), pain (20%), insomnia 
(18%), depression (18%), and anxiety (13%)—they remained as major sources of unresolved 
symptom in HFPC patients (Kavalieratos et al., 2014). 
Summary  
A model of palliative care that recognizes the specific pathophysiologic changes and 
variable trajectory of declining physical function unique to HF is offered simultaneously with 





assessment, (b) skilled management of pain and other distressing symptoms, and (c) expert 
communication about what is most important to patients and families and implementing care 
plans to achieve those goals. Despite the prevalence of guidelines and consensus statements, the 
evidence to establish the efficacy and effectiveness of palliative care to improve outcomes in HF 
is preliminary. A US national strategy for palliative care does not exist due to the nascent 
emergence of the palliative care physician specialty and high geographic variability of PC 
services and PC providers. It remains an unrealized opportunity to improve value in health care. 
This research addressed (a) the paucity of research demonstrating the effectiveness of HFPC to 
reduce hospital readmissions and (b) research priority #2 of the NIH, NPCRC, to better 
characterize and address the needs of the caregivers of advanced HF patients by evaluating an 
area of key interest to caregivers regarding whether palliative care consultation in a general 
medical population can reduce 90-day hospital HF readmission without increasing mortality. 
Outcomes demonstrating the benefit of HFPC utilization must consider the ascertainment bias of 
differential mortality; however, studies to date have failed to do so.  
Research Literature Specific to HFPC 
As discussed in the preceding historical review of the literature on heart failure, hospital 
readmissions, and palliative care, the increasing prevalence of HF coupled with the increasing 
cost associated with care, the complicated burden of HF symptoms, and comorbidities in the 
context of increasing regulatory and financial pressures to decrease hospital readmissions have 
promoted the adoption of novel strategies such as the adaptation of palliative care treatment 
models in the HF patient population. This section provides a more current review of the literature 





promoting a reduction in hospital readmissions for HF, and describes the theoretical framework 
of this investigation.  
Readmissions 
According to Dharmarajan et al. (2013), 20-25% of hospitalized HF patients will be 
readmitted within 30 days. Seventy percent of hospitalized HF patients will be readmitted within 
one year. Two-thirds of HF patients readmitted within 30 days will be readmitted for a condition 
other than HF. Evidence of the efficacy of palliative care consults to reduce readmissions for HF 
often cite palliative care studies that were performed in mixed populations, with heart disease 
representing only a small (5%-16%) proportion of the study population (Enguidanos et al., 2012; 
Fromme et al., 2006; Lukas et al., 2013). A retrospective observational review of palliative care 
enrolled by traditional referral patterns identified a statistically significant decreased 30-day 
hospital readmission rate of 14% for HF patients compared to non-enrolled subjects with a 
hospital readmission rate of 40% (Brian Cassel et al., 2016). The former reflects a rate similar to 
contemporaneously observed readmission rates post-HRRP implementation, while the latter 
reflects a rate significantly above general readmission rates observed for HF (Zuckerman et al., 
2016). Resource use was significantly less in a retrospective observational study of palliative 
care enrollees compared to a propensity-matched cohort of HF patients predominantly driven by 
a reduced number of hospitalizations and length of stay (Brian Cassel et al., 2016). 
Establishing the Goals of Care 
 Palliative care for HF has a primary objective to focus on improving quality of life rather 
than focusing on improving survival alone through medical interventions. The aim is to alleviate 
physical and psychological symptoms, support spiritual concerns, and create the opportunity to 





demonstrated to decrease the frequency of procedures near the end of life, decrease the length of 
stay, and decrease hospital and overall costs of care, such as pharmacy and imaging (Adler et al., 
2009). 
Resuscitation preferences in HF have been noted to change over the course of the disease, 
with 75% of patients electing do-not-resuscitate status before death, yet marked discordance 
exists between patients’ primary recovery goals and treating clinicians’ goals who often do not 
effectively elicit patients’ needs, concerns and expectations regarding their care (Dunlay et al., 
2014, Figueroa, 2016). In a recent single-site review at a large academic medical center, 20% of 
patients hospitalized with HF indicated a resuscitation preference that differed from what had 
been ordered by clinicians in the same hospitalization (Young et al., 2017). Guidelines routinely 
recommend discussions about prognosis and patient preferences for goals of care, advance care 
planning, surrogate decision making, and social and spiritual support; however, a cross-sectional 
analysis of a cohort study identified 32% had not discussed prognosis, 24% had not discussed 
what to expect in the future with respect to their HF diagnosis, 54% had not discussed advance 
care planning, and 77% had not discussed religion or spirituality preferences (Gordon et al., 
2017). Shared decision-making and future care planning are essential elements of HFPC and 
routinely employ communication methods with demonstrated effectiveness, such as motivational 
interviewing (Meyers & Goodlin, 2016; Riegel et al., 2016). 
Systematic Reviews and Randomized Clinical Trials  
 Multiple systematic reviews specifically relevant to the topic of HFPC have compiled the 
limited evidence available and largely focus on the prevalence of bias in much of the existing 





studies with minimal risk of bias (Diop et al., 2017; Fischer et al., 2015; Kane et al., 2015; 
Kavalieratos et al., 2016; Kavalieratos et al., 2017; Maciver & Ross, 2018; Singer et al., 2016). 
The systematic reviews and randomized clinical trials that have contributed to the 
evidence on HFPC are summarized in an annotated table found in Appendix A3. Only one study 
has been rated as having a low risk of bias. The mixed results and methodological issues present 
in these studies demonstrate the preliminary status of the evidence to guide assessment, patient 
management, and effective treatment interventions to achieve desired patient outcomes for 
decreasing symptom burden, improving quality of life, and optimizing resource utilization with 
decreasing hospital readmissions without increasing the risk of mortality. Previous evidence 
reviewed has demonstrated evidence for the potential of increased mortality associated with 
decreased hospital readmissions. Any policy that improves resource utilization should not come 
at the cost of increased risk of mortality. It is an important aspect of palliative care research to 
provide evidence that palliative care not only improves symptom burden, quality of life, and 
decreased hospital readmission but does so with no increased risk.   
Alternatively, HFPC may be the only safe and effective way to decrease hospital 
readmissions with the home-based services of PC. The hypothesis of this investigation was that 
the increased level of resources, education, facilitated decision-making, and future health 
planning would enable the patient to better understand their symptoms and improve health 
behaviors through a better understanding of the health system, and enable the patient to seek 
health care services in less hospital-oriented settings to ultimately decrease hospital 
readmissions. Also, this research evaluated whether or not an HFPC consult is associated with 
hospital readmission at 90 days after controlling for mortality. If an HFPC consult is associated 





positive finding and evidence of efficacy for HFPC consultation (reject the null hypothesis). If an 
HFPC consult is not associated with decreasing hospital readmissions after controlling for 
mortality, this would indicate a negative finding for HFPC consultation (fail to reject the null 
hypothesis). No study to date has evaluated patient outcomes in a propensity-matched cohort to 
evaluate the effect that mortality may have on the rate of hospital readmissions.  
Sidebottom et al. (2015) demonstrated non-significant differences in mortality in a 
population with marked differential loss to follow-up with 80% of intervention arm patients not 
completing intervention follow-up. Brannstrom and Boman (2014) and Rogers et al. (2017) 
found non-significant differences in survival or mortality at follow-up in resource-intensive 
health services environments atypical for health services in much of the United States. In the 
absence of such resource-intensive health services, it is intuitive that HFPC may be the only 
resource available to HF patients to achieve the outcomes of decreasing hospital readmission 
without increasing mortality. To attempt to decrease hospital readmissions without additional 
self-care support would intuitively be a significant risk of increased mortality, especially in the 
setting of observed increases in mortality associated with HRRP efforts to decrease hospital 
readmissions for HF. 
Retrospective Studies  
 The most frequent method of investigation of HFPC has been the retrospective cohort 
analysis. The findings from this approach have also had the highest frequency of mixed findings. 
Two recent large studies, conducted at large academic medical centers, produced directly 
contradicting findings (Chuang et al., 2017; Wiskar et al., 2017). Chuang et al. (2017) identified 





matched control group24. Wiskar et al. (2017) identified a significant reduction in hospital 
readmission for HF25 and all-cause readmission26 at nine-month follow-up. There were key 
differences in these two studies, the former, a single-site academic medical center, the latter, a 
linked nationwide analysis; the former monitored follow-up for 30 days and the latter for 90 days 
(Chuang et al., 2017; Wiskar et al., 2017). Both studies matched on severity using validated 
comorbidity indices. Neither study evaluated the effect of mortality despite differential mortality 
(39% - 37%) and differential average time to death (136-262 days) in the HFPC group compared 
to controls in the former study, an analysis that was perhaps unnecessary, given the existing 
absence of an observed association; in the latter study, mortality was not assessed, which was a 
significant limitation to the findings (Chuang et al., 2017; Wiskar et al., 2017).  
A previous study at a single-site large academic medical center identified statistically 
significant reductions in 30-day hospital readmission, with rates for HFPC recipients showing 
10.3%27 versus usual care at 15%28 (O'Connor et al., 2015). The authors acknowledged that at 
least some of the effect size might have been due to hospice referrals; mortality was not assessed 
in the cohort (O'Connor et al., 2015). In addition, the observed readmission rates were 
substantially different from rates in later retrospective studies and other studies evaluating HF 
readmission rates alone, suggesting fundamental differences in admission practice or 
ascertainment bias (Chuang et al., 2017; Desai et al., 2016; Wiskar et al., 2017). Earlier 
retrospective studies were predominantly descriptive in nature, included HF in a mixed 
 
24 respectively, 50.8% and 36.0% 
25 9.3% vs. 22.4%, p < 0.01 
26 29.0% vs. 63.2%, p < 0.01 
27 95% CI [8.9% - 12.0%] 





population, and evaluated implementation strategies for advance care planning and hospice use 
(Bekelman et al., 2011; Connor et al., 2007; Enguidanos et al., 2012; Schellinger et al., 2011). 
Prospective and Before-After Intervention Studies 
The majority of prospective studies have been small studies of HFPC models of care to 
test the feasibility of a planned future larger intervention study (Bekelman et al., 2014; Dionne-
Odom et al., 2014). One prospective case-control study is notable for its specific methodology 
using multiple validated measures of comorbidity, symptoms, depression, and quality of life at 
baseline and 90-day follow-up, with statistically significant improvements noted in each of the 
domains measured (Evangelista et al., 2012). Patients were excluded if they were currently 
receiving or had planned HFPC services; limitations noted included the small groups, lack of 
randomization, and the case-control method to test association without the ability to evaluate 
causality (Evangelista et al., 2012).  
Several non-randomized before-after HFPC intervention trials have been published 
describing the phased implementation of HFPC for advanced HF at single sites of inpatient and 
outpatient care (Bailey et al., 2005; Nelson et al., 2011; Pattenden et al., 2013). The bias of the 
historical control in the setting of rapid evolution and advocacy for the implementation of HFPC 
from published guidelines is significant (Gordis, 2009). One before-after HFPC intervention trial 
evaluated the effectiveness of a single RN versus an interdisciplinary team consisting of a 
physician, bioethicist, social worker, RN, and hospital chaplain. The study noted a 20% 
reduction in six-month hospital readmissions, p =0.025, with a calculated Bayesian probability of 
readmission of 73% for each individual in the former group, while the latter group had a 
calculated Bayesian probability of readmission of 33% (Nelson et al., 2011). 





 Other studies have included descriptive cross-sectional prevalence studies defining the 
availability of PC services, quantifying the unmet patient need for palliative care services, and 
resource utilization (Blecker et al., 2011; Szekendi et al., 2016; Twaddle et al., 2007). These 
analyses have identified significant gaps in the human resource and organizational capacity to 
deliver HFPC to eligible patients. A point prevalence study of 33 hospitals identified 18.8% of 
the inpatient populations as appropriate for palliative care referral. Of those deemed appropriate, 
39.1% received a palliative care referral or services, with wide variation in service delivery 
ranging from 12% to more than 90% (Szekendi et al., 2016). These findings indicate a sizable 
unmet need for PC services in general, which increases the demand for additional PC resource 
demands; the evidence supports the efficacy of the HFPC intervention to achieve the outcome 
desired-decreased hospital readmissions. 
In a review of 35 major US teaching hospitals, 12 (35%) did not have PC consultation 
available (Twaddle et al., 2007). The level of performance achieved on key performance 
measures rivaled that of hospitals where PC consultation was available but not utilized or 
requested late in the hospitalization. Hospitals with no PC consultation available achieved an 
average of 53.8% successful completion of key performance measures, while hospitals with PC 
consultation achieved 69.3% adherence to key performance measures when PC was received 
compared to 59.8% when it was not received (Twaddle et al., 2007). These findings demonstrate 
that PC services may be successfully delivered to the HF patient even in the absence of a specific 
PC consultation service, indicating the potential for innovative program design that maximizes 
the reach and utility of PC practitioners. These findings are also important to the definition of 
what constitutes delivery of PC. The definition is limited to the presence or absence of a 





consultation or delivery of the PC services, regardless of whether or not such services are 
provided in the context of a formal PC consultation. 
Qualitative Studies 
A limited number of studies have evaluated questions important to the practice of PC, 
such as goal definition and assessment of PC service delivery (Schellinger et al., 2018; Schwarz 
et al., 2012). Evaluating a mixed population comprising 68% with a primary diagnosis of HF, 
Schellinger et al. (2018) identified 13 unique domains that are essential to whole-person care. 
These findings provide an essential guide to achieving a comprehensive, holistic PC assessment 
that goes beyond the focus on physical, disease-specific, problem-oriented medical care. 
 
Cost-effectiveness Studies  
 Cost-effectiveness for HFPC has not been evaluated in the United States. Sequential 
studies evaluating the cost-effectiveness of PC indicate that pooled diagnostic categories were 
statistically significant, while stratification demonstrated a stronger association with cancer 
versus non-cancer diagnoses (May et al., 2014; May et al., 2018). In a statistical analysis 
accounting for multiple comparisons, statistically significant cost-effectiveness only remained 
among non-cancer patients with an Elixhauser comorbidity index > 4, indicating that PC is cost-
effective for those with non-cancer diagnoses with four or more multiple comorbidities 
(Elixhauser et al., 1998; May et al., 2018; Moore et al., 2017). Cost-effectiveness for home-based 
HFPC has been clearly established in Sweden, with statistically significant reductions in MD 
visits, emergency transport, and hospital care (Sahlen et al., 2016). Costs were increased for 
nurse visits and other primary health care visits, which resulted in non-significance for total 
combined costs. However, despite non-significant changes in costs, there was also a statistically 





for the cost-effectiveness determination (Sahlen et al., 2016). The limitation for generalizability 
of these findings to the United States is the fundamental differences in the health system 
priorities, health care preferences, and priorities of the United States versus Sweden. Whether 
HFPC is cost-effective in the US health system remains undetermined.  
Theoretical Framework 
 The theoretical framework for this research is nested within the foundational science of 
signal detection theory (Goldstein, 1999). The process of sensation and perception can be 
separated into the physiological process of neural transmission and the psychological process of 
perception, recognition, and action (Goldstein, 1999). The psychological process that prompts 
behavior is best described by Leventhal’s Common-sense model of self-regulation of health and 
illness (CSM). Leventhal’s Common-sense model is broadly used throughout the HFPC 
literature (Dionne-Odom et al., 2014; Horne et al., 2013; Turrise, 2016). 
Signal Detection Theory 
The sensations of sight, hearing, smell, taste, and touch inform our perceptions through 
established physiological pathways, but also through the cognitive influences formed by an 
individuals’ ability to remember and recognize grouping patterns, context, previous knowledge, 
familiarity with the method of delivery, and expectations based on culture, past experiences, and 
memory (Goldstein, 1999). The physiological pathways of sight, hearing, and touch are 
augmented by the chemical senses of taste and smell that form the individual’s ability to perceive 
their presence and position in this world (Goldstein, 1999). The physiologic pathway comprises a 
distal stimulus (diagnosis of HF), a proximal stimulus (symptoms of HF), transduction 
(transformation of sensory input to electrical energy), and neural processing (transmission to 





(interpretation of symptoms), recognition (contextual meaning of symptoms), and action 
(outcome of the perceptual process; Goldstein, 1999).  
Signal detection theory is the theoretical basis of measuring perception. It has two 
essential components, the ‘signal,’ which is the stimulus presented to the subject, and ‘noise,’ 
which is all the other stimuli in the environment that can sometimes be mistaken for a signal 
because the signal is usually very faint (Goldstein, 1999). This describes the complexities of the 
chronically ill HF patient struggling to differentiate signals of worsening disease from the noise 
of chronic illness with incredible accuracy. For example, in a signal detection experiment, an 
individual must interpret the presence or absence of a signal in the context of varying 
background noise. An individual who is motivated, intrinsically or extrinsically, to identify as 
many signals as possible will be a liberal responder and demonstrate a high sensitivity, low 
specificity, and a high false-positive rate of activation (Goldstein, 1999). An individual who is 
motivated to be ‘sure’ of the presence of a signal before responding will be a conservative 
responder and demonstrate a lower sensitivity, higher specificity, and a lower false-positive rate 
of activation (Goldstein, 1999).  
An important and directly applicable aspect of the theory is that if the payoff or reward 
for identifying a signal is high, all subjects will become liberal responders and demonstrate a 
high sensitivity and consequently high false-positive rate of activation, precisely the motivational 
system that is in place for the care and management of patients with HF (Goldstein, 1999). A 
high-valued reward (health) will be realized if the patient can identify as many signals as 
possible indicating a problem with their underlying disease that prompts them to seek expert 
opinion via medical care. Simultaneously, government and insurers provide incentives to health 





the need for hospital resources, to be ‘gatekeepers’ for hospital readmission, and from the 
patient’s perspective, limit access to the reward. 
 Varying the reward in a signal detection experiment will yield a ROC curve that would 
enable the investigator to determine whether individual responses exhibit the same or 
significantly different sensitivity to the signal regardless of their inherent high or low responder 
tendency. However, in an experiment with HFPC, it would be unethical to vary the reward, and 
as such, a natural or observational study design is required. In this type of study design, a 
response that can be evaluated is the presence or absence of 90-day hospital readmission for HF. 
By providing improved coping mechanisms, HFPC may improve the accuracy of perceived 
signals (symptoms), thus decreasing unnecessary health-seeking behaviors and consequently 
decreasing unnecessary 90-day hospital readmissions. 
Common Sense Model  
 The Common Sense Model (CSM) was proposed as an information-processing model 
that holds that individuals (a) interpret the meaning of illness and symptoms, (b) decide how to 
respond, (c) take action, (d) evaluate the effectiveness of the action or illness management 
strategy, and (e) revise their understanding of the criteria for evaluating the effectiveness of the 
action (Leventhal et al., 2003). CSM focuses on how patients shape their health-seeking 
behaviors based on their illness beliefs. The issues related to immunization during the ongoing 
COVID-19 pandemic clearly illustrate how extreme illness beliefs related to conspiracy theories, 
governmental interference, or wholesale fraud in the actual existence of the disease has shaped 
health-seeking behaviors related to obtaining the vaccination, with many individuals choosing to 
not be immunized despite clear risks to their own health and the health of others. Theories 





via an explanatory construct of chronic illness representation and focus on how people with 
chronic somatic disorders make sense of their illness (Kaptein et al., 2003). Goals and 
confidence are key self-regulatory elements that influence action (Scheier & Carver, 2003). 
Important aspects of medication adherence have been further described in the perceptual context 
of treatment risk versus side effects and are elaborated in the necessity-concerns framework 
(Horne, 2003). The effects of culture, gender, personality, cognition, and denial related to the 
application of the CSM have been described in detail (Baumann, 2003; Cameron, 2003; 
Contrada & Coups, 2003; Martin & Suls, 2003; Wiebe & Korbel, 2003). 
In the CSM, illness representations are formed by both individual experience and social 
inputs and have (a) an identity, label, or name associated with the condition (HF, HF 
exacerbation), (b) a timeline or perceived rate of onset, duration, and decline (progression of HF 
stage), (c) consequences or anticipated physical, cognitive and social disruption (decline in 
function, death), (d) a cause (heart attack as a cause of HF or idiopathic cause of HF), and (e) 
control or the perceived effectiveness of the ability of self or medical interventions to manage 
disease (Leventhal et al., 2003). Similar to the previously discussed signal detection theory, in 
which the signal must be accurately interpreted as present or absent in the context of background 
noise, the CSM provides insight into why patients with HF often misidentify symptoms of 
concern. Breathlessness, chronic fatigue, and swollen feet may be clear signs of HF for a 
physician but may be misinterpreted by the patient due to their previous experience or illness 
prototype and an illness representation that may falsely minimize or exaggerate the identity, 
timeline, consequences, cause, and control of HF elements. These result in suboptimal illness 
outcomes of excessive hospital readmission or preventable mortality (Leventhal et al., 2016). In 





and reliably identify symptoms associated with the condition, anticipate the progression of their 
disease, understand the consequences of specific medical and self-management choices or 
interventions, have knowledge of the cause of worsening symptoms and demonstrate an action 
plan exhibiting their ability to control their condition and measure the effectiveness of chosen 
self-management or medical interventions (Leventhal et al., 2016). 
The CSM was chosen over other models of health behavior, such as the Health Belief 
Model and Theory of Planned Behavior because concepts in the CSM are multi-level. The CSM 
focuses on not only the antecedent experience of severity (illness prototype) but also concurrent 
inputs from the senses and treatment beliefs. It also considers the projected future consequences 
and potential for cure or control (illness representation) of the health-seeking behavior 
(Leventhal et al., 2016). Moreover, the CSM requires examination beyond the ‘why’ a specific 
behavior occurred; it examines the context, what an individual did, and how the behavior is 
achieved (Leventhal et al., 2016).  
The CSM proposition that guided this dissertation study is that the relationship between 
illness representations with inputs from the illness prototype, sensory inputs and treatment 
beliefs, and the illness outcome of hospital readmission can be modified by improving coping 
procedures developed in the context of palliative care. Health care providers can do little to 
influence an individual patients’ illness prototype, sensory inputs, or treatment beliefs. However, 
health care providers can provide the patient with coping procedures that may impact the illness 
outcome of interest—to decrease hospital readmission. This study evaluated the relationship of 
coping procedures, as measured by the presence versus absence of palliative care consultation 





It is reasonable to presume that achievement of high patient perception competency in 
coping procedures would be more effectively delivered within the physician-driven model of 
HFPC. However, the difficulty demonstrated in previous studies is that the observed variation in 
HFPC service delivery is high, and determining the threshold of whether HFPC services have 
been adequately delivered is difficult. If presence versus absence of an order for HFPC consult is 
the differentiator, the consult may occur during the inpatient hospitalization or not; if presence 
versus absence of an actual HFPC consult on the medical record is the differentiator, the type of 
services delivered is highly variable. Since patient knowledge and competency are at the core of 
successful disease management, it is irrelevant where the derived source for HFPC competency 
arises. Rather, knowledge and skills are received, understood, and incorporated by the patient to 
inform a more accurate and reliable illness representation. Consideration of the need and referral 
for palliative care consultation is a reasonable if unvalidated proxy for the intent of the entire 
patient care team to provide HFPC competency via a mixed approach with nursing-driven 
education; primary care self-care recommendations, future planning with advanced directives, 
and designation of health care proxy and coordination of services; subspecialist management 
recommendations; case management referrals for available community support services and 
ideally, palliative care consultation. 
Summary of What is Known and Unknown About HFPC and Hospital Readmission 
In summary, what is known and unknown about the relationship between HFPC and 
hospital readmissions is that the prevalence of HF is increasing and is unlikely to decrease with 
significant and sustained risk factor prevalence of coronary artery disease, hypertension, diabetes 
mellitus, obesity, and smoking in the population (Benjamin et al., 2018; Heidenreich et al., 





acute care is unsustainable (Heidenreich et al., 2013). It is unknown whether HFPC is an 
effective alternative for patient management to improve outcomes for patients with HF. 
The interpretation of symptoms and health-seeking behaviors for HF is complex, difficult 
to assess, and exerts a strong influence on the individual’s illness representation, prompting 
health-seeking behaviors (Enguidanos et al., 2015; Kaptein et al., 2003; Leventhal et al., 2016; 
Turrise, 2016). Research demonstrates that coping mechanisms improve illness outcomes 
(Leventhal et al., 2016; Turrise, 2016). It is unknown whether improved coping mechanisms, 
represented by the presence of a PC consult, can affect the illness outcome of hospital 
readmission in patients with HF. 
Research has shown that the HRRP policy that seeks to reduce hospital readmissions was 
based on an inherently flawed premise that the hospital may influence health-seeking behaviors 
for a 30-day period post-discharge (Chin et al., 2016; National Quality Forum, 2016). In 
addition, studies have shown that 30-day hospital readmissions were not impacted by related 
hospital process of care indicators but were associated with individual and community factors 
such as resource availability, social support, and mental health issues (Barnett et al., 2015; Chin 
et al., 2016; Freedland et al., 2016; Pandey et al., 2017). It is unknown whether the acute care 
hospital system can reasonably facilitate access to a limited resource, like PC consultation, with a 
limited number of PC practitioners to fully serve the HF population in need of services. It is also 
unknown whether different modalities of care, service delivery models, or location of service 
delivery of PC interventions can deliver comparable outcomes. 
Lastly, the HRRP policy has met with a modicum of success in reducing 30-day HF 
hospital readmissions, but that reduction has continued controversy with its association with 





delivered by HFPC can achieve reductions in hospital readmission without an increase in 
mortality. In other words, it is unknown if HFPC modifies the relationship between the HF 
illness representation and the illness outcome of hospital readmission without an increase in 
mortality.  
Contribution 
 Practical application of the findings generated will: 
 Contribute to the existing knowledge gap identified as a research priority by the NIH, 
NPCRC to better characterize and address the needs of providers managing the care 
of advanced HF patients. 
 Contribute to the evidence evaluating the effectiveness of palliative care referral to 
reduce hospital readmissions for HF. 
 Contribute to the evidence evaluating the relationship between a PC consult and 90-
day hospital readmissions in a propensity-matched HF cohort, with adequate controls 
for the assessment of bias arising from differential mortality, an element that has been 













Chapter 3: Methodology 
Research Methods 
 The approach to this research is a concurrent cohort design with a prospective 
ascertainment of 90-day hospital readmission, HFPC consult and mortality. To ensure the 
capture of all discharges and readmissions, all live discharges with a primary diagnosis of HF, 
codified in Appendix A4, were abstracted from the AdventHealth data warehouse. Data 
abstraction included patient identifiers to enable future contact, all coded administrative ICD-10 
diagnosis codes, palliative care consult code, and mortality status and elements required to 
achieve propensity matching. The outcome of interest is hospital readmission for any cause 
within 90 days of index HF hospitalization. Readmission was assessed by medical record review 
and patient contact (if needed) conducted at 90-120 days post-discharge. IRB approval of the 
research plan, ascertainment of readmission, and mortality at 90 days post-discharge were 
ascertained in a stepwise manner:   
1. All 90-day hospital readmissions captured within the AdventHealth Tampa database 
were supplemented with additional metrics abstracted from the electronic medical 
record to enable propensity matching. 
2. Patients with an unascertained status at 90 days post index HF discharge were 
reviewed in the AdventHealth Tampa electronic medical record to determine 
readmission, palliative care consult, and mortality status. 
3. Any remaining patients with an unascertained status at 90 days post-HF discharge 
were contacted directly with the contact information provided at the time of the index 





the discharge from AdventHealth Tampa on ‘discharge date’?” after introductions 
defined by the IRB. 
4. Any remaining patients with an unascertained status at 90 days post-HF discharge 
were determined to be lost to follow-up (Lorenz et al., 2008). Ascertainment of status 
at 90-day post HF discharge was high, with only one patient excluded as lost to 
follow-up.  
CONSORT 
 The CONSORT flow diagram template was developed for standardized reporting of 
randomized clinical trials. It has been adapted to illustrate the research plan for this investigation 
(Schulz et al., 2010). Table 1 shows the index hospitalization for live HF discharges between 
October 1, 2019, and December 31, 2019. 
Table 1 
Index Hospitalization for Live HF Discharges 
Index Hospitalization for Live HF Discharges 
 Oct 1 - Dec. 31, 2019 
N=150 (estimated) 
Exclusions: Age < 18 
Transfer to another acute care / psychiatric hospital 
Left hospital against medical advice 
Hospitalizations for the same condition within 30 days of an index hospitalization 
were not considered an index event. 
Patients alive but without at least 90 days of post-discharge follow-up. 
Palliative Care Consult 
n= 











Excluded criteria used by Centers for Medicare & Medicaid Services (CMS) to calculate hospital 
mortality and readmission performance, but not used in this study: 
1. Exclusion of patients who did not have a full year of pre-admission enrollment in 
Medicare. 
2. Exclusion of patients alive but without at least 30 days of post-discharge follow-up. 
Specific Methodological Procedures 
Specific procedures defined herein make the analytic choices transparent to the reader 
and include a description of the specific plan to achieve propensity matching, the plan for logistic 
regression analysis, and the formats for the final presentation of results. 
Analytic Choices  
A key aspect of this investigation is the choice of analytic approach that was used. A 
review of the literature related to mortality and HF readmissions illustrated how different 
analytical choices can yield divergent results. Silberzahn et al. (2018) quantified the potential 
variability in the analytic approach with 32 equivalently competent research teams presented 
with the same dataset and research question and asked to determine a valid analytic approach and 
final result. The teams selected from one to seven covariates from the 14 covariates available; 15 
(52%) chose a Logistic approach, six (20%) teams chose a Linear approach, six (20%) chose a 
Poisson approach, and two (7%) chose a miscellaneous approach. Results varied from OR 0.89 
to 2.93; the theoretical approach, operationalization of the theory, statistical analytic choices, and 
the assumptions made during analysis can result in sizable variation in effect sizes even with a 
valid statistical methodological approach (Silberzahn et al., 2018). The authors recommended 





for selective reporting. The description of research methods employed in this study ensured 
transparency of analytic choices with the aim to decrease the opportunity for selective reporting. 
Logistic Regression  
 To answer the primary research question of interest, whether palliative care consultation 
can impact 90-day hospital readmission in a propensity-matched, mortality-adjusted HF 
population, the propensity-matched cohorts were compared in a logistic regression with the 
dependent variable of 90-day readmission and independent variables: 
 Palliative care consult (Y or N) 
 Propensity score (Continuous) 
 90-day mortality (Y or N) 
The relationship between 90-day hospital readmission and PCHF consult was further 
explored with a graphical analysis of time to readmission with a Kaplan-Meier survival analysis 
regression evaluating the presence/absence of differential survival time to readmission predicted 
by palliative care consult, including only those patients who had an ascertained status of alive at 
90 days, exclusive of the contribution of propensity.  
Propensity Matching. Propensity matching has been used frequently in the HF literature 
to ensure appropriately matched cohorts (Brian Cassel et al., 2016; Chuang et al., 2017; Wiskar 
et al., 2017). Propensity-matched cohorts were formed based on the development of a propensity 
score for each HF index hospitalization case. The propensity score is the conditional probability 
of receiving an exposure (e.g., palliative care consult) given a vector of measured covariates. It 
can be used to adjust for selection bias when assessing causal effects in observational studies 
(Andrey et al., 2011). The propensity score is defined as the probability of receiving treatment 
based on measured covariates e(x) =P(Z =1 | X) where e(x) is the abbreviation for propensity 





the "|" symbol stands for conditional on, and X is a set of observed covariates (Thoemmes, 
2012). The calculated propensity score enables matching on demographic characteristics and 
severity to ensure that patients who receive HFPC are matched to patients with a similar 
demographic and severity profile (O'Connor et al., 2015).  
  Propensity scores for receiving palliative care consult were calculated using a non-
parsimonious multi-variable logistic regression model with the treatment variable of palliative 
care consult as the dependent variable and independent variable covariates (Chuang et al., 2017; 
Garrido et al., 2014; Gupta et al., 2017; National Consensus Project, 2018): 
● age  
● gender 
● DNR status (Y or N) 




○ dual eligible 
● last known cardiac ejection fraction  
○ preserved 
○ borderline 
○ reduced < 25%  
● ICD implant 
○ ICD only 





○ ICD or CRT-D 
● all administratively coded ICD-10 diagnosis codes to identify comorbidities identified 
in Appendix A5 (Elixhauser et al., 1998) 
○ cardiac arrhythmias 
○ valvular disease 
○ pulmonary circulation disorders 
○ peripheral vascular disorders 
○ hypertension, uncomplicated 
○ hypertension, complicated 
○ paralysis 
○ other neurological disorders 
○ chronic pulmonary disease 
○ diabetes, uncomplicated 
○ diabetes, complicated 
○ hypothyroidism 
○ renal failure 
○ liver disease 
○ peptic ulcer disease, excluding bleeding 
○ AIDS or HIV 
○ lymphoma 
○ metastatic cancer 
○ solid tumor without metastasis 







○ weight loss 
○ fluid and electrolyte disorders 
○ blood loss anemia 
○ deficiency anemia 
○ alcohol abuse 
○ drug abuse 
○ psychoses 
○ depression 
● severity of HF index hospitalization at time of admission 
○ systolic blood pressure 





○ parenteral inotrope therapy (dopamine hydrochloride, dobutamine 
hydrochloride, milrinone lactate) 
○ intra-aortic balloon pump use during index hospitalization 
○ current smoking 
● adherence to guideline directed medical therapy determined by chart review 





○ If NYHA class II-III with adequate BP control on ACE/ARB and no C/I to 
ARB or sacubitril —> D/C ACEI or ARB; initiate ARNI 
○ If NYHA class II-III, LVEF <=35% (caveat: >1 year survival, >40d post 
MI) —> ICD 
○ If NYHA class II-IV, LVEF <=35%, NSR & QRS >=150ms with LBBB 
pattern —> CRT or CRT-D 
○ If NYHA class II-III, NSR< HR>=70 bpm on maximally tolerated dose 
beta blocker —> Ivabradine 
● length of stay, days 
● discharge destination 
○ home 
○ skilled nursing facility 
○ inpatient rehabilitation facility 
○ intermediate care facility 
○ long-term care facility 
○ hospice, home 
○ hospice, inpatient 
A logit of the propensity score enabled calculation of ORs for obtaining palliative care 





In the final analysis, the use of a propensity score as a continuous variable will enable matching 





observations, nearest neighbor-matching was employed because it reduces bias due to 
incomplete matching (Austin, 2013). The mean propensity score for the resulting palliative care 
and non-palliative care group before and after propensity matching was calculated, and a 
standardized difference was calculated. Residual imbalances in baseline covariates between 
treatment groups after propensity score matching was assessed by estimating the absolute 
standardized differences of the mean propensity scores (Austin, 2009). Standardized differences 
quantify the bias in the means (or proportions) of covariates across the groups, expressed as a 
percentage of the pooled standard deviation (Andrey et al., 2011). A t-test p-value was calculated 
to test statistically significant differences between the HFPC and non-HFPC groups before and 
after propensity-matching. 
Demographic Characteristics. Additional demographic characteristics that were 
abstracted include: 
 telephone contact information provided at the time of index HF admission. 
Formats for Presentation of Results 
CONSORT flow diagram summarizes the observed allocation of propensity matching, 
success with follow-up, and net cases included in the final analysis (Schulz et al., 2010). The 
resulting analysis is presented as tables demonstrating logistic regression of the primary research 
question of interest, whether 90-day readmissions can be influenced by HFPC consult after 
controlling for mortality and severity. The validity of this analysis is supported by tables of 
demographic characteristics before and after propensity-matching and calculated odds ratios for 
HFPC consult. Sub-analysis of time to readmission included calculated means and time to 
readmission. Survival curves demonstrate differential time to readmission for HFPC versus no-






 table of the outcome of a logistic regression of 90-day hospital readmission after 
controlling for mortality and severity (propensity-scoring) in the propensity-matched 
population 
 table of the outcome of a logistic regression of 90-day hospital readmission after 
controlling for mortality and severity (propensity-scoring) in the total un-matched 
population 
Demographic Characteristics and Propensity Scoring of HFPC Versus Non-HFPC Cohorts 
 table of demographic characteristics of HFPC versus non-HFPC cohorts before and 
after propensity-matching 
 table of means and standardized differences of HFPC versus non-HFPC cohorts 
before and after propensity-matching 
 box and whiskers plot of propensity scores stratified by HFPC versus non-HFPC 
cohorts 
Odds Ratio 
As a logit transformation of the individual 𝐵 obtained from the logistic regression 
equation to demonstrate the effect size of the relationship, OR will be calculated. 
 Odds ratio of 90-day hospital readmission predicted by the presence versus absence 
of a palliative care consult in propensity-matched, mortality adjusted cohort. 
 Odds ratio of HFPC consult predicted by demographic characteristics, markers of 
acuity at the time of hospital admission, and other comorbidities.  
Kaplan-Meier Survival Curve 
 table of mean time to readmission 





 distribution of time to readmission by cohort 
 Kaplan-Meier survival curve showing time to readmission for HFPC and non-HFPC 
patients in the total un-matched population (Chuang et al., 2017) 
 Kaplan-Meier survival curve showing time to readmission for HFPC and non-HFPC 
patients in the propensity-matched population 
Resource Requirement 
The research relied solely on the effort of the investigator to develop and execute the 
approach, rationale, study design, data collection, and data analysis. The data warehouse required 
for data abstraction is maintained by AdventHealth Tampa, consistent with their current standard 
practice. Access to the data was pursuant to the procedures defined respectively by the State of 
Florida and AdventHealth and specifically interpreted for this study by the AdventHealth Tampa 
Institutional Review Board. A computer with Windows 10 operating system that utilized 
Endnote 8.0 software to support reference management, Scrivener software to support 
manuscript development, access to Grammarly.com to support editing, a current subscription for 
SPSS software to analyze the data, and Microsoft Office to support final publication. 
Reliability and Validity 
A strength of the approach outlined in this proposal is that this investigation assessed the 
outcomes of a cohort comprising 100% of individuals admitted for HF in the time period, pre-
COVID Oct 1 - Dec 31, 2019, assessing the outcome of 90-day hospital readmission and 
accounting for mortality, minimizing the risk of ascertainment bias, and enhancing study validity 
and reliability. The impact of differential mortality between groups receiving and not receiving 
palliative care has been recognized as a significant risk of ascertainment bias in previous studies 





Propensity scores assigned from the use of the validated Elixhauser comorbidity scoring 
system enabled the assignment of a propensity score based on a validated weighting of 
comorbidities and validated metrics of HF severity taken from the index hospitalization. The use 
of a validated scoring system to derive the propensity score creates the best opportunity to ensure 
the greatest homogeneity of each cohort, creating the best opportunity to observe differential 
outcomes between cohorts should they, in truth, exist.  
Timeline 
The execution of this investigation from the time of IRB submission was estimated to be: 
 four weeks IRB submission. 
 four weeks  IRB clarifications and edits. 
 four weeks Execute electronic data request to site. 
 six weeks  Data abstraction from medical records. 
 six weeks  Compilation of all data into analysis file. 
 six weeks  Data analysis. 
 six weeks  Preparation of dissertation results and discussion. 
The actual timeline required approximately one year compared to the estimated six months, 
primarily due to the need to obtain multiple IRB approvals and unanticipated delays with 










Chapter 4: Results 
Chapter Introduction 
This chapter reviews the compilation of the final dataset, provides a detailed review of the 
data analysis procedures and findings of the a priori data analysis plan, and discusses the findings 
of this investigation. The primary outcome of the propensity-matched, mortality-adjusted logistic 
regression showed that for every unit reduction in 90-day hospital readmission, there was a 
statistically significant 1.468 increase in no HFPC consult (reduction in HFPC consult), p =.001. 
Compilation of Final Dataset  
The final dataset used for analysis was compiled from multiple data output files that were 
compiled into a comprehensive dataset through a process of linking variables on four different 
patient identifiers. This compilation resulted in an n =268. After exclusion of an additional 18 
cases that were expired (8), left the hospital against medical advice (AMA; 5), ineligible 
hospitalization (4), and discharged to Psychiatry (1), left a dataset n =250 for the index 
hospitalization period Oct. 1 - Dec. 31, 2019.  
Multiple transformation and recoding of variables were required to transform individual 
vital signs and laboratory values that were output list-wise as a ‘value’ field, identified by case 
and specific test in the original data file into separate variables for each case. Likewise, selected 
comorbidities were organized as a subset of all comorbidities and transformed from unsorted 
lists into variables that defined the presence/absence of each selected condition for each 
respective identified index case. Lastly, the identification of the presence/absence of a 90-day 
hospital readmission was incorporated into the final dataset. Multiple readmissions were 
common in the original dataset and had to be de-selected, as they were not pertinent to this 
investigation. It is notable that at this juncture, when palliative care consults from the original 





matched to the index hospitalization cohort. Despite employing validated methods for identifying 
palliative care consult occurrence, there were no coded PC events or any listed PC consults for 
this cohort of hospitalized HF patients. All PC consults listed were attributed to hospitalized 
cancer patients exclusively. 
With a full cohort of index hospitalizations defined (n =254), data abstraction proceeded 
with the planned chart review abstraction of mortality events, ejection fraction (EF%), 
ACE/ARB use,  presence/absence of ICD or CRT device implant, and IABP at the time of index 
hospitalization. It was at this juncture that insight was gained into the reason that there were no 
palliative care events listed in the abstracted data file. Due to the unique nature of the physician 
consult note naming convention, there is no standardized name for a “Palliative Care,” 
“Cardiology,” or any other type of consult. Each consult note is named according to the 
individual naming convention determined by the consulting physician. Thus, a cardiology 
consult may be listed as “Cardiology,” but it also may be listed as “Florida Heart.” All HFPC 
consults were consistently named “Palliative Care” and were thus available for abstraction as a 
part of chart review but could not be abstracted through automated means, as a standardized 
naming convention did not exist. Lastly, the final determination of mortality events at 90 days 
was largely determined by chart review and pharmacy utilization. Patient contact was required to 
determine mortality status in only two cases; one patient had moved out of the area, and the 
other’s family represented the patient as both alive and deceased. 
Transformation of Variables 
All vital sign and laboratory values were normally distributed, including initial systolic 
blood pressure (SBP), initial heart rate (HR), initial sodium (Na), initial blood urea nitrogen 





and initial hemoglobin A1C (Hgb A1C; see Appendix A7). Despite the presence of normal 
distributions for each of these variables, it was important to stratify these variables on established 
laboratory normals, which provided a greater level of clinical meaningfulness. While both 
continuous and stratified values are equivalent for the purposes of statistical analysis, the 
creation of clinically meaningful strata facilitates clinically applicable interpretation of results. 
For example, outcomes for patients that are hypotensive versus normotensive versus 
hypertensive are more clinically applicable than the statistically equivalent but less meaningful 
outcomes for single gradations of blood pressure or any other vital sign or laboratory value 
metric included in the model. In addition, directionality may not always be implicit in a 
continuous variable and would be a source of confusion in the interpretation of results. In this 
dataset, a very low or very high SBP or Na is clinically meaningful; that same interpretation does 
not apply to Hemoglobin (low is bad) or Cr (high is bad).  
Stratification enables analysis against a pre-defined ‘normal.’ Categorical variable coding 
enabled the specification of a defined reference population and will allow the reader to draw 
meaningful conclusions more easily about the interpretation of the statistical associations with 
the outcome of interest. For example, mid-range or normal range of SBP was defined as the 
reference population, while the high range of values for EF% was defined as the ‘normal’ 
reference, and the low range of values for Cr was defined as the ‘normal’ reference group (See 






An overview of the data collection process and resulting population (n) is best reviewed 
with the CONSORT diagram. The CONSORT flow diagram template was developed for 
standardized reporting of randomized clinical trials (Schulz et al., 2010). It was adapted to 
illustrate the research plan and outcomes for data collection in this investigation. Table 2 shows 
the index hospitalization for live HF discharges between October 1, 2019, and December 31, 
2019. 
Table 2  
Index Hospitalization for live HF Discharges: Oct. 1 – Dec. 31, 2019 
Index Hospitalization for Live HF Discharges: Oct 1 - Dec. 31, 2019 
n=250 
Exclusions:     Age < 18 
      Transfer to another acute care hospital / psychiatric   
      hospital 
      Left hospital against medical advice 
      Hospitalizations for same condition within 30 days   
      of an index hospitalization were not considered   
      index events. 
      Patients alive but without at least 90 days of post-  
      discharge follow-up. 
 
     Palliative Care Consult - Yes 
      n=92 
Palliative Care Consult - No 
n=142 
     Propensity-matched cohort30 




30 This procedure excluded those that were so low on propensity scoring that likelihood to 





Excluded criteria used by Centers for Medicare and Medicaid Services (CMS) to calculate 
hospital mortality and readmission performance, but not used in this study: 
 exclusion of patients who did not have a full year of pre-admission enrollment in 
Medicare 
 exclusion of patients alive but without at least 30 days of post-discharge follow-up. 
Data Analysis 
Data analysis was conducted in accordance with the a priori outlined data analysis plan. 
Logistic regression was used to assess the association of the independent variables of 90-day 
mortality, HFPC consult, and propensity score (severity) against the primary outcome of interest, 
90-day hospital readmission. The analysis yielded statistically significant findings in the 
propensity-matched cohort; there were similar statistically significant findings in the overall 
unmatched study population. Key steps in this final analysis included:   
1. Logistic regression of the primary research question of interest, whether 90-day 
hospital readmissions are influenced by HFPC consult after controlling for mortality 
and severity. 
2. An analysis of demographic characteristics of the overall unmatched study population 
demonstrated statistically significant population differences that could confound the 
outcome of interest.  
3. Propensity-matching enabled the creation of cohorts that were similar in severity and 
eliminated the potentially confounding population differences.  
 
propensity scoring that likelihood of PC consult was a certainty, n=132 was the final number 





4. Demographic characteristics of the propensity-matched population demonstrated 
similarity across a broad array of characteristics, with no residual demographic 
statistical differences.  
5. A more in-depth analysis of risk factors predicting the occurrence of an HFPC consult 
was conducted with logistic regression of the individual predictor study variables for 
the outcome of HFPC.  
6. A more in-depth analysis of time to readmission with survival analysis found 
statistically significant differences in the survival curve of time to readmission 
between patients who received an HFPC consult and those that did not. Findings were 
statistically significant in both the overall unmatched study population as well as the 
propensity-matched cohort. 
Logistic Regression 
 Logistic regression was employed to assess the primary research question of this 
investigation. The primary outcome of interest, 90-day hospital readmission, was predicted by 
the independent variables of 90-day mortality, HFPC consult and propensity score (severity; see 
Table 3). Logistic regression was most applicable with a binary outcome of 90-day readmission 
(Y/N) and predictors that were binary (90-day mortality and HFPC consult), while propensity 
score was a continuous variable.  
Propensity Matched Model. Outcomes of the logistic regression of the propensity-
matched model found that for every unit reduction in 90-day hospital readmission, 
contributing factors were a: 
 Statistically significant 1.468 increase in no HFPC consult (reduction in HFPC 





 .482 increase in mortality (no survivorship at 90-day), p =.36 
 -0.631 reduction in severity, p =.50 
 Palliative Care OR 4.3, 95% CI [1.8 - 10.6]  
Table 3 shows the logistic regression of propensity-matched 90-day readmissions. 
Table 3 
Logistic Regression of Propensity-Matched 90-Day Readmissions 
 B S.E. Wald df Sig. Exp(B) 
Palliative Care Consult (No) 1.468 .455 10.418 1 .001 4.342 
Survivor @ 90-day (No) .482 .531 .827 1 .363 1.620 
Propensity_Match -.631 .944 .447 1 .504 .532 
Constant -.779 .537 2.105 1 .147 .459 
This analysis indicates that after controlling for mortality and severity, there is a 
statistically significant association between no HFPC consult and no 90-day hospital 
readmission. In other words, HFPC consultation is statistically significantly associated with 
hospital readmission within 90-day of discharge, after controlling for both mortality and severity. 
For every 1.5 HFPC consults performed, one 90-day hospital readmission will be predicted by 
this B trendline (e.g., if 30 HFPC consults are performed each month, 20 of those patients can be 
expected to have a hospital readmission within 90 days). The OR of 90-day hospital readmission 
for the HFPC consult cohort was OR 4.3, 95% CI [1.8 - 10.6], or patients who are appropriately 
targeted for an HFPC consult are four times more likely to have a 90-day hospital readmission 
than a patient who does not qualify for an HFPC consult. 
Non-propensity Matched Model. To assess the robustness of the model without 
propensity-matching, a calculation of logistic regression for the total population was performed. 





Table 4). Results were similar in that for every unit reduction in 90-day hospital readmission, 
contributing factors were:  
 statistically significant 1.44 increase in no HFPC consult (reduction in HFPC 
consult), p =.001  
 0.611 increase in mortality (no survivorship at 90-day), p =.12  
 .460 increase in severity (propensity score), p =.44 
 Palliative Care OR 4.2, 95% CI [1.8 - 10.1]. 
Table 4 
Logistic Regression of Un-Matched 90-Day Readmissions 
  
 
 B S.E. Wald df Sig. Exp(B) 
Palliative Care Consult (No) 1.442 .444 10.546 1 .001 4.231 
Survivor @ 90-day (No) .611 .388 2.486 1 .115 1.843 
Propensity_Match .460 .596 .594 1 .441 1.584 
Constant -.944 .491 3.701 1 .054 .389 
This analysis demonstrated the robustness of the model in that even when the broader 
non-propensity matched population is used, statistically significant negative associations persist 
between HFPC consult and 90-day hospital readmission. In other words, HFPC consultation 
remains statistically significantly associated with hospital readmission within 90-day of hospital 
discharge after controlling for mortality and severity, even when outliers that were initially 
restricted from the propensity-matched analysis are included. 
Demographics -Total Population. Evaluation of the demographic characteristics of 
populations to be compared in a statistical analysis is important to ensure that there are no 
significant differences in the two populations that could confound the outcomes of the analysis. 





demographic differences are the primary cause of observed outcomes. There are numerous 
statistically significant differences between the cohort that had an observed palliative care 
consult compared to the cohort that did not. Table 5 demonstrates these differences.  
Table 5 
Demographic Characteristics - Total Un-Matched Study Population 
 
 
Palliative Care Consult 
___________________________ 
 
No Yes *p31 
Count 
Column 
N % Mean Count 
Column 
N % Mean 
 
                                               
 
Age cohort 
< 55 35 23.0%  17 17.3%   
55-75 70 46.1%  38 38.8%   
75+ 47 30.9%  43   43.9%*  .037 
Gender Female 71 46.7%  56 57.1%   
Male 81 53.3%  42 42.9%   
Do Not 
Resuscitate 
. 148   97.4%*  85 86.7%  .001 
DNR 4 2.6%  13   13.3%*  .001 
Primary 
Insurance 
Commercial 102 67.1%  55 56.1%   
Medicaid 6 3.9%  1 1.0%   
Medicare 44 28.9%  42   42.9%*  .024 
Secondary 
Insurance 
None 76   50.0%*  34 34.7%  .017 
Commercial 47 30.9%  40 40.8%   
Medicaid 26 17.1%  23 23.5%   
Medicare 3 2.0%  1 1.0%   
Ejection Fraction % (Low)   .41   .43  
Ejection 
Fraction cohort 









31 Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table 





Table 5 continued 
Demographic Characteristics - Total Un-Matched Study Population 
 
 
Palliative Care Consult 
___________________________ 
 
No Yes *p31 
Count 
Column 
N % Mean Count 
Column 
N % Mean 
 
                                               
 
 .50+ Preserved 53 35.3%  42 43.8%   
Ejection Fraction % (High)   .46   .47  
AICD or CRT-
D Implant 
No 111 73.0%  74 75.5%   
Yes 41 27.0%  24 24.5%   
ACE or ARB 
Prescribed 
No 55 36.2%  57   58.2%*  .001 
Yes 97   63.8%*  41 41.8%  .001 
Guideline 
Adherence 
No 63 41.4%  60   61.2%*  .002 
Yes 89   58.6%*  38 38.8%  .002 
Length of Stay   5   8  
Hospitalization 
duration 
Admission 57 37.5%  36 36.7%   
Observation 60   39.5%*  19 19.4%  .001 
Prolonged 35 23.0%  43   43.9%*  .001 
Discharge 
disposition 



























31 Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table 





Table 5 continued 
Demographic Characteristics - Total Un-Matched Study Population 
 
 
Palliative Care Consult 
___________________________ 
 
No Yes *p31 
Count 
Column 
N % Mean Count 
Column 
N % Mean 
 
                                               
 











23   23.5%* 
 .024 
90-day Readmit No 99   65.1%*  39 39.8%  .000 
Yes 53 34.9%  59   60.2%*  .000 
Survivor @ 90-
day 
No 19 12.5%  26   26.5%*  005 
Yes 133   87.5%*  72 73.5%  .005 
BP Hypertension 87 57.2%  59 60.2%   
Hypotension 0 0.0%  2 2.0%   
Normal 65 42.8%  37 37.8%   
HR. Normal 108 71.1%  64 65.3%   
Bradycardia 9 5.9%  3 3.1%   
Tachycardia 35 23.0%  31 31.6%   
Na Hypernatremia 4 2.7%  3 3.1%   
Hyponatremia 26 17.4%  18 18.4%   
Normal 119 79.9%  77 78.6%   
BUN/Cr Low 20 13.4%  11 11.2%   
Normal 83 55.7%  54 55.1%   
Renal  46 30.9%  33 33.7%   
Cr High 26 17.6%  13 13.7%   
 
31 Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table 





Table 5 continued 
Demographic Characteristics - Total Un-Matched Study Population 
 
 
Palliative Care Consult 
___________________________ 
 
No Yes *p31 
Count 
Column 
N % Mean Count 
Column 
N % Mean 
 
                                               
 
 Elevated 38 25.7%  37   38.9%*  .029 
Normal 84 56.8%  45 47.4%   
Hgb Anemia 79 53.0%  58 59.2%   
Normal 69 46.3%  40 40.8%   
Polycythemia 1 0.7%  0 0.0%   
Hgb A1C Normal 21 42.0%  18 60.0%   









No 145 95.4%  95 96.9%   
Yes 7 4.6%  3 3.1%   
Intra Aortic 
Balloon Pump 
No 152 100.0%  97 99.0%   
Yes 0 0.0%  1 1.0%   
Tobacco Use Cognitive Def 0 0.0%  0 0.0%   





















31 Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table 





Table 5 continued 
Demographic Characteristics - Total Un-Matched Study Population 
 
 
Palliative Care Consult 
___________________________ 
 
No Yes *p31 
Count 
Column 
N % Mean Count 
Column 
N % Mean 
 
                                               
 






AIDS No 151 99.3%  96 98.0%   
Yes 1 0.7%  2 2.0%   
Alcohol abuse No 151 99.3%  96 98.0%   
Yes 1 0.7%  2 2.0%   
Alcohol abuse 
w mild liver dz 
No 152 100%  98 100%   
Yes 0 0.0%  0 0.0%   
Deficiency 
Anemias 
No 117   77%*  64 65.3%  .044 
Yes 35 23.0%  34   34.7%*  .044 
Arthropathies No 145 95.4%  94 95.9%   
Yes 7 4.6%  4 4.1%   
Chronic blood 
loss anemia 
No 151 99.3%  97 99.0%   
Yes 1 0.7%  1 1.0%   
Leukemia No 152 100.0%  97 99.0%   
Yes 0 0.0%  1 1.0%   
Lymphoma No 150 98.7%  96 98.0%   
Yes 2 1.3%  2 2.0%   
Metastatic 
cancer 
No 151 99.3%  97 99.0%   




31 Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table 





Table 5 continued 
Demographic Characteristics - Total Un-Matched Study Population 
 
 
Palliative Care Consult 
___________________________ 
 
No Yes *p31 
Count 
Column 
N % Mean Count 
Column 
N % Mean 
 
                                               
 
Solid tumor w/o 
metastasis,insitu 
 
No 152 100%  98 100%   
Yes 0 0.0%  0 0.0%   
Solid tumor w/o 
mets, malignant 
No 149 98.0%  96 98.0%   
Yes 3 2.0%  2 2.0%   
Cerebrovascular 
disease - POA 
No 148 97.4%  95 96.9%   
Yes 4 2.6%  3 3.1%   
Cerebrovascular 
disease - seq 
No 152 100%  96 98.0%   
Yes 0 0.0%  2 2.0%   
Cerebrovascular 
dz - paralysis 
No 151   99.3%*  91 92.9%  .014 
Yes 1 0.7%  7   7.1%*  .014 
Congestive 
heart failure 
No 16 10.5%  8 8.2%   
Yes 136 89.5%  90 91.8%   
CHF w HTN, 
complicated 
No 42 27.6%  18 18.4%   
Yes 110 72.4%  80 81.6%   
CHF w HTN, w 
renal failure 
No 144 94.7%  91 92.9%   
Yes 8 5.3%  7 7.1%   
Coagulopathy No 143 94.1%*  83 84.7%   
Yes 9 5.9%  15   15.3%*   
Dementia No 142 93.4%  88 89.8%   
Yes 10 6.6%  10 10.2%   
Depression No 139 91.4%  84 85.7%   
 
 
31 Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table 





Table 5 continued 
Demographic Characteristics - Total Un-Matched Study Population 
 
 
Palliative Care Consult 
___________________________ 
 
No Yes *p31 
Count 
Column 
N % Mean Count 
Column 
N % Mean 
 
                                               
 
 Yes 13 8.6%  14 14.3%   
Diabetes w 
chronic comp 
No 87 57.2%  58 59.2%   
Yes 65 42.8%  40 40.8%   
Diabetes w/o 
chronic comp 
No 137 90.1%  88 89.8%   
Yes 15 9.9%  10 10.2%   
Drug abuse No 145 95.4%  94 95.9%   
Yes 7 4.6%  4 4.1%   
Drug abuse w 
psychoses 
No 152 100.0%  98 100.0%   
Yes 0 0.0%  0 0.0%   
Hypertension, 
complicated 
No 132 86.8%  91 92.9%   
Yes 20 13.2%  7 7.1%   
Hypertension, w 
renal failure 
No 151 99.3%  98 100.0%   
Yes 1 0.7%  0 0.0%   
Hypertension, 
uncomplicated 
No 124 81.6%  88 89.8%   
Yes 28 18.4%  10 10.2%   
Liver disease, 
mild 
No 148 97.4%  92 93.9%   
Yes 4 2.6%  6 6.1%   
Liver disease, 
mod to severe 
No 151 99.3%  96 98.0%   
Yes 1 0.7%  2 2.0%   
Chronic 
pulmonary dz 
No 100 65.8%  54 55.1%   
Yes 52 34.2%  44 44.9%   
 
 
31 Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table 





Table 5 continued 
Demographic Characteristics - Total Un-Matched Study Population 
 
 
Palliative Care Consult 
___________________________ 
 
No Yes *p31 
Count 
Column 
N % Mean Count 
Column 
N % Mean 
 




No 151 99.3%  95 96.9%   
Yes 1 0.7%  3 3.1%   
Other neuro-
logical disorders 
No 137 90.1%  85 86.7%   
Yes 15 9.9%  13 13.3%   
Seizures and 
epilepsy 
No 149 98.0%  96 98.0%   
Yes 3 2.0%  2 2.0%   
Obesity No 89 58.6%  56 57.1%   
Yes 63 41.4%  42 42.9%   
Paralysis No 151 99.3%  95 96.9%   
Yes 1 0.7%  3 3.1%   
Peripheral 
vascular disease 
No 139 91.4%  90 91.8%   
Yes 13 8.6%  8 8.2%   
Psychoses No 149 98.0%  97 99.0%   
Yes 3 2.0%  1 1.0%   
Pulmonary 
circulation dz 
No 140   92.1%*  74 75.5%  .000 
Yes 12 7.9%  24   24.5%*  .000 
Renal failure, 
moderate 
No 117   77.0%*  64 65.3%  .044 
Yes 35 23.0%  34   34.7%*  .044 
Renal failure, 
severe 
No 135 88.8%  84 85.7%   
Yes 17 11.2%  14 14.3%   
Hypothyroidism No 131 86.2%  75 76.5%   
 
 
31 Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table 





Table 5 continued 
Demographic Characteristics - Total Un-Matched Study Population 
 
 
Palliative Care Consult 
___________________________ 
 
No Yes *p31 
Count 
Column 
N % Mean Count 
Column 
N % Mean 
 
                                               
 
 Yes 21 13.8%  23 23.5%   
Other thyroid 
disorders 
No 151 99.3%  98 100.0%   
Yes 1 0.7%  0 0.0%   
Peptic ulcer 
with bleeding 
No 148 97.4%  96 98.0%   
Yes 4 2.6%  2 2.0%   
Valvular disease No 121   79.6%*  60 61.2%  .002 
Yes 31 20.4%  38   38.8%*  .002 
Weight loss No 146   96.1%*  82 83.7%  .001 
Yes 6 3.9%  16   16.3%*  .001 
These statistically significant population differences are likely to confound the outcome of 
interest; thus, it is important to create cohorts that are matched on their likelihood or propensity 
to receive a palliative care consult.  
Propensity-Matching. The population cohort was matched on propensity or the 
likelihood that two individuals who did and did not receive HFPC consult were otherwise 
similarly matched on other markers of acute illness severity (lab values and vital signs), 
prevention (HF guideline adherence), demographic characteristics, and comorbidities. A 
propensity score was calculated in SPSS version 27 for each case as a regression of all 
demographic characteristics thus far described (see Figure 1). SPSS version 27 was used to 
 
31 Tests are adjusted for all pairwise comparisons within a row of each innermost sub-table 





perform a regression of all variables collected, including demographic characteristics of age, 
gender, and insurance; prevention characteristics of adherence to evidence-based HF treatment, 
including tobacco use, drug therapy, and electrical therapy; index hospitalization severity 
markers, including selected laboratory values and vital signs present on arrival, DNR status, 
hospitalization duration, advanced interventions required, discharge disposition, and 
comorbidities. This regression analysis generated a propensity score that enabled matching of the 
HFPC and non-HFPC cohorts. The propensity score was then used as a continuous variable to 
match patients in the non-HFPC consult cohort. Multiple non-HFPC consult patients could be 
matched to HFPC consult patients with similar characteristics, preserving as much of the data as 
possible.  
At the extremes of scoring, there were a sizable number of patients (n =102) that could 
not be matched to similar peers in the non-HFPC consult cohort because their score was so low 
(indicating minimal severity markers) that no HFPC consult was a certainty. Likewise, at the 
other end of the spectrum, there was a sizable (n =102) number of patients who could not be 
matched to a similar peer in the non-HFPC consult cohort because their score was so high 
(indicating numerous severity markers), predicting a certain likelihood of HFPC consult. Thus, 
propensity matching helped to achieve a more homogeneous population with less variability, 











Propensity Score by HFPC Consult 
 
 
Demographics - Propensity-Matched Cohort. The resulting matched cohort (n =132) is 
more homogeneous, and both HFPC and non-HFPC cohorts are equivalently matched on 
demographic characteristics (see Table 4). One hundred and two patients were eliminated as 
unmatched, which is a significant loss of data but reflects the extremes of propensity scoring. 
Those at the extremes did not exhibit sufficient variability to contribute to a meaningful answer 
in the final analysis. (For example, all patients that did not match at the low end of propensity 
had no palliative care consult, while all patients that did not match at the high end of propensity 
scoring had a palliative care consult. Chi-square testing of the total population demographic 
characteristics demonstrated statistically significant differences between the population receiving 
HFPC consult and the population not receiving HFPC consult p <.0001 prior to matching and p 
=.077 after matching (see Appendix 10). Likewise, after matching, the range of propensity scores 
was minimized, and standard deviations were likewise minimized compared to the total 
population cohort, creating a more homogeneous population and limiting the ability of extreme 





Table 6  





Matched 32(132) Unmatched 33(102) 
Palliative Care Consult Palliative Care Consult 
No Yes No Yes 
Count 
Column 
N % Count 
Column 
N % Count 
Column 
N % Count 
Column 
N % 
Age cohort < 55 23 24.0% 7 19.4% 10 21.7% 9 16.1% 
55-75 40 41.7% 14 38.9% 25 54.3% 20 35.7% 
75+ 33 34.4% 15 41.7% 11 23.9% 27 48.2% 
Gender Female 46 47.9% 17 47.2% 21 45.7% 36 64.3% 
Male 50 52.1% 19 52.8% 25 54.3% 20 35.7% 
Do Not 
Resuscitate 
. 95 99.0% 34 94.4% 44 95.7% 46 82.1% 
DNR 1 1.0% 2 5.6% 2 4.3% 10 17.9% 
Primary 
Insurance 
Commercial 67 69.8% 21 58.3% 29 63.0% 31 55.4% 
Medicaid     6 13.0%   
Medicare 29 30.2% 15 41.7% 11 23.9% 25 44.6% 
Ejection Fraction 
cohort 
.25 Reduced 25 26.0% 10 27.8% 10 21.7% 14 25.0% 
.25-.50 Borderli 35 36.5% 12 33.3% 21 45.7% 16 28.6% 
.50+ Preserved 36 37.5% 14 38.9% 15 32.6% 26 46.4% 
AICD or CRT-D 
Implant 
No 70 72.9% 25 69.4% 34 73.9% 43 76.8% 
Yes 26 27.1% 11 30.6% 12 26.1% 13 23.2% 
Guideline 
Adherence 
No 41 42.7% 15 41.7% 18 39.1% 40 71.4% 
Yes 55 57.3% 21 58.3% 28 60.9% 16 28.6% 
Hospitalization 
duration 
Admission 37 38.5% 14 38.9% 16 34.8% 20 35.7% 
Observation 33 34.4% 11 30.6% 21 45.7% 7 12.5% 
 
 
32 No statistically significant differences 
33 Unmatched demographics reflect those at the extremes of the propensity scoring scale such 
that matching was not feasible. As such it is not appropriate to test population statistically 





Table 6 continued 





Matched 32(132) Unmatched 33(102) 
Palliative Care Consult Palliative Care Consult 
No Yes No Yes 
Count 
Column 
N % Count 
Column 
N % Count 
Column 




 Prolonged 26 27.1% 11 30.6% 9 19.6% 29 51.8% 
Discharge 
disposition 
Home – 01 58 60.4% 20 55.6% 35 76.1% 13 23.2% 
Home w 
Services 
21 21.9% 6 16.7% 6 13.0% 15 26.8% 
Hospice – 
Home 
      3 5.4% 
Hospice – 
Facility 
      7 12.5% 
Inpt Rehab 
Facility 
1 1.0%     2 3.6% 
LTC Hospital 2 2.1% 1 2.8%   1 1.8% 
Short Term 
Inpatient 
    1 2.2% 1 1.8% 
SNF -Skilled 
Nurse  
14 14.6% 9 25.0% 4 8.7% 14 25.0% 
BP Hypertension 59 61.5% 22 61.1% 23 50.0% 35 62.5% 
Hypotension       2 3.6% 
Normal 37 38.5% 14 38.9% 23 50.0% 19 33.9% 
HR. Normal 71 74.0% 26 72.2% 30 65.2% 36 64.3% 
Bradycardia 2 2.1% 1 2.8% 6 13.0% 2 3.6% 
Tachycardia 23 24.0% 9 25.0% 10 21.7% 18 32.1% 
 
32 No statistically significant differences 
33 Unmatched demographics reflect those at the extremes of the propensity scoring scale such 
that matching was not feasible. As such it is not appropriate to test population statistically 





Table 6 continued 





Matched 32(132) Unmatched 33(102) 
Palliative Care Consult Palliative Care Consult 
No Yes No Yes 
Count 
Column 
N % Count 
Column 
N % Count 
Column 




Na Hypernatremia 4 4.2% 1 2.8%   2 3.6% 
Hyponatremia 13 13.5% 6 16.7% 12 26.1% 9 16.1% 
Normal 79 82.3% 29 80.6% 34 73.9% 45 80.4% 
BUN/Cr Low 10 10.4% 3 8.3% 8 17.4% 4 7.1% 
Normal 53 55.2% 20 55.6% 25 54.3% 33 58.9% 
Renal 
compromise 
33 34.4% 13 36.1% 13 28.3% 19 33.9% 
Cr Abnormal – 
High 
14 14.6% 6 16.7% 10 21.7% 6 10.7% 
Elevated 25 26.0% 9 25.0% 10 21.7% 28 50.0% 
Normal 57 59.4% 21 58.3% 26 56.5% 22 39.3% 
Hgb Anemia 52 54.2% 21 58.3% 24 52.2% 32 57.1% 
Normal 44 45.8% 15 41.7% 22 47.8% 24 42.9% 
Hgb A1C Normal 12 38.7% 5 50.0% 6 40.0% 13 68.4% 
Poor Control 9 29.0% 5 50.0% 7 46.7% 6 31.6% 
Very Poor 
Control 
10 32.3%   2 13.3%   
Pressors required No 94 97.9% 36 100% 42 91.3% 53 94.6% 
Yes 2 2.1%   4 8.7% 3 5.4% 
Intra Aortic 
Balloon Pump 
No 96 100% 36 100% 46 100% 55 98.2% 
 
32 No statistically significant differences 
33 Unmatched demographics reflect those at the extremes of the propensity scoring scale such 
that matching was not feasible. As such it is not appropriate to test population statistically 





Table 6 continued 





Matched 32(132) Unmatched 33(102) 
Palliative Care Consult Palliative Care Consult 
No Yes No Yes 
Count 
Column 
N % Count 
Column 
N % Count 
Column 




 Yes       1 1.8% 
Tobacco Use Cognitive 
Deficits 
        
         
Never 53 55.2% 18 50.0% 25 54.3% 36 64.3% 
         
Last Tobacco 
Use <30d 
13 13.5% 4 11.1% 9 19.6% 6 10.7% 
Last Tobacco 
Use >1yr 
27 28.1% 13 36.1% 8 17.4% 9 16.1% 
Last Tobacco 
Use >30d <1yr 
2 2.1% 1 2.8% 2 4.3% 3 5.4% 
Unable to 
answer 
1 1.0%   2 4.3% 2 3.6% 
AIDS No 96 100% 36 100% 46 100% 54 96.4% 
Yes       2 3.6% 
Alcohol abuse No 95 99.0% 36 100% 46 100% 55 98.2% 
Yes 1 1.0%     1 1.8% 
Alcohol abuse w/ 
mild liver disease 
No 96 100% 36 100% 46 100% 56 100% 
Yes         
Deficiency 
Anemias 
No 72 75.0% 26 72.2% 37 80.4% 37 66.1% 
Yes 24 25.0% 10 27.8% 9 19.6% 19 33.9% 
 
 
32 No statistically significant differences 
33 Unmatched demographics reflect those at the extremes of the propensity scoring scale such 
that matching was not feasible. As such it is not appropriate to test population statistically 





Table 6 continued 





Matched 32(132) Unmatched 33(102) 
Palliative Care Consult Palliative Care Consult 
No Yes No Yes 
Count 
Column 
N % Count 
Column 
N % Count 
Column 




Arthropathies No 90 93.8% 35 97.2% 45 97.8% 53 94.6% 
Yes 6 6.3% 1 2.8% 1 2.2% 3 5.4% 
Chronic blood 
loss anemia 
No 96 100% 36 100% 45 97.8% 55 98.2% 
Yes     1 2.2% 1 1.8% 
Leukemia No 96 100% 36 100% 46 100% 55 98.2% 
Yes       1 1.8% 
Lymphoma No 94 97.9% 35 97.2% 46 100% 56 100% 
Yes 2 2.1% 1 2.8%     
Metastatic cancer No 95 99.0% 35 97.2% 46 100% 56 100% 
Yes 1 1.0% 1 2.8%     
Solid tumor w/o 
metastasis, in situ 
No 96 100% 36 100% 46 100% 56 100% 
Yes         
Solid tumor w/o 
mets, malignant 
No 95 99.0% 35 97.2% 44 95.7% 55 98.2% 
Yes 1 1.0% 1 2.8% 2 4.3% 1 1.8% 
Cerebrovascular 
disease - POA 
No 94 97.9% 35 97.2% 45 97.8% 54 96.4% 
Yes 2 2.1% 1 2.8% 1 2.2% 2 3.6% 
Cerebrovascular 
disease - seq 
No 96 100% 36 100% 46 100% 55 98.2% 
Yes       1 1.8% 
Cerebrovascular 
disease -paralysis 
No 95 99.0% 36 100% 46 100% 50 89.3% 
 
32 No statistically significant differences 
33 Unmatched demographics reflect those at the extremes of the propensity scoring scale such 
that matching was not feasible. As such it is not appropriate to test population statistically 





Table 6 continued 





Matched 32(132) Unmatched 33(102) 
Palliative Care Consult Palliative Care Consult 
No Yes No Yes 
Count 
Column 
N % Count 
Column 
N % Count 
Column 




 Yes 1 1.0%     6 10.7% 
Congestive heart 
failure 
No 9 9.4% 4 11.1% 5 10.9% 3 5.4% 




No 21 21.9% 6 16.7% 16 34.8% 8 14.3% 
Yes 75 78.1% 30 83.3% 30 65.2% 48 85.7% 
CHF with 
hypertension w 
renal failure, sev 
No 91 94.8% 34 94.4% 45 97.8% 54 96.4% 
Yes 5 5.2% 2 5.6% 1 2.2% 2 3.6% 
Coagulopathy No 90 93.8% 35 97.2% 44 95.7% 42 75.0% 
Yes 6 6.3% 1 2.8% 2 4.3% 14 25.0% 
Dementia No 89 92.7% 32 88.9% 43 93.5% 51 91.1% 
Yes 7 7.3% 4 11.1% 3 6.5% 5 8.9% 
Depression No 87 90.6% 32 88.9% 42 91.3% 49 87.5% 
Yes 9 9.4% 4 11.1% 4 8.7% 7 12.5% 
Diabetes with 
chronic comp 
No 55 57.3% 22 61.1% 24 52.2% 33 58.9% 
Yes 41 42.7% 14 38.9% 22 47.8% 23 41.1% 
Diabetes w/o 
chronic comp 
No 83 86.5% 31 86.1% 46 100% 51 91.1% 
Yes 13 13.5% 5 13.9%   5 8.9% 
Drug abuse No 91 94.8% 34 94.4% 45 97.8% 54 96.4% 
 
32 No statistically significant differences 
33 Unmatched demographics reflect those at the extremes of the propensity scoring scale such 
that matching was not feasible. As such it is not appropriate to test population statistically 





Table 6 continued 





Matched 32(132) Unmatched 33(102) 
Palliative Care Consult Palliative Care Consult 
No Yes No Yes 
Count 
Column 
N % Count 
Column 
N % Count 
Column 




 Yes 5 5.2% 2 5.6% 1 2.2% 2 3.6% 
Drug abuse with 
psychoses 
No 96 100% 36 100% 46 100% 56 100% 
Yes         
Hypertension, 
complicated 
No 85 88.5% 33 91.7% 38 82.6% 53 94.6% 
Yes 11 11.5% 3 8.3% 8 17.4% 3 5.4% 
Hypertension, w/ 
renal failure, sev 
No 96 100% 36 100% 45 97.8% 56 100% 
Yes     1 2.2%   
Hypertension, 
uncomplicated 
No 78 81.3% 31 86.1% 39 84.8% 51 91.1% 
Yes 18 18.8% 5 13.9% 7 15.2% 5 8.9% 
Liver disease, 
mild 
No 95 99.0% 36 100% 44 95.7% 50 89.3% 
Yes 1 1.0%   2 4.3% 6 10.7% 
Liver disease, 
mod to sev 
No 95 99.0% 36 100% 46 100% 54 96.4% 
Yes 1 1.0%     2 3.6% 
Chronic 
pulmonary dz 
No 59 61.5% 22 61.1% 34 73.9% 29 51.8% 
Yes 37 38.5% 14 38.9% 12 26.1% 27 48.2% 
Neurological dz 
affecting mvmt 
No 95 99.0% 35 97.2% 46 100% 54 96.4% 
Yes 1 1.0% 1 2.8%   2 3.6% 
Other neuro-
logical disorders 
No 85 88.5% 32 88.9% 44 95.7% 47 83.9% 
Yes 11 11.5% 4 11.1% 2 4.3% 9 16.1% 
 
32 No statistically significant differences 
33 Unmatched demographics reflect those at the extremes of the propensity scoring scale such 
that matching was not feasible. As such it is not appropriate to test population statistically 





Table 6 continued 





Matched 32(132) Unmatched 33(102) 
Palliative Care Consult Palliative Care Consult 
No Yes No Yes 
Count 
Column 
N % Count 
Column 
N % Count 
Column 






No 94 97.9% 34 94.4% 45 97.8% 56 100% 
Yes 2 2.1% 2 5.6% 1 2.2%   
Obesity No 53 55.2% 19 52.8% 28 60.9% 34 60.7% 
Yes 43 44.8% 17 47.2% 18 39.1% 22 39.3% 
Paralysis No 95 99.0% 35 97.2% 46 100% 54 96.4% 
Yes 1 1.0% 1 2.8%   2 3.6% 
Peripheral 
vascular disease 
No 87 90.6% 33 91.7% 43 93.5% 52 92.9% 
Yes 9 9.4% 3 8.3% 3 6.5% 4 7.1% 
Psychoses No 94 97.9% 35 97.2% 45 97.8% 56 100% 
Yes 2 2.1% 1 2.8% 1 2.2%   
Pulmonary 
circulation dz 
No 84 87.5% 33 91.7% 46 100% 36 64.3% 
Yes 12 12.5% 3 8.3%   20 35.7% 
Renal failure, 
moderate 
No 73 76.0% 25 69.4% 35 76.1% 35 62.5% 
Yes 23 24.0% 11 30.6% 11 23.9% 21 37.5% 
Renal failure, 
severe 
No 86 89.6% 32 88.9% 42 91.3% 49 87.5% 
Yes 10 10.4% 4 11.1% 4 8.7% 7 12.5% 
Hypothyroidism No 83 86.5% 32 88.9% 39 84.8% 39 69.6% 
Yes 13 13.5% 4 11.1% 7 15.2% 17 30.4% 
 
 
32 No statistically significant differences 
33 Unmatched demographics reflect those at the extremes of the propensity scoring scale such 
that matching was not feasible. As such it is not appropriate to test population statistically 





Table 6 continued 





Matched 32(132) Unmatched 33(102) 
Palliative Care Consult Palliative Care Consult 
No Yes No Yes 
Count 
Column 
N % Count 
Column 
N % Count 
Column 






No 96 100% 36 100% 45 97.8% 56 100% 
Yes     1 2.2%   
Peptic ulcer with 
bleeding 
No 92 95.8% 35 97.2% 46 100% 55 98.2% 
Yes 4 4.2% 1 2.8%   1 1.8% 
Valvular disease No 72 75.0% 25 69.4% 41 89.1% 31 55.4% 
Yes 24 25.0% 11 30.6% 5 10.9% 25 44.6% 
Weight loss No 91 94.8% 34 94.4% 45 97.8% 43 76.8% 
Yes 5 5.2% 2 5.6% 1 2.2% 13 23.2% 
 
 Table 6 demonstrates that the resulting propensity-matched cohorts exhibit strong 
demographic similarities, and no statistically significant differences remain. The residual 
unmatched cohort included those that did not match into the propensity-matched cohort and 
illustrate characteristics of the outliers that were redacted during the process of propensity-
matching from the final propensity-matched cohort used in the final analysis. Importantly, 
ANOVA analysis of the total population and matched cohorts showed that even after matching, 
 
32 No statistically significant differences 
33 Unmatched demographics reflect those at the extremes of the propensity scoring scale such 
that matching was not feasible. As such it is not appropriate to test population statistically 





statistically significant differences in the mean remain between the HFPC consult x =.25, 95% CI 
[.21 - 29] and non-HFPC consult x =.42, 95% CI [.35-.49] cohorts (see Table 7).  
 Further analysis continued based on these findings. If the ANOVA had demonstrated a 
loss of statistical significance after matching, it would have been interpreted that matching 
eliminated all sources of difference, and further analysis would have been futile. Likewise, 
calculation of standardized differences (effect size) of the means before and after matching found 
a persistently strong effect size of Cohen’s d =0.86 in the unadjusted model and Cohen’s d =0.83 
in the propensity-matched model, indicating that there is no substantial loss of predictive ability 
after matching. 
Table 7  
Comparison of Means and Standardized Difference of Total Study Population vs. Propensity-
matched Cohort for Presence/Absence of HFPC Consult 
 
 Palliative Care Consult – No Palliative Care Consult - Yes Cohen’s 
d 















.16965 .13712 .20218 .19608 .73815 .67685 .79945 .29600 0.86 
Matched 
cohort 
.24879 .20879 .28759 .19444 .41754 .34612 .48896 .21107 0.83 
 
Odds Ratios Predictive of HFPC   
 While logistic regression was used to answer the primary research question of interest, 
whether 90-day hospital readmission is affected by HFPC consult after controlling for mortality 
and severity, it was also part of the a priori analysis plan to further evaluate the important 
contributing factors to the occurrence of an HFPC consult to gain insight into why a specific 





targeted. Logistic regression of the total population characteristics produced calculated odds or 
risk of each individual characteristic to contribute to the overall likelihood of a patient having an 
HFPC consult (see Table 8). Odds ratio is a measure of association that provides an indication of 
the effect size existing between the predicting factor and the outcome of interest.  
Table 8  





Characteristics Odds Ratio 
 
Age cohort <55  
 55-75   .180* 
 75+ .402 
Gender Gender (Female) 2.943 
Do Not Resuscitate Do Not Resuscitate 2.574 
Primary insurance Commercial  
 Medicaid .000 
 Medicare   3.670* 
Ejection Fraction cohort 50%+ Preserved  
 25% Reduced 3.035 
 25-50% Borderline .995 
AICD/CRT-D AICD or CRT-D Implant (Yes) 3.127 
Guideline Adherence Guideline Adherence (No) 2.475 
Hospitalization duration Admission  
 Observation 1.004 
 Prolonged .611 
Discharge disposition Home  
 Home w/ Home Health   5.342* 
 Hospice 4877036073.909 
 Inpatient Rehabilitation Facility 115.070 






Table 8 continued 





Characteristics Odds Ratio 
 
 Short Term Gen Hospital .000 
 Skilled Nursing Facility  13.418* 
Blood Pressure on arrival Normal  
 Hypertensive   3.672* 
 Hypotensive 74028849642.421 
HR on arrival Normal  
 Bradycardic .043 
 Tachycardic 3.569 
Na on arrival Normal  
 Hypernatremic 2.635 
 Hyponatremic .358 
BUN/Cr on arrival Low  
 Normal 3.639 
 Renal compromise 2.449 
Cr on arrival Normal  
 Abnormal .733 
 Elevated   7.509* 
Hgb on arrival Anemia  .550 
Pressors required Pressors required (Yes) .506 
IntraAortic Balloon Pump Intra Aortic Balloon Pump (Yes) 506772158989469180 
Tobacco Use Denies  
 Tobacco use < 30 d .158 
 Tobacco use > 1 yr .966 
 Tobacco Use >30d <1yr .148 
 Unable to answer .018 
Comorbidities coded AIDS 376707060855.6 






Table 8 continued 





Characteristics Odds Ratio 
 
 Deficiency Anemias 1.7 
 Arthropathies .027* 
 Chronic blood loss anemia 6.9 
 Leukemia 12130545869000848.0 
 Lymphoma .028 
 Metastatic cancer 806628941303.5 
 Solid tumor w/o mets, malignant .000 
 Cerebrovascular disease - POA 9.6 
 Cerebrovascular dz - sequelae 487343389861.8 
 Cerebrovascular dz - paralysis 10.4 
 Congestive heart failure   .047* 
 CHF with HTN, complicated 4.4 
 CHF with HTN w renal failure   66.8* 
 Coagulopathy 7.7 
 Dementia .6 
 Depression 1.1 
 Diabetes w/ chronic complications .3 
 Diabetes w/o chronic complications   19.0* 
 Drug abuse 3.1 
 Hypertension, complicated .2 
 Hypertension, comp with renal 
failure, severe 
.000 
 Hypertension, uncomplicated .4 
 Liver disease, mild 9.3 
 Liver disease, moderate to severe .2 







Table 8 continued 





Characteristics Odds Ratio 
 
 Neurological disorders affecting 
movement 
.3 
 Other neurological disorders .6 
 Seizures and epilepsy 8.2 
 Obesity 2.8 
 Paralysis 16.8 
 Peripheral vascular disease .75 
 Psychoses .91 
 Pulmonary circulation disease 8.9 
 Renal failure, moderate 1.9 
 Renal failure, severe 1.8 
 Hypothyroidism 1.0 
 Other thyroid disorders .22 
 Peptic ulcer with bleeding .2 
 Valvular disease   4.2* 
 Weight loss 6.8 
Note. Statistically significant factors p <.05 are signified by * 
*p <.05 
This sub-analysis demonstrates the underlying factors that are statistically significantly 
associated with HFPC consult, a key independent variable in the primary research question of 
interest, whether 90-day hospital readmission is affected by HFPC consult after controlling for 
90-day mortality and severity (propensity score). This sub-analysis provides context and clarity 
for interpreting the meaning of the primary study findings. From the primary analysis, it was 
shown that HFPC consultation is negatively associated with hospital readmission after 





understanding of the individual characteristics that are likely to produce an HFPC consult during 
an inpatient hospitalization. It includes age 55-75, Medicare insurance, discharge with home 
health services and discharge to SNF, hypertensive on admission, and elevated Cr on admission. 
Comorbidities likely to result in an HFPC consult include arthropathies, HF, HF with renal 
failure, Diabetes without chronic complications, COPD, and valvular disease. 
Survival Analysis 
 A further a priori planned sub-analysis that also provided additional context and clarity to 
the primary study findings is an analysis of time to hospital readmission which was used in the 
primary analysis as a binary outcome of 90-day hospital readmission (Y/N). However, hospital 
readmission can also be viewed as a continuous variable. The a priori plan to include survival 
analysis in the data analysis was to take full advantage of the data available on the temporal 
patterns of readmission that occur within the 90-day window of hospital readmission. Among the 
total unmatched population, the average time to hospital readmission for patients with no HFPC 
consult was 5.6 weeks, and 3.6 weeks for patients with an HFPC consult (see Table 9). This 
finding further describes the results in the preliminary logistic regression that noted the negative 
association between HFPC and no hospital readmission; as HFPC events increased, hospital 
readmission events were more frequent. 
Table 9 
Mean Time to Readmission, Weeks  
Palliative Care 




No 5.626 53 3.1240 
Yes 3.588 60 2.8264 






Hospital-related admissions were those that occurred within seven days of hospital 
discharge and were directly related to the hospitalization (Chin et al., 2016). HFPC-related 
admissions were those that occurred from 8-30 days post index hospitalization and account for 
more predominantly HFPC-related factors of patient management (Chin et al., 2016). While the 
majority of patients with no HFPC consult did not require readmission, a more flattened 
distribution of patients who received an HFPC consult experienced a readmission within the 90-
day observation period, perhaps indicating a more significant level of morbidity and 
complications requiring hospital readmission than the no HFPC consult cohort (see Figure 2). 
Figure 2 
Time to Hospital Readmission Stratified by Presence/Absence of HFPC Consult 
 
Likewise, a graphical depiction of the time to readmission (see Figure 3), stratified by HFPC 
consult for the entire study population, illustrates a strong tendency for earlier hospital 
readmission if the patient had an HFPC consult compared to the cohort that did not have an 






Distribution of Time to Readmission by HFPC Consult 
 
Patterns of hospital readmission stratified by cohorts that had an HFPC consult/no HFPC 
consult added additional clarity and context to the primary research question of interest that 
found a strong statistically significant relationship between 90-day hospital readmission and 
HFPC consult. Time to readmission happened more frequently in patients who have an HFPC 
consult. Readmissions occurred earlier in the post-discharge period and were strongly skewed to 
the immediate 30-day post-discharge period.  
Kaplan-Meier Survival Curve of Time to Readmission 
To gain further insight into the patterns of hospital readmission, survival analysis was 
chosen for this sub-analysis because it enables statistical analysis of time to event data, in this 
case, time to hospital readmission, stratified by cohorts, presence/absence of HFPC consult. The 
primary research question of interest demonstrated that HFPC consult was statistically 





and severity (propensity-score). Survival analysis provides additional insight into the differential 
burden of hospital readmission borne by the cohorts and illustrates the difficulties this population 
experiences with avoiding 90-day hospital readmission. A survival curve of time to readmission 
by HFPC consult was constructed for the entire study population (see Figure 4) and found 
statistically significant differences in the time to hospital readmission for the cohorts with Log 
Rank (Mantel-Cox) tests significant at <.0001, and Breslow (Generalized Wilcoxon) tests 
significant at <.0001. 
Figure 4 
Kaplan-Meier Survival Curve of Time to Readmission by HFPC Consult
 
In the second survival curve analysis, results were even more profound with the 
population restricted to the propensity-matched cohorts used in the primary logistic regression 





consult, the difference in the two curves was even greater and remained statistically significant 
by Log Rank (Mantel-Cox) tests significant at <.0001 and Breslow (Generalized Wilcoxon) tests 
significant at <.0001 (see Figure 5). 
Figure 5  
Kaplan-Meier Survival Curve of Time to Readmission Restricted to Propensity-matched HF 
Discharges 
 
     
This survival analysis demonstrated that <30% of HF patients who have an HFPC consult 
are unable to avoid hospital readmission for >90 days. Over 50% of HF patients who have an 
HFPC consult experience a hospital readmission within 30 days of discharge. Over 75% of HF 
patients who have an HFPC consult will have a hospital readmission within 90 days of discharge. 
Among patients who do not have an HFPC consult, >60% of patients will not require a hospital 







The data analysis of this investigation yielded a breadth of findings. Compilation of the 
final dataset identified an average of 83 patients per month with a primary diagnosis of HF. Data 
abstraction was facilitated by a robust data architecture that enabled an automated abstraction of 
a broad array of data variables. The need to re-sort, re-order and transform data variables from 
multiple raw data files to integrate them into a single dataset remains. For example, laboratory 
values are output listwise. For example, there is a ‘case’ for every lab value that requires re-
ordering such that all values appear as an individual variable for each case. Likewise, all coded 
comorbidities are output listwise and require selection of the comorbidities of interest before the 
data can be re-ordered and incorporated into the final dataset.   
Lastly, while evidence has previously suggested that the most valid and reliable method 
to abstract HFPC consultations was found to be an abstraction of the coded PC consult, it is 
important to note that this coded or ‘billed’ visit may not appear in an individual hospital 
database if that hospital does not directly bill for the service. Dependent on state regulations, 
third-party billing may allow the physician to bill the patient/insurance directly; thus, those codes 
do not appear on an abstraction of hospital administrative data. Also, the ease with which highly 
customizable data can be abstracted within the existing data architecture is dependent on whether 
a field is standardized and abstractable.  
In this investigation, zero-coded PC visits were abstracted. Abstraction of consults was 
likewise unfeasible because of the absence of standardized data abstraction fields. Within this 
data architecture, there were no standardized naming conventions for consults; thus, this 
individualization of the consult name meant that the HFPC consult events were not abstractable. 





individual hospital data architecture systems that may limit access to the occurrence of the event 
and underestimate the event occurrence. It is further offered as a caution to investigations that 
primarily rely on administrative coding data to assess the efficacy of HFPC consult interventions. 
Transformation of data once incorporated into the final dataset was necessary to enable 
clinically meaningful and interpretable data. While continuous data was available for laboratory 
and vital sign data, the meaning or clinical applicability of a single unit change in blood pressure 
was less important than the meaning and clinical applicability of a comparison of strata of blood 
pressure measurements. Comparison of hypertensive or hypotensive values to normal values was 
much more clinically meaningful and applicable than comparison of a systolic blood pressure 
value that varied from 99 to 100. Likewise, directionality may be a clinically important element 
but may not be appropriate for a parameter that exhibits reverse or bi-directionality. For example, 
Cr could be evaluated with a continuous measure as a low creatinine is ‘bad,’ and a high Cr is 
‘bad.’ Conversely, with BP, low and high values are ‘bad,’ while middle values are ‘normal. 
Similarly, EF percentages, with high values are ‘good,’ and low values are ‘bad.’ This insight is 
offered as an important finding and caution that it is important not only to use the data that is 
available (continuous) and statistically valid but to maintain awareness that transformation or 
stratification may be preferred to ensure those resulting findings are clinically meaningful. 
The CONSORT study summary format is a helpful tool to summarize important elements 
of a study investigation to convey important elements of the study construct. The construct is 
helpful to the reader and reviewers to understand the critical elements of the investigation. 
Logistic regression to evaluate the primary research question of interest, whether there was a 
statistically significant association between the dependent variable of 90-day hospital 





score (severity). In this model, no HFPC-consult was statistically significantly associated with no 
90-day hospital readmission, B =1.468, p <.001, OR 4.3, 95% CI [1.8-10.6]. Likewise, increased 
mortality was associated with no 90-day hospital readmission, although it was not statistically 
significant, B =.482, p =.36 (OR 1.8). Decreased severity was also associated with no 90-day 
hospital readmission B =-0.631, p =.504 (OR 1.6), but was not statistically significant (see Table 
3).  
These results reveal that avoidance of 90-day hospital readmission is best achieved by 
having no criteria for the performance of an HFPC-consult, experiencing a mortality event, or 
having fewer comorbidities. All of these elements: (1) having no criteria for the performance of 
an HFPC-consult, (2) experiencing a mortality event, or (3) having fewer comorbidities are all 
largely out of the control of any individual patient. Thus, while HFPC may be an important 
aspect of continuity of care and care planning for the HF patient, it is not a valid or effective 
method for reducing 90-day hospital readmissions. Patients with an acute decompensation of 
their HF, evidenced by abnormal key lab indicators on arrival or patients with numerous 
comorbidities or approaching end-of-life, are more likely to be referred for HFPC consult. In this 
investigation, HFPC consult was predicted by and served as a proxy for the HF patient who has 
an acute decompensation with abnormal lab values on admission, with numerous comorbidities, 
or approaching end-of-life. HFPC consultation has many values in the care and management of 
the HF patient. However, reducing 90-day hospital readmission is not an achievable goal. 
Conversely, HFPC consult should serve as a proxy signal to expect the increased frequency of 
admissions in a population with high morbidity approaching end-of-life. 
To evaluate the robustness of the model, the non-propensity matched model was analyzed 





readmission and no HFPC consult B =1.442, p <.001 (OR 4.2; see Table 4). Likewise, no 90-day 
hospital readmission was associated with a non-statistically significant .611, p =.115 increase in 
post-discharge mortality (OR 1.8) after controlling for HFPC consultation and severity. Lastly, 
90-day hospital readmission was associated with a non-statistically significant .0.46 increase in 
severity (propensity score; OR 1.6) after controlling for mortality and HFPC consult. It is 
congruent that avoidance of 90-day hospital readmission would be associated with no HFPC 
consult (less sick) and increased mortality (patients died); however, it is incongruent that 
increased severity would be associated with no 90-day readmission and perhaps reflect the 
influence of the inclusion of outliers redacted in the propensity-matched model. 
An important aspect of any statistical analysis is an assessment of underlying 
demographic differences that may exist and potentially confound the results of the planned 
analysis. The demographic characteristics of the total study population, n =234, after exclusion 
of ineligible subjects, clearly illustrated important and statistically significant differences in the 
study cohort that received an HFPC consult compared to the cohort that did not (see Table 5). 
There were statistically significant differences in age, DNR status, primary insurance, secondary 
insurance, adherence to evidence-based guidelines for the treatment of HF, specifically 
ACE/ARB use, duration of hospitalization, discharge disposition, 90-day readmission, mortality, 
and renal compromise on admission. There were further statistically significant differences in 
comorbidities, including deficiency anemias, paralysis as a sequela to cerebrovascular disease, 
pulmonary circulation disease, renal failure, valvular heart disease, and weight loss. 
Propensity-matching was planned during the initial study plan to ensure comparable 
study cohorts of individuals who did and did not have an HFPC consult. Propensity-matching 





demographic characteristics list. When incorporated in the final analysis, the propensity score 
ensures that comparisons are made between subjects who are a best match on all characteristics 
with the exception of the outcome of interest, HFPC consultation. Thus, the investigator can be 
assured that a comparison is being made between homogeneous populations and not being 
influenced by outliers. 
The resulting propensity-matched cohort, n =132, demonstrated improved homogeneity 
with the absence of statistical significance for any individual characteristic (see Table 6). 
However, while propensity-matching achieved population homogeneity, it did not eradicate 
statistically significant differences between the HFPC consult and non-HFPC consult cohort with 
a mean propensity score of 0.25, 95% CI [0.21-0.29] in the no HFPC consult cohort, and the 
HFPC consult cohort demonstrating a mean of 0.42, 95% CI [0.35 - 0.49] (see Table 7). 
Likewise, a comparison of the standardized difference in the un-propensity matched cohort and 
propensity-matched cohort with Cohen’s d indicates a persistently strong effect size in both 
models, suggesting that there is no loss of the predictive ability of the model after matching (see 
Table 7). Cohen’s d measures the magnitude of the relationship between the variable measured 
(propensity score) and the outcome of interest (HFPC consult). 
To further investigate the relationship between HFPC consult and hospital readmission as 
part of the a priori analysis plan, a logistic regression of the model variables was performed to 
obtain the associated OR or risk of individual demographic characteristics to contribute to the 
occurrence of a palliative care consult (see Table 8). Statistically significant and clinically 
important associations were found with these characteristics: recipient having Medicare 
insurance (OR 3.7), discharge home with home health (OR 5.3), discharge to skilled nursing 





hypertension w/severe renal failure (OR 66.8), diabetes without chronic complications (OR 
19.0), chronic pulmonary disease (OR 10.6) and valvular disease (OR 4.2). Statistically 
significant but clinically meaningless associations were found with the age cohort 55-75 
(OR.18); comorbidities of arthropathies (OR .03) and CHF (OR .05) were likely attributable to 
collinearity as by definition, all members of the cohort had a primary discharge diagnosis of HF. 
  To further evaluate the relationship between HFPC consult and hospital readmission, 
means were calculated. For the entire cohort that experienced a hospital readmission n =113, the 
mean time to hospital readmission for patients who had no HFPC consult was 5.6 weeks, while 
the mean for patients who had an HFPC consult was 3.6 weeks (see Table 9). The pattern of 
hospital readmissions is likewise significantly different. Patients with an HFPC consult 
demonstrated earlier hospital readmission, with 88% of subjects realizing a hospital readmission 
within the first 30 days, compared to just 36% of patients with no HFPC consult. Forty percent 
of patients in the HFPC consult group had no 90-day readmission, while 75% of patients in the 
no-HFPC consult cohort had no 90-day hospital readmission (see Figure 4). Figure 5 
demonstrates the almost flat curve of readmissions amongst patients with no HFPC consult while 
the patients with an HFPC consult spiked very early in the first 30-days post-discharge and then 
tapered to a minimum. Patients with HF targeted for HFPC consult were more likely to 
experience not only more frequent hospital readmissions but also earlier times to readmission in 
the post-discharge period, the majority within the first 30 days. 
This investigation has fully established that there is a statistically significant difference in 
90-day hospital readmission between the cohort of subjects with an HFPC consult versus those 
with no HFPC consult; thus, it is important to fully appreciate the granularity present within the 





readmissions, but the differential trend in hospital readmission is further appreciated with a 
survival analysis of time to readmission. The survival analysis of the total study population 
identified a statistically significant difference between subjects with and without HFPC consult 
(see Figure 4). The propensity-matched survival analysis identified an even greater magnitude of 
difference in the curves (see Figure 5). Both analyses were strongly statistically significant by 
Log Rank (Mantel-Cox)  <.0001 and Breslow (Generalized Wilcoxon) <.0001.  
An overview of the entire study population demonstrated that <30% of HF patients who 
have an HFPC consult are unable to avoid hospital readmission for >90 days, >50% of HF 
patients who have an HFPC consult experienced a hospital readmission within 30 days of 
discharge, and > 75% of HF patients who have an HFPC consult will have a hospital readmission 
within 90 days of discharge. This survival analysis conveyed the real disparity in the experience 
of patients with respect to hospital readmission for subjects with an HFPC consult compared to 
those with no HFPC consult.  
HF patients receiving appropriately targeted HFPC consultation experience earlier and 
more frequent hospital readmissions, higher mortality, and suffer greater severity of their illness. 
It is counterproductive to attempt to advocate HFPC to achieve reductions in 90-day hospital 
readmissions. If anything, this study has established that once appropriately targeted HF patients 
have been referred to HFPC, plans should be implemented to accommodate an expected 
increased frequency of hospital readmissions and decreased time to readmission with 








Chapter 5: Discussion 
Introduction 
This section discusses the findings of the study, whether the study has met its specified 
objectives, the findings in relation to the existing literature, and the strengths, weaknesses, and 
limitations of this investigation. The implications section discusses the impact of this 
investigation, contributions to knowledge and professional practice, and the future implications 
of this research with recommendations for further/future research. Lastly, the chapter provides a 
discussion of limitations and delimitations.  
Outcomes of the logistic regression of the propensity-matched model showed that for 
every unit reduction in 90-day hospital readmission, there was a statistically significant 1.468 
increase in no HFPC consult (reduction in HFPC consult), p =.001. Propensity-matching ensures 
that comparisons are made between subjects who are a best match on all characteristics with the 
exception of the outcome of interest. The resulting propensity-matched cohort, n =132, 
demonstrated improved homogeneity with the absence of statistical significance for any 
individual characteristic. To further evaluate the relationship between HFPC consult and hospital 
readmission, means were calculated. For the entire cohort that experienced a hospital 
readmission n =113, the mean time to hospital readmission for patients who had no HFPC 
consult was 5.6 weeks, while the mean for patients who had an HFPC consult was 3.6 weeks. 
Survival analysis of the unmatched population identified statistically significant differences 
between subjects with and without HFPC consult, p <.001. The propensity-matched survival 
analysis identified an even greater magnitude of difference in the curves, p < .001. Less than 
30% of HF patients who have an HFPC consult will avoid hospital readmission for over 90 days, 





of discharge, and > 75% of HF patients who have an HFPC consult will have a hospital 
readmission within 90 days of discharge.  
Discussion 
The investigation set out to evaluate the association of palliative care consultation in the 
hospital setting with hospital readmissions at 90 days post-discharge with statistical controls for 
mortality and severity through propensity-matching. Numerous guidelines on ensuring 
excellence in HF management have established recommendations that palliative care should be a 
part of the multidisciplinary health care team managing patients with HF. Numerous studies have 
explored the relationship between palliative care and 30-day hospital readmission to provide 
support for these recommendations. Some of the studies found that HFPC consult decreased the 
risk of hospital readmission; others found only an equivocal association, while others found a 
negative association. Most of these studies were retrospective and relied on administrative 
datasets to quantify their results. These studies did not assess the relationship of palliative care 
with 90-day hospital readmission with adequate controls for mortality and severity.  
Studies that have assessed mortality associated with palliative have done so primarily 
with comparisons of pre- and post- HRRP implementation population-based metrics or 
comparison to severity-adjusted populations. This investigation aimed to not simply compare 
whether mortality rates are the same in HFPC versus non-HFPC consult groups but to control for 
mortality and assess the ability of HFPC consult to decrease hospital 90-day readmissions in a 
defined hospital population that has actively promoted the adoption of HFPC consults in its HF 
population. The findings of this investigation indicate that in a propensity-matched population, 
adjusting for mortality, HFPC consultation is positively associated with 90-day hospital 





significantly more likely to have a readmission within 90 days compared to the propensity-
matched cohort that did not have an HFPC consult. As such, an HFPC consult may not be causal 
for the increased prevalence of 90-day hospital readmissions, as it more than likely reflects a 
level of morbidity that cannot be quantified by even the most exhaustive measurement of 
covariates. This investigation included an exhaustive list of covariates, and if the relationship 
between HFPC consult and 90-day hospital readmission were weak, it would have been 
eradicated by ‘overmatching.’ However, this did not occur. Rather, the relationship between 
HFPC consult and 90-day hospital readmission remained strong and highly statistically 
significant.  
An alternative explanation is that care providers in this institution are highly attuned to 
the intangible aspects of patient management that predict which individuals are likely to be high 
utilizers of health system resources and thus selected for an HFPC consult. Thus, selection bias 
may exist at the provider level, embedded within the individualized care management planning 
for patients. These study findings may suggest that such high utilizers are being given all the 
resources that the health system has at its disposal to attempt to meet the patient’s needs. Such an 
aim is intuitively a value-added intervention for the patient. As such, these findings should not 
suggest that HFPC has no value, but the findings are clear that as a method to decrease 90-day 
hospital readmission, HFPC consultation is not a valid approach. 
The hypothesis of this investigation was that the increased level of resources, education, 
facilitated decision-making, and future health planning would enable the patient to better 
understand their symptoms and improve health behaviors through a better understanding of the 
health system and enable them to seek health care services in less hospital-oriented settings, 





countries with a greater population-focused system of health care, have demonstrated decreased 
hospital readmissions, at best, equivocal findings in reducing hospital readmission have been 
found in the United States. This study highlighted those equivocal findings that typically did not 
incorporate controls for severity or mortality—there, in truth, is no association between HFPC 
consult and 90-day hospital readmission. Due to the nature of the health care system and its 
focus on acute care, it may be a plausible alternative that the hospital environment is the best 
location of care for patients with end-stage HF who suffer from a significant level of morbidity, 
acute decompensation, and limited expertise and find it difficult to access their primary care or 
any other alternative care setting in a timely way. 
Implications 
The implications for this study include that it has identified a significant finding that 
improves upon other authors who have found negligible or no association between HFPC consult 
and HF readmissions. It also is the first study that provided individual follow-up of a 
retrospectively defined cohort (index HF hospitalization Oct 1 - Dec 31, 2019) and prospectively 
followed the cohort to observe their experience with HFPC consult, subsequent mortality events, 
and 90-day hospital readmission. This study has evaluated this question with substantial 
methodological rigor and would likely withstand the criticism of peer review. Limitations to the 
success of peer review would be that this study was conducted at a single site with availability 
and support for palliative care referrals. Not all hospital systems have similar levels of support or 
availability of palliative care practitioners, compromising generalizability. However, if such 
findings are reproducible in other settings with the availability and similar support for palliative 
care referral, it would be important that the dissemination of palliative care programs not be 





decrease hospital 30-day readmissions as advocated by the HRRP. It further supports other 
researchers who have questioned the objectives of the HRRP that call for palliative care referral 
as a mechanism to decrease hospital 30-day readmissions. HFPC may support other important 
aspects of patient care but reducing hospital readmission is not an objective that can be achieved 
with HFPC consult. 
It is important that hospital resources be utilized in the most useful and efficient ways. If 
HFPC resources are tasked with providing an HFPC consult to every patient with end-stage heart 
failure, with the primary intention that such referral will minimize hospital readmissions, it is a 
clear misuse of HFPC resources. HFPC may provide other necessary supports for decision-
making and future health planning, which are important aspects of patient management. 
However, if the primary aim is to reduce hospital 30-day readmission, HFPC resources are being 
misspent.  
The best outcome arising out of the implications of this study would be the refocusing 
and reallocation of HFPC resources to meet realizable goals and provide meaningful support for 
decision-making and future health planning. This may constitute the same population of HF 
patients with high morbidity, poor health knowledge, and limited social resources, but the 
objectives would be more closely aligned with quality-of-life issues rather than a hospital 
operations focus to reduce hospital readmissions, given the current state of the health care system 
that often focuses on operational efficiency imperatives that are measurable and have a direct 
contribution to the financial bottom line versus quality-of-life imperatives that are very difficult 








Recommendations for future research include testing the reproducibility of this research 
at a similar site that supports referral of end-stage HF patients for an HFPC consult and has the 
availability of HFPC resources to provide consistent and timely access to those resources. It is 
known that there is broad variation in the level of PC services available at health systems across 
the country. A cross-sectional study to determine what services are provided in a PC consult 
should be conducted to standardize definitions for the level of service. 
 Likewise, it is important that the PC professional community define what the target 
population should be, what the objectives for treatment should be, and what the measurable 
outcomes should be. This standardization is necessary to ensure consistent dissemination of PC 
interventions that are identified in future research. As an observational study, this study could not 
establish causation. A randomized clinical trial would be more likely to provide further insight 
into the level of HFPC services that may exert a threshold effect and exert an influence on 
hospital readmissions. A cost-effectiveness study would be a value-add to health systems to 
explore whether it is more cost-effective to utilize HFPC resources to reduce hospital 
readmissions that continue to occur versus creating an alternative care setting that more directly 
meets the needs of the end-stage HF patient that may include HFPC but also provide access to 
the acute care interventions required by the patient in a timely and accessible way such that they 
do not need to seek acute care hospitalization. 
Limitations and Delimitations 
These findings may represent a hospital system that has developed a robust system for 
identifying and referring an HF patient to HFPC in a timely way. Such timely identification may 





were not assessed in this study. While patients were matched on severity, health-seeking 
behaviors and coping mechanisms were beyond the scope of this study. Indeed, the referral 
patterns for this hospital may identify the individuals with the poorest health-seeking behaviors 
and the fewest social supports and coping mechanisms. Even though HFPC is appropriately 
offered as another aspect of treatment, it should not be viewed as a mechanism to reduce hospital 
30-day readmissions. 
The underlying natural variation within this investigation lies in the complexity of 
clinical care management, associated morbidity and mortality, prevalence and health care costs 
of heart failure, and the difficulty in developing reliable solutions that meet the complex and 
varied course of disease discussed in the previous sections of this dissertation. The optimal 
treatment regimen for HF continues to evolve with a significant body of literature and cannot be 
identified as a single best approach at this time, resulting in significant variations in care. Thus, 
significant treatment heterogeneity is unavoidable in any HF cohort.  
Recent commentary has highlighted the importance of delineating the duration of HF, 
with a key aspect being the timing of initiation of HFPC with recommendations for early 
initiation to ensure a smooth and timely integration of HFPC services (von Schwarz et al., 2020). 
This issue is part of a larger issue, which is defining more specifically not only the timing of 
initiation of HFPC consultation but more specifically delineating the services that comprise the 
essential services that ensure HFPC effectiveness. While the scope of this question exceeds the 
scope of this investigation, it remains an important area for future research. 
Insurance providers, including the US government by way of the Medicare program, have 
a vested interest in controlling costs associated with treatment, with the result that interventions 





administrative mandates demonstrate clear futility or harm. More importantly, patients and their 
families rely on health care providers and the broader health system to receive optimal, life-
preserving medical care and quality of life. HFPC would appear to be the best option of 
addressing complex individualized care needs in an outpatient setting but requires validation. 
This research contributes to the development of incremental knowledge specific to the validity of 
HFPC interventions to decrease hospital readmissions after controlling for mortality. Also, this 
research addressed the underlying barriers and issues by addressing a specific gap in medical 
knowledge that has not been assessed (whether the effect of mortality on HFPC readmission 
rates is substantive or negligible and whether HFPC is an effective intervention for patients with 
end-stage heart disease to reduce 90-day hospital readmissions). Lastly, this investigation fully 
established that there is a statistically significant difference in 90-day hospital readmission 
between the cohort of subjects with an HFPC consult versus those with no HFPC consult with 
individuals with an HFPC consult realizing statistically significant earlier hospital readmission 
than their propensity-matched counterparts. 
Summary 
Recent administrative mandates from the Centers for Medicare and Medicaid Services 
(CMS) embodied in the Hospital Readmission Reduction Program (HRRP) have aimed to reduce 
the frequency of heart failure (HF) 30-day hospital readmissions. To fill the health care needs of 
patients with end-stage heart failure, palliative care (HFPC) and hospice referrals are promoted 
to provide additional support to patients in addition to their primary care and specialist 
physicians and reduce unnecessary hospital readmission. While HFPC is a plausible and logical 





heart failure population with adequate controls to assess potential sources of confounding and 
interaction.  
Currently, hospital readmission metrics include in their numerator all patients with a 
diagnosis of HF who are readmitted within a 30-day time period with the denominator including 
all patients discharged with a diagnosis of HF. If the patient experiences a mortality event in the 
30-day period after hospital discharge, there is no opportunity for readmission, and the mortality 
event does not accrue to the numerator of the admitting hospital readmission metric. Studies to 
date have evaluated the efficacy of palliative care to achieve reductions in hospital readmissions 
but have not evaluated this potential for significant differential mortality. This investigation 
assessed the mortality-adjusted, propensity-matched (severity-adjusted) relationship between 
HFPC consult and 90-day hospital readmission in patients with a diagnosis of end-stage heart 
failure (HF) in the current context of administrative mandates that aim to reduce the frequency of 
HF hospital readmissions.  
Heart failure is the most common discharge diagnosis in the United States, affecting 5.1 
million annually (Arora et al., 2017; Fasolino & Phillips, 2016). The Centers for Medicare and 
Medicaid Services (CMS) implemented components of the 2010 Affordable Care Act with the 
introduction of the Hospital Readmission Reduction Program (HRRP) and began to publicly 
report hospital 30-day all-cause risk-standardized mortality rates and 30-day all-cause risk-
standardized readmission rates for acute myocardial infarction (AMI), heart failure (HF) and 
pneumonia (Krumholz et al., 2013). In October 2012, CMS introduced penalties and began 
reducing Medicare payments for excess readmissions in a broad array of inpatient 
hospitalizations, specifically HF, based on a ratio of predicted versus expected 30-day 





following HF hospitalization can negatively impact hospital performance measures and incur 
reimbursement penalties (Davis et al., 2017). 
The expansion of palliative care programs beyond cancer to end-stage organ failure 
patients is new and has received increasing popular attention worldwide in the last decade (Ng et 
al., 2016). A key element of the hospital interest in palliative care is the risk adjustment it affords 
the hospital submitting data for CMS readmission metrics. The presence of a coded palliative 
care consult (V667) or hospice referral on the electronic medical record of the patient admitted 
with HF increases the expected count of HF readmissions in CMS quality calculations and 
creates a greater opportunity for the hospital to have a less than the expected count of HF 
readmissions which translates into a higher quality score for the admitting hospital (Trivette, 
2017).  
Research evaluating the effectiveness of an HFPC consult in the setting of acute 
hospitalization for HF as an intervention to decrease 30-day hospital readmission has shown 
mixed results and methodological limitations. A broad array of guidelines promotes its adoption, 
while the literature has demonstrated poor reproducibility of the reliability of a PC consult to 
effectively reduce hospital readmissions (Chuang & Fausto, 2014; Chuang et al., 2017; Nelson et 
al., 2011; O'Connor et al., 2015; Wiskar et al., 2017). The goal of this research was to assess the 
effectiveness of HFPC consult to effect change in 90-day hospital readmissions in a propensity-
matched model that adequately controls for mortality at a single-site 526-bed tertiary-care 
facility. 
This research is relevant to several key health care areas, including heart failure, hospital 
readmissions, and palliative care. Heart failure prevalence is increasing, administrative pressures 





palliative care require an evidence-based and methodologically rigorous evaluation of outcomes. 
The sustained incidence, increasing prevalence, and significant lifetime risk of HF create the 
strong imperative to improve all aspects of care associated with the diagnosis of HF. The 
prevalence of risk factors in the US population, the increasing prevalence of obesity and 
diabetes, the associated cost for care, and potentially significant increases in the future cost of 
care for patients with HF indicate a significant imperative to improve the care and management 
of individuals with HF. The challenges of a clinical syndrome with high mortality, complex 
medical management of multiple comorbidities, and challenges with identifying interventions 
with associated mortality benefit create the imperative for identifying new strategies, such as 
palliative care to prevent HF hospital readmission and improve management of patients with HF. 
The development of readmission metrics is flawed as a measure of hospital quality of care and is 
more likely to represent administrative priorities to promote the development of improved 
systems of care that incorporate individual and community aspects of care that are more likely to 
contribute to improved continuity of care and result in fewer unplanned hospital readmissions 
(Barnett et al., 2015; Chin et al., 2016; Freedland et al., 2016; National Quality Forum, 2016; 
Pandey et al., 2017). According to Cook et al. (2016), mortality risk increases after hospital 
readmission and never returns to pre-admission levels. Palliative care may provide the needed 
transition and continuity of care to address the observed increase in mortality risk associated with 
hospitalization.  
The theoretical approach to this study employed the Common Sense Model in that the 
relationship between illness representations with inputs from the illness prototype, sensory 
inputs, and treatment beliefs, and the illness outcome of hospital readmission can be modified by 





antecedent experience of severity (illness prototype) and concurrent inputs from the senses and 
treatment beliefs. Moreover, it considers the projected future consequences and potential for cure 
or control (illness representation) of the health-seeking behavior (Leventhal et al., 2016). The 
interpretation of symptoms and health-seeking behaviors for HF is complex, difficult to assess, 
and exerts a strong influence on the individual’s illness representation and prompting health-
seeking behaviors (Enguidanos et al., 2015; Kaptein et al., 2003; Leventhal et al., 2016; Turrise, 
2016). Coping mechanisms have been demonstrated to improve illness outcomes (Leventhal et 
al., 2016; Turrise, 2016). 
Statistical analysis encompassed:  
a) logistic regression and odds ratio calculation of risk of the primary research question 
of interest, the dependent variable 90-day hospital readmission against the 
independent variables of mortality and severity (propensity-score) in both the 
propensity-matched and total unmatched population 
b) demographic characterization of the total unmatched population and the resulting 
propensity-matched cohort 
c) calculation of odds ratios for risk of HFPC consult based on demographic 
characteristics, markers of acuity, and comorbidity  
d) sub-analysis of time to readmission with histograms and survival curve analysis 
Results were statistically significant for a strong association between HFPC consult and 
90-day hospital readmission in a propensity-matched population, OR 4.3, 95% CI [1.8-10.6]. 
Statistically significant differences in the demographic characteristics of the population were 
eliminated with propensity-matching but maintained strong model predictive ability with 





meaningful patient characteristics that predict HFPC consult. Time to readmission analysis 
demonstrated that patients with an HFPC consult have a different mean time to readmission, and 
survival analysis demonstrated the statistically significant differences in the experience of 
patients who received an HFPC consult compared to those that did not, p <.0001. 
 <30% of HF patients who have an HFPC consult are unable to avoid hospital 
readmission for >90 days. 
 >50% of HF patients who have an HFPC consult experience a hospital readmission 
within 30 days of discharge.  
 75% of HF patients who have an HFPC consult will have a hospital readmission 
within 90 days of discharge.  
This study demonstrated that while HFPC may be an important aspect of continuity of 
care and care planning for the HF patient, it is not a valid or effective method for reducing 90-
day hospital readmissions. In this investigation, HFPC consult was predicted by and served as a 
proxy for the HF patient that has an acute decompensation with abnormal lab values on 
admission, with numerous comorbidities or approaching end-of-life. HFPC consultation has 
many values in the care and management of the HF patient. However, reducing 90-day hospital 
readmission is not an achievable goal. Conversely, HFPC consult should serve as a proxy signal 
to expect the increased frequency of admissions in a population with high morbidity approaching 
end-of-life. 
It is important that hospital resources be utilized in the most useful and efficient ways. If 
HFPC resources are tasked with providing an HFPC consult to every patient with end-stage heart 
failure, with the primary intention that such referral will minimize hospital readmissions, it is a 





decision-making and future health planning, which are important aspects of patient management. 
However, if the primary aim is to reduce hospital 30-day readmission, PC resources are being 
misspent.  
The best outcome arising out of the implications of this study would be the refocusing 
and reallocation of PC resources to meet realizable goals and provide meaningful support for 
decision-making and future health planning. This may constitute the same population of HF 
patients with high morbidity, poor health knowledge, and limited social resources, but the 
objectives would be more closely aligned with quality of life issues rather than a hospital 
operations focus to reduce hospital readmissions, given the current state of the health care system 
that too often focuses on operational efficiency imperatives that are measurable and have a direct 




































































Summary of Findings Pertaining to HF Readmission Rates 
______________________________________________________________________ 





(Krumholz et al., 
2009) 
Jul 2005 - Jun 
2008 
1,430,053 Median 24.4% (range 15.9% to 
34.4%; 25th to 75th percentile 
23.4% to 25.6%) 
 
 
(DeVore et al., 
2016) 
2006 - 2012 100,189 2006 - 7  21.5% 
2007 - 8  21.8% 
2008 - 9  22.2% 
2009 - 10  22.2% 
2010 - 11  22.1% 
2011 - 12  22.5%  
 
Adjusted trend 
Before public reporting 
0.0% (-1.4 to 1.5) 
After public reporting -
1.8% (-3.3 to -0.2) 
(Bergethon et al., 
2016) 
2009 - 2012 21,264 2009  20.0% (SD, 1.3%) 
2012  19.0% (SD, 1.2%) (p =0.001) 
Get With the Guidelines is 
a voluntary program 
   Trend in relative HRR by quartile 
of performance Q1(best), 
Q4(worse) 
Q1 -0.9% (13.1 to 4.8) 
Q2 -4.9% (-7.4 to 0.5) 
Q3  -7.0% (-10.4 to -2.6) 
Q4  -8.7% (-12.9 to -5.0) 
 
 
(Wasfy et al., 
2017) 
Jan 2000 - Nov 
30, 2013 




per 10,000 discharges per year 
Pre-ACA law 5.1 (4.8 to 5.3) 
Post-ACA law -84.7 (-83.9 to -
85.4) 
 
Averted admissions by 
quartile of performance 
Q1(best) Q4(worse) 
Q1  77.6 (76.4 to 79.2) 
Q2  86.8 (85.6 to 88.0) 
Q3  100.8 (98.4 to 102.8) 
Q4  112.0 (108.0 to 115.6) 
(Zuckerman et al., 
2016) 




2007 - 08  21.5% 
2014 - 15  17.8% 
Slope of change: 
Oct 2007 - Apr 2010  -0.017 
Apr 2010 - Oct 2012  -0.103 
Oct 2012 - Apr 2015  -0.005 
 
Aggregate HRR for all 
target conditions inclusive 
of AMI, HF, and 
pneumonia 
(Desai et al., 
2016) 









2008  27.5% mean HRR 
Difference in annualized rate of 
change: 
2008 - 2010   0.10% (-0.12 to 0.32) 
2010 - 2012  -0.50% (-1.18 to -
0.62) 
2012 - 2015  0.72% (0.40 to 0.95) 
 
2010 - 2012 Penalty 
hospitals had a -1.25% 
difference in annualized 
rate of change as 






No penalty hospitals: 
2008  24.2%  mean HRR 
2008 - 2010  -0.26% (-0.56 to 0.04) 
2010 - 2012  0.08% (-0.30 to 0.46) 
2015 - 2015  0.14% (-0.17 to 0.46) 
 
(Sukul et al., 
2017) 





Younger patients 18 - 64 had 
higher rates of readmission (21.4%) 
compared to elderly patients 




(Gilotra et al., 
2017) 
Jul 2014 - Mar 
2015 
93 29 (30%) HF 30-day readmission 











































Summary of Findings Pertaining to HF Readmission Rates and Mortality 
 
 











(Krumholz et al., 
2009) 
Jul 2005 - Jun 
2008 
1,161,165 Median 11.1% 




(Krumholz et al., 
2013) 










r2 =-0.17, 95% CI 
[-0.20 to -0.14] 
 
  
(Arundel et al., 
2016) 
1998 - 2001 7578 12-month 
mortality for 
patients with 30-
day readmit 41% 
 
With no 30-day 
readmission, 27% 
 
 HR 1.68, p < 
0.001, 95% CI 
[1.48 - 1.90] 










(DeVore et al., 
2016) 
2006 - 2012 100,189 Adjusted all-cause 
mortality trend -




trend 3.1% (-1.3 
to 7.6) 
p =0.15 
(Bergethon et al., 
2016) 
2009 - 2012 21,264 2009  7.8% 2012  7.6% p =0.71 
(Dharmarajan et 
al., 2017) 











0.008% (0.007% to 
0.010%) monthly 
(Fonarow et al., 
2017) 















(Gupta et al., 2017) Jan 1, 2006 - 











30-day HR 1.15, 
95% CI [1.08 - 
1.24] 
1-yr HR 1.10, 
95% CI [1.07 - 
1.14] 
Population subset 




(Chatterjee & Joynt 
Maddox, 2018) 
2009 - 2015 2009 - 2751 












per year among 
all other hospitals 
p < .001 
(Wadhera, Joynt 
Maddox, Wang, 
Shen, & Yeh, 
2018) 
Jul 1,2011 - 
Jun 30, 2014  
1,343,792 pts, 2948 
hospitals 






 p < 0.001 
 








Jan 1, 2006 - 














































Summary of Findings Pertaining to HF Readmission Rates and Palliative Care 
 
 
Study Dates n Intervention Outcomes Risk of bias 
assessment (Higgins 
et al., 2011; Savovic 
et al., 2018) 
 









Interdisciplinary PC team 
meetings led by PC MD 
providing: 
(a) written 
recommendations to PCP 
in five domains of PC at 
study entry, midway, and 
end. 
(b) Social work case 
management 




(e) Chaplain offered 
spiritual and 
psychological support 
(f) Monthly patient and 
family support groups 
(g) Weekly telephone 
contact, monthly visits 
providing communication 
with PC team about 
patient needs. 
Physical  
  UCSD SOB p =0.01 
  Brief Pain Inventory 
(ns) 
  Sleep items from MOS 
p =0.05 
Psychological 
  Profile of Mood States 
(ns) 
  CES Depression scale 
(ns) 
Spiritual 
  Spiritual well-being 
scale p =0.007 
Social 
  QoL scale-Cancer (ns) 
Health care satisfaction 
  GHAA survey (ns) 
Advanced care planning 
p =0.03 in one of three 
outcomes 
Utilization 
  Clinic visits p =0.03 
  Urgent care p =0.04 
  Specialist, ED visits, 
hospital admissions, 




Moderate risk of bias. 
 




population with HF 
minority (34 - 35%). 
 
Selection bias with 58% 
(intervention) to 65% 
(control) refused to 
enroll because they were 
“too ill.” 
 














with service delivery by 
RN case managers 
conducting home visits, 
phone calls, and 
accompanying patients to 
MD visits 
Receipt of sufficient 
information or education 
p < 0.05 for four of 12 
outcomes 
Preparation for end-of-
life p < 0.05 for two of 
10 outcomes. 
Symptom burden p < 
0.05 for one of six 
outcomes. 














SF-36 physical and 
mental functioning p < 
0.05 for two out of eight 
domains for HF subset. 
ED visits (ns) 
 
High loss to follow-up, 
retaining 43% of 
intervention pts. and 













to usual care or in-home 
palliative care with an 
assigned coordinating PC 
physician preventing 
service fragmentation. 
Satisfaction with care p 
< .05, decreased use of 
medical services (ED 
visits) p =.01, site of 
death at home p < .001, 









representative of HF 
population (33% HF). 
Intervention 
representative of hospice 










53 usual care 
54 PC 
intervention 
Daily inpatient PC visits 
and phone call two weeks 
after discharge. 
Symptom rating 0 - 10 
of pain (ns), dyspnea 
(ns), and anxiety (ns).  
High risk of bias. 
 


















management and PC 
services 
 
Nurse visits p =0.0001 
MD phone calls or Rx 
meds (ns) 
MD visits (ns) 
Symptom burden 
(ESAS) (ns) 
Quality-of-life             
    EuroQol (EQ-5D) p 
=0.05 
    (KCCQ) (ns) 
Survival at six months. 
(ns) 
Total Readmissions p 
=0.009 
 
High risk of bias. 
 
Single center, unblinded 
Core health system 
differences limit 
generalizability to the 
US. 
Differential allocation to 
control or intervention 
by age 
(Sidebottom 











Standard process of 
hospital PC team and 
survey responses to 
MLHFQ, ESAS, and 
PHQ-9 acquired at 
baseline interview and no 
patient cost for initial PC 
consult. 
Quality-of-life 
(MLHFQ) p < 




(ESAS) p < 
0.0001 at one 
or three 
months. 
Depression (PHQ-9) p < 
0.0001 at one 
or three 
months. 
Advance care planning p 
=0.033 at six 
months 
30-day readmission (ns)  
Hospice use (ns) at six 
months 
Mortality (ns) at six 
months 
 
High risk of bias 
 
Single center, unblinded 
Selection bias - enrolled 
subjects not ordered for 




to intervention subjects 
providing free initial PC 
consult. 
 
Differential loss to 
follow-up with 80% of 
individuals in the 
intervention arm 





















collaborative care HF 
disease management: 
Screening for and 
treatment of depression 
Telemonitoring with 
patient self-care support 
Quality-of-life (KCCQ) 
(ns) 




Subgroup analysis of HF 
patients with Depression 
(PHQ-9) p =0.01 
 
Equivocal risk of bias  
 
Very high variance in 
KCCQ trajectories 











43 usual care 
42 PC 
intervention 
At least one inpatient PC 
consultation, with the 





oriented care (hospice or 





from medical record. 
 
High risk of bias 
 
Unblinded 
92% African American 













41 usual care 
43 PC 
intervention 
MD supported RN case 
managers provided 
patient visits, training, 
home visits and 
telephone visits weekly 
for the first four weeks, 
then monthly through 12 
weeks. 
Readmission at four 
weeks (ns)  




Functional status (PPS) 
(ns) 
Quality-of-life 
     MQOL-HK p < 
0.001 at 
            12 weeks,  
      CHHQ p < 0.001 at 
12 weeks) 
Satisfaction with care 
(ns) 
 
High risk of bias 
 
Differential loss-to-
follow-up (25% control, 
14% intervention (I) 
Differential allocation to 
control or intervention 
by HF class (I) 
Differential allocation to 
control or intervention 
for advanced HF 
interventions (CRT and 
Pacemaker) (I) 



















management. PC MD led 
team with PC NP 
collaborating with 
cardiology and a focus on 
shared goal setting. After 
discharge NP participated 




     KCCQ, FACIT-PAL 
p =0.021 
Anxiety and depression  
     HADS p =0.063 
Spiritual well-being  









12% loss to follow-up 
Selection bias - subjects 
recruited from 
















Psychosocial care model 
- Collaborative Care to 
Alleviate Symptoms and 
Adjust to Illness (CASA) 
RN symptom evaluation 
Social worker providing 
psychosocial care 
Consulting team, 
including PC, PCP, and 
Cardiology providing 
orders for tests and 
medications to patients’ 





Depression (PHQ-9) p 
=0.02 
Anxiety (GADQ) (ns) 
Global symptoms 
(GSD)(ns) 
Specific symptoms: pain 
(ns), fatigue p =0.02, 
shortness of breath (ns) 
Hospitalizations (ns) 
Mortality at three and 
six months(ns) 




SOC PC consultation 



























2020 ICD-10-CM Heart Failure Diagnostic Codes 
__________________________________________________________________________ 
Code  Description 
__________________________________________________________________________ 
 
I09.81     Rheumatic heart failure  
I11.0    Hypertensive heart disease with heart failure  
I50     Heart failure 
I50.1     Left ventricular failure, unspecified 
I50.2     Systolic (congestive) heart failure 
I50.20    Unspecified systolic (congestive) heart failure 
I50.21     Acute systolic (congestive) heart failure 
I50.22     Chronic systolic (congestive) heart failure 
I50.23     Acute on chronic systolic (congestive) heart failure 
I50.3     Diastolic (congestive) heart failure 
I50.30     Unspecified diastolic (congestive) heart failure 
I50.31     Acute diastolic (congestive) heart failure 
I50.32     Chronic diastolic (congestive) heart failure 
I50.33     Acute on chronic diastolic (congestive) heart failure 
I50.4     Combined systolic (congestive) and diastolic (congestive) heart failure 
I50.40     Unspecified combined systolic (congestive) and diastolic (congestive) heart  
  failure 
I50.41     Acute combined systolic (congestive) and diastolic (congestive) heart failure 
I50.42     Chronic combined systolic (congestive) and diastolic (congestive) heart failure 
I50.43     Acute on chronic combined systolic (congestive) and diastolic (congestive) heart  
  failure 
I50.8     Other heart failure 
I50.81    Right heart failure 
I50.810  Right heart failure, unspecified 
I50.811  Acute right heart failure 
I50.812  Chronic right heart failure 
I50.813  Acute on chronic right heart failure 
I50.814  Right heart failure due to left heart failure 
I50.82     Biventricular heart failure 
I50.83     High output heart failure 
I50.84     End stage heart failure 
I50.89     Other heart failure 









000 - 007, 008.8 Heart failure complicating abortion or ectopic or molar pregnancy 
008.8     Other complications following an ectopic and molar pregnancy 
075.4     Heart failure complicating obstetrical procedure or delivery  
I13.0    Hypertensive heart and chronic kidney disease with heart failure and stage one  
    through four chronic kidney disease, or unspecified chronic kidney disease 
I13.2     Hypertensive heart and chronic kidney disease with heart failure and with stage  
  five chronic kidney disease, or end stage renal disease 
I46     Cardiac arrest 
I97.13     Postprocedural heart failure  
P29.0     Heart failure originating in the perinatal period 
R57.0     Cardiogenic shock  
R57.9     Shock, unspecified 
 
Including MS-DRG v37.0: 
__________________________________________________________________________ 
 
222   Cardiac defibrillator implant with cardiac catheterization with ami or hf or shock  
  with mcc 
223   Cardiac defibrillator implant with cardiac catheterization with ami or hf or shock  
  without mcc 
291   Heart failure and shock with mcc 
292   Heart failure and shock with cc 
293   Heart failure and shock without cc or mcc 
 
Excluding MS-DRG v37.0: 
__________________________________________________________________________ 
 
791   Prematurity with major problems 















































Figure A7  
































Dependent Variable Encoding 




Categorical Variables Codings 
 Frequency 
Parameter coding 
(1) (2) (3) (4) (5) (6) 
Discharge 
disposition 
Home - 0 126 .000 .000 .000 .000 .000 .000 
Home W/ 48 1.000 .000 .000 .000 .000 .000 
Hospice 10 .000 1.000 .000 .000 .000 .000 
Inpt Reh 3 .000 .000 1.000 .000 .000 .000 
Long Ter 4 .000 .000 .000 1.000 .000 .000 
Short Te 2 .000 .000 .000 .000 1.000 .000 
Skilled 41 .000 .000 .000 .000 .000 1.000 
Tobacco Use Denies 132 .000 .000 .000 .000   
Tob<30d 32 1.000 .000 .000 .000   
Tobuse1+ 57 .000 1.000 .000 .000   
Tobuse30 8 .000 .000 1.000 .000   
Unable t 5 .000 .000 .000 1.000   
Hospitalization 
duration 
Admissio 87 .000 .000     
Observat 72 1.000 .000     
Prolonge 75 .000 1.000     
Primary 
Insurance 
Commerci 148 .000 .000     
Medicaid 6 1.000 .000     
Medicare 80 .000 1.000     







.25-.50 84 .000 1.000     
.50+ Pre 91 .000 .000     
Age cohort < 55 49 .000 .000     
55-75 99 1.000 .000     
75+ 86 .000 1.000     
BP Hyperten 139 1.000 .000     
Hypotens 2 .000 1.000     
Normal 93 .000 .000     
HR. 0 Normal 163 .000 .000     
1 Bradyc 11 1.000 .000     
2 Tachyc 60 .000 1.000     
Na Hypernat 7 1.000 .000     
Hyponatr 40 .000 1.000     
Normal 187 .000 .000     
Cr Abnormal 36 1.000 .000     
Elevated 72 .000 1.000     
Normal 126 .000 .000     
BUN/Cr Low 25 .000 .000     
Normal 131 1.000 .000     
Renal co 78 .000 1.000     
Guideline 
Adherance 
No 114 1.000      
Yes 120 .000      
Gender Female 120 1.000      
Male 114 .000      
Do Not 
Resuscitate 
. 219 .000      
DNR 15 1.000      
Hgb Anemia 129 1.000      
Normal 105 .000      
Intra Aortic 
Balloon Pump 
No 233 .000      
Yes 1 1.000      
AICD or CRT-
D Implant 
No 172 .000      
Yes 62 1.000      







Yes 9 1.000 





























Table A7  
Classification Tablea 




Palliative Care Consult Percentage 
Correct No Yes 
Step 1 Palliative Care 
Consult 
No 126 16 88.7 
Yes 20 72 78.3 
Overall Percentage   84.6 
a. The cut value is .500 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 
1a 
Age cohort   4.132 2 .127  
Age cohort(1) -1.716 .876 3.839 1 .050 .180 
Age cohort(2) -.911 .928 .963 1 .326 .402 
Gender(1) 1.079 .634 2.899 1 .089 2.943 
Do Not 
Resuscitate(1) 










13055.527 .000 1 .999 .000 
Primary 
Insurance(2) 

















-.005 .656 .000 1 .994 .995 
AICD or CRT-
D Implant(1) 
1.140 .670 2.898 1 .089 3.127 
Guideline 
Adherance(1) 








.004 .691 .000 1 .996 1.004 
Hospitalization 
duration(2) 








1.676 .826 4.116 1 .042 5.342 
Discharge 
disposition(2) 
22.308 10366.699 .000 1 .998 4877036073.909 
Discharge 
disposition(3) 
4.746 3.552 1.785 1 .182 115.070 
Discharge 
disposition(4) 





40192.970 .000 1 1.000 .000 
Discharge 
disposition(6) 
2.597 .896 8.399 1 .004 13.418 
BP   4.199 2 .123  
BP(1) 1.301 .635 4.199 1 .040 3.672 
BP(2) 25.028 24543.706 .000 1 .999 74028849642.421 
HR.   6.102 2 .047  
HR.(1) -3.141 1.700 3.414 1 .065 .043 
HR.(2) 1.272 .779 2.670 1 .102 3.569 





Na(1) .969 1.419 .467 1 .495 2.635 
Na(2) -1.027 .783 1.718 1 .190 .358 
BUN/Cr   1.854 2 .396  
BUN/Cr(1) 1.292 1.040 1.543 1 .214 3.639 
BUN/Cr(2) .896 1.141 .616 1 .432 2.449 
Cr   11.075 2 .004  
Cr(1) -.311 1.248 .062 1 .804 .733 
Cr(2) 2.016 .693 8.462 1 .004 7.509 
Hgb(1) -.598 .581 1.059 1 .303 .550 
Pressors 
required(1) 




40.767 56841.443 .000 1 .999 506772158989469180.000 
Tobacco Use   7.070 4 .132  
Tobacco Use(1) -1.848 .914 4.086 1 .043 .158 
Tobacco Use(2) -.035 .630 .003 1 .956 .966 
Tobacco Use(3) -1.908 1.660 1.320 1 .251 .148 
Tobacco Use(4) -4.021 2.251 3.189 1 .074 .018 
AIDS 26.655 23895.083 .000 1 .999 376707060855.558 
Alcohol abuse 2.020 5.497 .135 1 .713 7.536 
Deficiency 
Anemias 
.542 .747 .526 1 .468 1.719 
Arthropathies -3.616 1.442 6.290 1 .012 .027 
Chronic blood 
loss anemia 
1.924 6.860 .079 1 .779 6.851 
Leukemia 37.035 46700.500 .000 1 .999 12130545869000848.000 
Lymphoma -3.563 2.111 2.849 1 .091 .028 
Metastatic 
cancer 













disease - present 
on admission 









2.339 2.321 1.015 1 .314 10.366 
Congestive 
heart failure 









4.202 2.084 4.065 1 .044 66.789 
Coagulopathy 2.040 1.371 2.214 1 .137 7.690 
Dementia -.529 1.010 .274 1 .601 .589 








2.945 1.003 8.631 1 .003 19.019 
Drug abuse 1.136 1.326 .733 1 .392 3.113 
Hypertension, 
complicated 











40192.970 .000 1 1.000 .000 
Hypertension, 
uncomplicated 
-.833 .889 .879 1 .348 .435 
Liver disease, 
mild 

















-.475 .981 .234 1 .628 .622 
Seizures and 
epilepsy 
2.109 1.632 1.669 1 .196 8.238 
Obesity 1.037 .597 3.017 1 .082 2.820 
Paralysis 2.821 2.902 .945 1 .331 16.801 
Peripheral 
vascular disease 
-.289 .948 .093 1 .761 .749 




2.181 1.049 4.318 1 .038 8.854 
Renal failure, 
moderate 







.573 1.293 .197 1 .657 1.774 
Hypothyroidism .032 .829 .002 1 .969 1.033 
Other thyroid 
disorders 
-1.527 42260.166 .000 1 1.000 .217 
Peptic ulcer 
with bleeding 
-1.615 1.620 .994 1 .319 .199 
Valvular 
disease 
1.427 .645 4.886 1 .027 4.165 
Weight loss 1.917 1.172 2.678 1 .102 6.803 

























Predicted probability * Palliative Care Consult 
Chi-Square Tests 




Pearson Chi-Square 234.000a 232 .451 
Likelihood Ratio 313.626 232 .000 
N of Valid Cases 234   
 
a. 466 cells (100.0%) have expected count less than 5. The 
minimum expected count is .39. 
 
 
PVar_Match * Palliative Care Consult 
 
Chi-Square Tests 




Pearson Chi-Square 132.000a 131 .459 
Likelihood Ratio 154.691 131 .077 
















Abraham, W. T., Adamson, P. B., Bourge, R. C., Aaron, M. F., Costanzo, M. R., Stevenson, L. 
W., Strickland, ., Neelagaru, S., Raval, N., Krueger, S., Weiner, S., Shavelle, D., Jeffries, 
B., Yadav, J., & Champion Trial Study Group. (2011). Wireless pulmonary artery 
haemodynamic monitoring in chronic heart failure: A randomised controlled trial. Lancet, 
377(9766), 658-666. https://doi.org/10.1016/S0140-6736(11)60101-3 
Adler, E. D., Goldfinger, J. Z., Kalman, J., Park, M. E., & Meier, D. E. (2009). Palliative care in 
the treatment of advanced heart failure. Circulation, 120(25), 2597-2606. 
https://doi.org/10.1161/CIRCULATIONAHA.109.869123 
Aiken, L. S., Butner, J., Lockhart, C. A., Volk-Craft, B. E., Hamilton, G., & Williams, F. G. 
(2006). Outcome evaluation of a randomized trial of the PhoenixCare intervention: 
Program of case management and coordinated care for the seriously chronically ill. 
Journal of Palliative Medicine, 9(1), 111-126. https://doi.org/10.1089/jpm.2006.9.111 
Al-Khazaali, A., Arora, R., & Helu, H. K. (2016). Effective strategies in reducing 
rehospitalizations in patients with heart failure. American Journal of Therapeutics, 23(3), 
e799-804. https://doi.org/10.1097/MJT.0000000000000065 
Allen, L. A., Stevenson, L. W., Grady, K. L., Goldstein, N. E., Matlock, D. D., Arnold, R. M., 
Cook, N. R., Felker, G. M., Francis, G. S., Hauptman, P. J., Havranek, E. P., Krumholz, 
H. M., Mancini, D., Riegel, B., Spertus, J. A., American Heart Association, Council on 
Quality of Care and Outcomes Research, Council on Cardiovascular Nursing, Council on 
Clinical Cardiology, Council on Cardiovascular Radiology and Intervention, … Council 
on Cardiovascular Surgery and Anesthesia (2012). Decision making in advanced heart 





Association. Circulation, 125(15), 1928–1952. 
https://doi.org/10.1161/CIR.0b013e31824f2173  
Alpert, C. M., Smith, M. A., Hummel, S. L., & Hummel, E. K. (2017). Symptom burden in heart 
failure: assessment, impact on outcomes, and management. Heart Failure Reviews, 22(1), 
25-39. https://doi.org/10.1007/s10741-016-9581-4 
American Academy of Hospice Palliative Medicine, Center to Advance Palliative Care, Hospice 
Palliative Nurses Association, Last Acts Partnership, & National Hospice Palliative Care 
Organization. (2004). National consensus project for quality palliative care: Clinical 
practice guidelines for quality palliative care, executive summary. Journal of Palliative 
Medicine, 7(5), 611-627. https://doi.org/10.1089/jpm.2004.7.611 
American College of Cardiology and Institute for Healthcare Improvement. (n.d.). Hospital to 
home (H2H) excellence in transitions. https://cvquality.acc.org/initiatives/hospital-to-
home 
Andrey, J. L., Romero, S., Garcia-Egido, A., Escobar, M. A., Corzo, R., Garcia-Dominguez, G., 
Lechuga, V., & Gomez, F. (2011). Mortality and morbidity of heart failure treated with 
digoxin. A propensity-matched study. International Journal of Clinical Practice, 65(12), 
1250-1258. https://doi.org/10.1111/j.1742-1241.2011.02771.x 
Arora, S., Lahewala, S., Hassan Virk, H. U., Setareh-Shenas, S., Patel, P., Kumar, V., Tripathi, 
B., Shah, H., Patel, V., Gidwani, U., Deshmukh, A., Badheka, A., & Gopalan, R. (2017). 
Etiologies, trends, and predictors of 30-day readmissions in patients with diastolic heart 






Arora, S., Patel, P., Lahewala, S., Patel, N., Patel, N. J., Thakore, K., Amin, A., Tripathi, B., 
Kumar, V., Shah, H., Shah, M., Panaich, S., Deshmukh, A., Badheka, A., Gidwan, U., & 
Gopalan, R. (2017). Etiologies, trends, and predictors of 30-day readmission in patients 
with heart failure. American Journal of Cardiology, 119(5), 760-769. 
https://doi.org/10.1016/j.amjcard.2016.11.022 
Arundel, C., Lam, P. H., Khosla, R., Blackman, M. R., Fonarow, G. C., Morgan, C., Zung, Q., 
Fletcher, R., Butler, J., Wu, W., Deedwania, P., Love, T., White, M., Aronow, W., Anker, 
S., Allman, R., & Ahmed, A. (2016). Association of 30-day all-cause readmission with 
long-term outcomes in hospitalized older Medicare beneficiaries with heart failure. 
American Journal of Medicine, 129(11), 1178-1184. 
https://doi.org/10.1016/j.amjmed.2016.06.018 
Austin, P. C. (2009). Using the standardized difference to compare the prevalence of a binary 
variable between two groups in observational research. Communications in Statistics - 
Simulation and Computation, 38(6), 1228-1234. 
https://doi.org/10.1080/03610910902859574 
Austin, P. C. (2013). A comparison of 12 algorithms for matching on the propensity score. 
Statistics in Medicine, 33(6), 1057-1069. https://doi.org/10.1002/sim.6004 
Bailey, F. A., Burgio, K. L., Woodby, L. L., Williams, B. R., Redden, D. T., Kovac, S. H., 
Durham, R., & Goode, P. S. (2005). Improving processes of hospital care during the last 






Bain, K. T., Maxwell, T. L., Strassels, S. A., & Whellan, D. J. (2009). Hospice use among 
patients with heart failure. American Heart Journal, 158(1), 118-125. 
https://doi.org/10.1016/j.ahj.2009.05.013 
Barker, W. H., Mullooly, J. P., & Getchell, W. (2006). Changing incidence and survival for heart 
failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation, 
113(6), 799-805. https://doi.org/10.1161/CIRCULATIONAHA.104.492033 
Barnett, M. L., Hsu, J., & McWilliams, J. M. (2015). Patient characteristics and differences in 
hospital readmission rates. JAMA Intern Med, 175(11), 1803-1812. 
https://doi.org/10.1001/jamainternmed.2015.4660 
Baumann, L. C. (2003). Culture and illness representation. In The self-regulation of health and 
illness behaviour. Routledge. 
Bekelman, D. B., Allen, L. A., McBryde, C. F., Hattler, B., Fairclough, D. L., Havranek, E. P., 
Turvey, C., & Meek, P. M. (2018). Effect of a collaborative care intervention vs usual 
care on health status of patients with chronic heart failure: The CASA randomized 
clinical trial. JAMA Intern Med, 178(4), 511-519. 
https://doi.org/10.1001/jamainternmed.2017.8667 
Bekelman, D. B., Hooker, S., Nowels, C. T., Main, D. S., Meek, P., McBryde, C., Hattler, B., 
Lorenz, K., & Heidenreich, P. A. (2014). Feasibility and acceptability of a collaborative 
care intervention to improve symptoms and quality of life in chronic heart failure: mixed 






Bekelman, D. B., Nowels, C. T., Allen, L. A., Shakar, S., Kutner, J. S., & Matlock, D. D. (2011). 
Outpatient palliative care for chronic heart failure: A case series. Journal of Palliative 
Medicine, 14(7), 815-821. https://doi.org/10.1089/jpm.2010.0508 
Bekelman, D. B., Plomondon, M. E., Carey, E. P., Sullivan, M. D., Nelson, K. M., Hattler, B., 
McBryde, C., Lehmann, K., Gianola, K., Heidenrich, P., & Rumsfeld, J. S. (2015). 
Primary results of the patient-centered disease management (PCDM) for heart failure 
study: A randomized clinical trial. JAMA Intern Med, 175(5), 725-732. 
https://doi.org/10.1001/jamainternmed.2015.0315 
Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., . . 
. Mutner, P. (2018). Heart disease and stroke statistics-2018 update: A report from the 
American Heart Association. Circulation, 137(12), e67-e492. 
https://doi.org/10.1161/CIR.0000000000000558 
Berenson, R. A., Paulus, R. A., & Kalman, N. S. (2012). Medicare's readmissions-reduction 
program--a positive alternative. New England Journal of Medicine, 366(15), 1364-1366. 
https://doi.org/10.1056/NEJMp1201268 
Bergethon, K. E., Ju, C., DeVore, A. D., Hardy, N. C., Fonarow, G. C., Yancy, C. W., 
Heidenreich, P., Bhatt, D., Petersen, E., & Hernandez, A. F. (2016). Trends in 30-day 
readmission rates for patients hospitalized with heart failure: Findings from the get with 
the guidelines-heart failure registry. Circulation: Heart Failure, 9(6). 
https://doi.org/10.1161/CIRCHEARTFAILURE.115.002594 
Bharadwaj, P., Helfen, K. M., Deleon, L. J., Thompson, D. M., Ward, J. R., Patterson, J., 





Making the case for palliative care at the system level: Outcomes data. Journal of 
Palliative Medicine, 19(3), 255-258. https://doi.org/10.1089/jpm.2015.0234 
Blecker, S., Anderson, G. F., Herbert, R., Wang, N. Y., & Brancati, F. L. (2011). Hospice care 
and resource utilization in Medicare beneficiaries with heart failure. Medical Care, 
49(11), 985-991. https://doi.org/10.1097/MLR.0b013e318235c221 
Bradley, E. H., Curry, L., Horwitz, L. I., Sipsma, H., Wang, Y., Walsh, M. N., Goldmann, D., 
White, N., Pina, I., & Krumholz, H. M. (2013). Hospital strategies associated with 30-day 
readmission rates for patients with heart failure. Circulation: Cardiovascular Quality and 
Outcomes, 6(4), 444-450. https://doi.org/10.1161/CIRCOUTCOMES.111.000101 
Brannstrom, M., & Boman, K. (2014). Effects of person-centred and integrated chronic heart 
failure and palliative home care. PREFER: A randomized controlled study. European 
Journal of Heart Failure, 16(10), 1142-1151. https://doi.org/10.1002/ejhf.151 
Braun, L. T., Grady, K. L., Kutner, J. S., Adler, E., Berlinger, N., Boss, R., Butler, J., 
Enguidanos, S., Friebert, S., Gardner, T. J., Higgins, P., Holloway, R., Konig, M., Meier, 
D., Morrissey, M. B., Quest, T. E., Wiegand, D. L., Coombs-Lee, B., Fitchett, G., Gupta, 
C., … American Heart Association Advocacy Coordinating Committee (2016). Palliative 
care and cardiovascular disease and stroke: A policy statement from the American Heart 
Association/American Stroke Association. Circulation, 134(11), e198–e225. 
https://doi.org/10.1161/CIR.0000000000000438  
Brian Cassel, J., Kerr, K. M., McClish, D. K., Skoro, N., Johnson, S., Wanke, C., & Hoefer, D. 
(2016). Effect of a home-based palliative care program on healthcare use and costs. 






Brumley, R., Enguidanos, S., Jamison, P., Seitz, R., Morgenstern, N., Saito, S., Mcllwane, J., 
Hillary, K., & Gonzalez, J. (2007). Increased satisfaction with care and lower costs: 
Results of a randomized trial of in-home palliative care. Journal of the American 
Geriatrics Society, 55(7), 993-1000. https://doi.org/10.1111/j.1532-5415.2007.01234.x 
Bueno, H., Ross, J. S., Wang, Y., Chen, J., Vidan, M. T., Normand, S. L., Curtis, J., Drye, E., 
Lichtman, J,m Keenan, P., Kosiborod, M., & Krumholz, H. M. (2010). Trends in length 
of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 
1993-2006. JAMA, 303(21), 2141-2147. https://doi.org/10.1001/jama.2010.748 
Burke, R. E., Schnipper, J. L., Williams, M. V., Robinson, E. J., Vasilevskis, E. E., Kripalani, S., 
Metlay, J., Fletcher, G., Auerbach, A., & Donze, J. D. (2017). The HOSPITAL score 
predicts potentially preventable 30-day readmissions in conditions targeted by the 
hospital readmissions reduction program. Medical Care, 55(3), 285-290. 
https://doi.org/10.1097/MLR.0000000000000665 
Cameron, L. D. (2003). Anxiety, cognition, and responses to health threats. In L. D. Cameron & 
H. Leventhal (Eds.), The self-regulation of health and illness behaviour (p. 157–183). 
Routledge. 
Centers for Medicare & Medicaid Services. (2012). Revisions to quality of care standards. 
https://www.cms.gov/ 
Centers for Medicare & Medicaid Services. (2013). Decision memo for ventricular assist devices 







Centers for Medicare and Medicaid Services. (n.d.). Readmissions reduction program (HRRP). 
https://www.cms.gov/medicare/medicare-fee-for-service-
payment/acuteinpatientpps/readmissions-reduction-program.html 
Centers for Medicare and Medicaid Services. (2015). Medicare program; hospital inpatient 
prospective payment systems for acute care hospitals and the long-term care hospital 
prospective payment system policy changes and fiscal year 2016 rates; revisions of 
quality reporting requirements for specific providers, including changes related to the 
Electronic Health Record Incentive Program; extensions of the Medicare-dependent, 
Small Rural Hospital Program and the low-volume payment adjustment for hospitals. 
Final rule; interim final rule with comment period. Federal Register, 80(158), 49325-
49886. https://pubmed.ncbi.nlm.nih.gov/26292371/ 
Chamberlain, A. M., Dunlay, S. M., Gerber, Y., Manemann, S. M., Jiang, R., Weston, S. A., & 
Roger, V. L. (2017). Burden and timing of hospitalizations in heart failure: A community 
study. Mayo Clinic Proceedings, 92(2), 184-192. 
https//doi.org/10.1016/j.mayocp.2016.11.009 
Chatterjee, P., & Joynt Maddox, K. E. (2018). US national trends in mortality from acute 
myocardial infarction and heart failure: Policy success or failure? JAMA Cardiol, 3(4), 
336-340. https//doi.org/10.1001/jamacardio.2018.0218 
Chaudhry, S. I., Mattera, J. A., Curtis, J. P., Spertus, J. A., Herrin, J., Lin, Z., Phillips, C., 
Hodshon, B., Cooper, L., & Krumholz, H. M. (2010). Telemonitoring in patients with 






Cheung, W. Y., Schaefer, K., May, C. W., Glynn, R. J., Curtis, L. H., Stevenson, L. W., & 
Setoguchi, S. (2013). Enrollment and events of hospice patients with heart failure vs. 
cancer. Journal of Pain and Symptom Management, 45(3), 552-560. 
https//doi.org/10.1016/j.jpainsymman.2012.03.006 
Chin, D. L., Bang, H., Manickam, R. N., & Romano, P. S. (2016). Rethinking thirty-day hospital 
readmissions: Shorter intervals might be better indicators of quality of care. Health 
Affairs, 35(10), 1867-1875. https//doi.org/0.1377/hlthaff.2016.0205 
Chuang, E., & Fausto, J. (2014). Effect of inpatient palliative care consultation on CMS-based 
30-day readmission rates: A retrospective cohort study. [Paper presentation]. American 
Academy of Hospice and Palliative Medicine Annual Meeting, San Diego, United States.  
Chuang, E., Kim, G., Blank, A. E., Southern, W., & Fausto, J. (2017). 30-Day readmission rates 
in patients admitted for heart failure exacerbation with and without palliative care 
consultation: A retrospective cohort study. Journal of Palliative Medicine, 20(2), 163-
169. https//doi.org/10.1089/jpm.2016.0305 
Claret, P. G., Stiell, I. G., Yan, J. W., Clement, C. M., Rowe, B. H., Calder, L. A., & Perry, J. J. 
(2016). Characteristics and outcomes for acute heart failure in elderly patients presenting 
to the ED. American Journal of Emergency Medicine, 34(11), 2159-2166. 
https//doi.org/10.1016/j.ajem.2016.08.015 
Connor, S. R. (2007). Development of hospice and palliative care in the United States. Omega 
(Westport), 56(1), 89-99. https://www.ncbi.nlm.nih.gov/pubmed/18051022 
Connor, S. R., Pyenson, B., Fitch, K., Spence, C., & Iwasaki, K. (2007). Comparing hospice and 





of Pain and Symptom Management, 33(3), 238-246. 
https//doi.org/10.1016/j.jpainsymman.2006.10.010 
Contrada, R. J., & Coups, E. J. (2003). Personality and self-regulation in health and disease: 
Toward an integrative perspective. In The self-regulation of health and illness behaviour 
(pp. 66-94). Taylor and Francis. 
Cook, T. D., Greene, S. J., Kalogeropoulos, A. P., Fonarow, G. C., Zea, R., Swedberg, K., . . . 
Butler, J. (2016). Temporal changes in postdischarge mortality risk after hospitalization 
for heart failure (from the EVEREST Trial). American Journal of Cardiology, 117(4), 
611-616. https://doi.org/10.1016/j.amjcard.2015.11.050 
Dahlin, C. (2013). The clinical practice guidelines for quality palliative care. 
https://www.nationalcoalitionhpc.org/wp-
content/uploads/2017/04/NCP_Clinical_Practice_Guidelines_3rd_Edition.pdf 
Davies, E., & Higginson, I. J. (2004). Better palliative care for older people. World Health 
Organization. https://www.euro.who.int/__data/assets/pdf_file/0009/98235/E82933.pdf 
Davis, J. D., Olsen, M. A., Bommarito, K., LaRue, S. J., Saeed, M., Rich, M. W., & Vader, J. M. 
(2017). All-payer analysis of heart failure hospitalization 30-day readmission: 
comorbidities matter. American Journal of Medicine, 130(1), 93 e99-93 e28. 
https://doi.org/10.1016/j.amjmed.2016.07.030 
Desai, N. R., Ross, J. S., Kwon, J. Y., Herrin, J., Dharmarajan, K., Bernheim, S. M., Krumholz, 
H., & Horwitz, L. I. (2016). Association between hospital penalty status under the 
hospital readmission reduction program and readmission rates for target and nontarget 





DeVore, A. D., Hammill, B. G., Hardy, N. C., Eapen, Z. J., Peterson, E. D., & Hernandez, A. F. 
(2016). Has public reporting of hospital readmission rates affected patient outcomes?: 
Analysis of Medicare claims data. Journal of the American College of Cardiology, 67(8), 
963-972. https://doi.org/10.1016/j.jacc.2015.12.037 
Dharmarajan, K., Hsieh, A. F., Lin, Z., Bueno, H., Ross, J. S., Horwitz, L. I., Barreto-Filho, J. 
A., Kim, N., Bernheim, S. M., Suter, L. G., Drye, E. E., & Krumholz, H. M. (2013). 
Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute 
myocardial infarction, or pneumonia. JAMA, 309(4), 355–363. 
https://doi.org/10.1001/jama.2012.216476 
Dharmarajan, K., Wang, Y., Lin, Z., Normand, S. T., Ross, J. S., Horwitz, L. I., Desai, N., Suter, 
L., Drye, E., Bernheim, S., & Krumholz, H. M. (2017). Association of changing hospital 
readmission rates with mortality rates after hospital discharge. JAMA, 318(3), 270-278. 
https://doi.org/10.1001/jama.2017.8444 
Dionne-Odom, J. N., Kono, A., Frost, J., Jackson, L., Ellis, D., Ahmed, A., Azuero, A., & 
Bakitas, M. (2014). Translating and testing the ENABLE: CHF-PC concurrent palliative 
care model for older adults with heart failure and their family caregivers. Journal of 
Palliative Medicine, 17(9), 995-1004. https://doi.org/10.1089/jpm.2013.0680 
Diop, M. S., Rudolph, J. L., Zimmerman, K. M., Richter, M. A., & Skarf, L. M. (2017). 
Palliative care interventions for patients with heart failure: A systematic review and meta-






Dumanovsky, T., Augustin, R., Rogers, M., Lettang, K., Meier, D. E., & Morrison, R. S. (2016). 
The growth of palliative care in U.S. hospitals: A status report. Journal of Palliative 
Medicine, 19(1), 8-15. https://doi.org/10.1089/jpm.2015.0351 
Dunlay, S. M., Gheorghiade, M., Reid, K. J., Allen, L. A., Chan, P. S., Hauptman, P. J., Zannad, 
F., Maggioni, A. P., Swedberg, K., Konstam, M. A., & Spertus, J. A. (2010). Critical 
elements of clinical follow-up after hospital discharge for heart failure: insights from the 
EVEREST trial. European Journal of Heart Failure, 12(4), 367-374. 
https://doi.org/10.1093/eurjhf/hfq019 
Dunlay, S. M., & Roger, V. L. (2014). Understanding the epidemic of heart failure: Past, present, 
and future. Current Heart Failure Reports, 11(4), 404-415. 
https://doi.org/10.1007/s11897-014-0220-x 
Dunlay, S. M., Shah, N. D., Shi, Q., Morlan, B., VanHouten, H., Long, K. H., & Roger, V. L. 
(2011). Lifetime costs of medical care after heart failure diagnosis. Circulation: 
Cardiovascular Quality and Outcomes, 4(1), 68-75. 
https://doi.org/10.1161/CIRCOUTCOMES.110.957225 
Dunlay, S. M., Swetz, K. M., Redfield, M. M., Mueller, P. S., & Roger, V. L. (2014). 
Resuscitation preferences in community patients with heart failure. Circulation: 
Cardiovascular Quality and Outcomes, 7(3), 353-359. 
https://doi.org/10.1161/CIRCOUTCOMES.113.000759 
Elixhauser, A., Steiner, C., Harris, D. R., & Coffey, R. M. (1998). Comorbidity measures for use 






Enguidanos, S., Coulourides Kogan, A. M., Schreibeis-Baum, H., Lendon, J., & Lorenz, K. 
(2015). "Because I was sick": seriously ill veterans' perspectives on reason for 30-day 
readmissions. Journal of the American Geriatrics Society, 63(3), 537-542. 
https://doi.org/10.1111/jgs.13238 
Enguidanos, S., Vesper, E., & Lorenz, K. (2012). 30-day readmissions among seriously ill older 
adults. Journal of Palliative Medicine, 15(12), 1356-1361. 
https://doi.org/10.1089/jpm.2012.0259 
Evangelista, L. S., Lombardo, D., Malik, S., Ballard-Hernandez, J., Motie, M., & Liao, S. 
(2012). Examining the effects of an outpatient palliative care consultation on symptom 
burden, depression, and quality of life in patients with symptomatic heart failure. Journal 
of Cardiac Failure, 18(12), 894-899. https://doi.org/10.1016/j.cardfail.2012.10.019 
Fang, J. C., Ewald, G. A., Allen, L. A., Butler, J., Westlake Canary, C. A., Colvin-Adams, M., . . 
. Heart Failure Society of America Guidelines, C. (2015). Advanced (stage D) heart 
failure: A statement from the Heart Failure Society of America guidelines committee. 
Journal of Cardiac Failure, 21(6), 519-534. 
https://doi.org/10.1016/j.cardfail.2015.04.013 
Fasolino, T., & Phillips, M. (2016). Utilizing risk readmission assessment tool for nonhospice 
palliative care consults in heart failure patients. Journal of Palliative Medicine, 19(10), 
1098-1101. https://doi.org/10.1089/jpm.2015.0228 
Feldman, D., Pamboukian, S. V., Teuteberg, J. J., Birks, E., Lietz, K., Moore, S. A., . . . Lung, T. 
(2013). The 2013 International Society for Heart and Lung Transplantation Guidelines 
for mechanical circulatory support: Executive summary. Journal of Heart and Lung 





Figueroa, J. F., Tsugawa, Y., Zheng, J., Orav, E. J., & Jha, A. K. (2016). Association between 
the value-based purchasing pay for performance program and patient mortality in US 
hospitals: Observational study. BMJ, 353, i2214. 
https://www.ncbi.nlm.nih.gov/pubmed/27160187 
Fischer, C., Steyerberg, E. W., Fonarow, G. C., Ganiats, T. G., & Lingsma, H. F. (2015). A 
systematic review and meta-analysis on the association between quality of hospital care 
and readmission rates in patients with heart failure. American Heart Journal, 170(5), 
1005-1017 e1002. https://doi.org/10.1016/j.ahj.2015.06.026 
Fonarow, G. C., Konstam, M. A., & Yancy, C. W. (2017). The hospital readmission reduction 
program is associated with fewer readmissions, more deaths: Time to reconsider. Journal 
of the American College of Cardiology, 70(15), 1931-1934. 
https://doi.org/10.1016/j.jacc.2017.08.046 
Freedland, K. E., Carney, R. M., Rich, M. W., Steinmeyer, B. C., Skala, J. A., & Dávila-Román, 
V. G. (2016). Depression and multiple rehospitalizations in patients with heart failure. 
Clinical Cardiology, 39(5), 257-262. https://doi.org/10.1002/clc.22520 
Fromme, E. K., Bascom, P. B., Smith, M. D., Tolle, S. W., Hanson, L., Hickam, D. H., & 
Osborne, M. L. (2006). Survival, mortality, and location of death for patients seen by a 
hospital-based palliative care team. Journal of Palliative Medicine, 9(4), 903-911. 
https://doi.org/10.1089/jpm.2006.9.903 
Garrido, M. M., Kelley, A. S., Paris, J., Roza, K., Meier, D. E., Morrison, R. S., & Aldridge, M. 
D. (2014). Methods for constructing and assessing propensity scores. Health Services 





Gelfman, L. P., Bakitas, M., Warner Stevenson, L., Kirkpatrick, J. N., & Goldstein, N. E. (2017). 
The state of the science on integrating palliative care in heart failure. Journal of 
Palliative Medicine, 20(6), 592-603. https://doi.org/10.1089/jpm.2017.0178 
Gerber, Y., Weston, S. A., Redfield, M. M., Chamberlain, A. M., Manemann, S. M., Jiang, R., 
Killian, J., & Roger, V. L. (2015). A contemporary appraisal of the heart failure epidemic 
in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med, 175(6), 996-1004. 
https://doi.org/10.1001/jamainternmed.2015.0924 
Gheorghiade, M., Pang, P. S., Ambrosy, A. P., Lan, G., Schmidt, P., Filippatos, G., Konstam, 
M., Swedberg, K., Cook, T., Traver, B., Maggioni, A., Burnett, J., Grinfeld, L., Udelson, 
J., & Zannad, F. (2012). A comprehensive, longitudinal description of the in-hospital and 
post-discharge clinical, laboratory, and neurohormonal course of patients with heart 
failure who die or are re-hospitalized within 90 days: Analysis from the EVEREST trial. 
Heart Failure Reviews, 17(3), 485-509. https://doi.org/10.1007/s10741-011-9280-0 
Gilotra, N. A., Shpigel, A., Okwuosa, I. S., Tamrat, R., Flowers, D., & Russell, S. D. (2017). 
Patients commonly believe their heart failure hospitalizations are preventable and identify 
worsening heart failure, nonadherence, and a knowledge gap as reasons for admission. 
Journal of Cardiac Failure, 23(3), 252-256. 
https://doi.org/10.1016/j.cardfail.2016.09.024 
Goldstein, E. B. (1999). Sensation & Perception (5th ed.). Brooks/Cole. 
Gooding, J., & Jette, A. M. (1985). Hospital readmissions among the elderly. Journal of the 






Goodlin, S. J. (1997). What is palliative care? Hospital Practice, 32(2), 13-16. 
https://www.ncbi.nlm.nih.gov/pubmed/9040418 
Goodlin, S. J. (2005). Palliative care for end-stage heart failure. Current Heart Failure Reports, 
2(3), 155-160. https://www.ncbi.nlm.nih.gov/pubmed/16138952 
Goodlin, S. J. (2009). Palliative care in congestive heart failure. Journal of the American College 
of Cardiology, 54(5), 386-396. https://doi.org/10.1016/j.jacc.2009.02.078 
Goodlin, S. J., Hauptman, P. J., Arnold, R., Grady, K., Hershberger, R. E., Kutner, J., Masoudi, 
F., Spertus, J., Dracup, K., Cleary, J., Medak, R., Crispell, K., Pina, I., Stuart, B., 
Whitney, C., Rector, T., Teno, J., & Renlund, D. G. (2004). Consensus statement: 
Palliative and supportive care in advanced heart failure. Journal of Cardiac Failure, 
10(3), 200-209. https://www.ncbi.nlm.nih.gov/pubmed/15190529 
Gordis, L. (2009). Epidemiology (4th ed.). Elsevier/Saunders. 
Gordon, N. A., O'Riordan, D. L., Dracup, K. A., De Marco, T., & Pantilat, S. Z. (2017). Let us 
talk about it: Heart failure patients' preferences toward discussions about prognosis, 
advance care planning, and spiritual support. Journal of Palliative Medicine, 20(1), 79-
83. https://doi.org/10.1089/jpm.2016.0097 
Gu, Q., Koenig, L., Faerberg, J., Steinberg, C. R., Vaz, C., & Wheatley, M. P. (2014). The 
Medicare Hospital Readmissions Reduction Program: potential unintended consequences 
for hospitals serving vulnerable populations. Health Services Research, 49(3), 818-837. 
https://doi.org/10.1111/1475-6773.12150 
Gupta, A., Allen, L. A., Bhatt, D. L., Cox, M., DeVore, A. D., Heidenreich, P. A., Hernandez, 
A., Peterson, E., Matsouaka, R., Yancy, C., & Fonarow, G. C. (2017). Association of the 





outcomes in heart failure. JAMA Cardiol, 10.1001/jamacardio.2017.4265. 
https://doi.org/10.1001/jamacardio.2017.4265 
Heidenreich, P. A., Albert, N. M., Allen, L. A., Bluemke, D. A., Butler, J., Fonarow, G. C., 
Ikonomidis, J., Khavjou, O., Konstam, M.,  Maddox, T.,  Nichol, G.,   Pham, M.,  Piña, 
I., & Trogdon, J. . . Stroke Council. (2013). Forecasting the impact of heart failure in the 
United States: a policy statement from the American Heart Association. Circulation: 
Heart Failure, 6(3), 606-619. https://doi.org/10.1161/HHF.0b013e318291329a 
Higgins, J. P., Altman, D. G., Gøtzsche, P. C., Jüni, P., Moher, D., Oxman, A. D., Savovic, J., 
Schulz, K. F., Weeks, L., Sterne, J. A., Cochrane Bias Methods Group, & Cochrane 
Statistical Methods Group (2011). The Cochrane Collaboration's tool for assessing risk of 
bias in randomised trials. BMJ (Clinical Research Ed.), 343, d5928. 
https://doi.org/10.1136/bmj.d5928  
Hopp, F. P., Zalenski, R. J., Waselewsky, D., Burn, J., Camp, J., Welch, R. D., & Levy, P. 
(2016). Results of a hospital-based palliative care intervention for patients with an acute 
exacerbation of chronic heart failure. Journal of Cardiac Failure, 22(12), 1033-1036. 
https://doi.org/10.1016/j.cardfail.2016.04.004 
Horne, R. (2003). Treatment perceptions and self-regulation. In L. D. Cameron & H. Leventhal 
(Eds.), The self-regulation of health and illness behaviour (p. 138-153). Routledge. 
Horne, R., Chapman, S. C., Parham, R., Freemantle, N., Forbes, A., & Cooper, V. (2013). 
Understanding patients' adherence-related beliefs about medicines prescribed for long-
term conditions: A meta-analytic review of the Necessity-Concerns Framework. PloS 





Hua, M., Li, G., Clancy, C., Morrison, R. S., & Wunsch, H. (2017). Validation of the V66.7 code 
for palliative care consultation in a single academic medical center. Journal of Palliative 
Medicine, 20(4), 372-377. https://doi.org/10.1089/jpm.2016.0363 
Huffman, M. D., Berry, J. D., Ning, H., Dyer, A. R., Garside, D. B., Cai, X., Daviglus, M., & 
Lloyd-Jones, D. M. (2013). Lifetime risk for heart failure among white and black 
Americans: cardiovascular lifetime risk pooling project. Journal of the American College 
of Cardiology, 61(14), 1510-1517. https://doi.org/10.1016/j.jacc.2013.01.022 
Hunt, S. A., American College of Cardiology, & American Heart Association Task Force on 
Practice Guidelines. (2005). ACC/AHA 2005 guideline update for the diagnosis and 
management of chronic heart failure in the adult: A report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines (Writing 
Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart 
Failure). Journal of the American College of Cardiology, 46(6), e1-82. 
https://doi.org/10.1016/j.jacc.2005.08.022 
Jaarsma, T., Beattie, J. M., Ryder, M., Rutten, F. H., McDonagh, T., Mohacsi, P., Murray, S. A., 
Grodzicki, T., Bergh, I., Metra, M., Ekman, I., Angermann, C., Leventhal, M., Pitsis, A., 
Anker, S. D., Gavazzi, A., Ponikowski, P., Dickstein, K., Delacretaz, E., Blue, L., … 
Advanced Heart Failure Study Group of the HFA of the ESC (2009). Palliative care in 
heart failure: A position statement from the palliative care workshop of the Heart Failure 
Association of the European Society of Cardiology. European Journal of Heart 
Failure, 11(5), 433-443. https://doi.org/10.1093/eurjhf/hfp041  
Jayaram, N. M., Khariton, Y., Krumholz, H. M., Chaudhry, S. I., Mattera, J., Tang, F., Herrin, J., 





Circulation: Cardiovascular Quality and Outcomes, 10(12). 
https://doi.org/10.1161/CIRCOUTCOMES.117.004148 
Jenkins, R. L., Bemiss, E. L., Jr., & Lorr, M. (1953). Duration of hospitalization, readmission 
rate and stability of diagnoses in veterans hospitalized with neuropsychiatric diagnoses. 
Psychiatric Quarterly, 27(1), 59-72. https://www.ncbi.nlm.nih.gov/pubmed/13014200 
Jha, A. K. (2015). Seeking rational approaches to fixing hospital readmissions. JAMA, 314(16), 
1681-1682. https://doi.org/10.1001/jama.2015.13254 
Joynt, K. E., & Jha, A. K. (2012). Thirty-day readmissions--truth and consequences. New 
England Journal of Medicine, 366(15), 1366-1369. 
https://doi.org/10.1056/NEJMp1201598 
Joynt, K. E., & Jha, A. K. (2013). Characteristics of hospitals receiving penalties under the 
Hospital Readmissions Reduction Program. JAMA, 309(4), 342-343. 
https://doi.org/10.1001/jama.2012.94856 
Joynt, K. E., Orav, E. J., & Jha, A. K. (2011). Thirty-day readmission rates for Medicare 
beneficiaries by race and site of care. JAMA, 305(7), 675-681. 
https://doi.org/10.1001/jama.2011.123 
Jurgens, C. Y., Goodlin, S., Dolansky, M., Ahmed, A., Fonarow, G. C., Boxer, R., Arena, R., 
Blank, L., Buck, H. G., Cranmer, K., Fleg, J. L., Lampert, R. J., Lennie, T. A., 
Lindenfeld, J., Piña, I. L., Semla, T. P., Trebbien, P., Rich, M. W., & American Heart 
Association Council on Quality of Care and Outcomes Research and the Heart Failure 
Society of America (2015). Heart failure management in skilled nursing facilities: a 





of America. Circulation. Heart Failure, 8(3), 655–687. 
https://doi.org/10.1161/HHF.0000000000000005 
Kane, P. M., Murtagh, F. E., Ryan, K., Mahon, N. G., McAdam, B., McQuillan, R., Ellis-Smith, 
C., Tracey, C., Howley, C., Raleigh, C., O'Gara, G., Higginson, I. J., & Daveson, B. A. 
(2015). The gap between policy and practice: a systematic review of patient-centred care 
interventions in chronic heart failure. Heart Failure Reviews, 20(6), 673–687. 
https://doi.org/10.1007/s10741-015-9508-5 
Kansagara, D., Englander, H., Salanitro, A., Kagen, D., Theobald, C., Freeman, M., & Kripalani, 
S. (2011). Risk prediction models for hospital readmission: a systematic review. JAMA, 
306(15), 1688-1698. https://doi.org/10.1001/jama.2011.1515 
Kaptein, A. A., Scharloo, M., Helder, D. I., Kleijn, W. C., van Korlaar, I. M., & Woertman, M. 
(2003). Representations of chronic illness. In L. D. Cameron & H. Leventhal (Eds.), The 
self-regulation of health and illness behaviour (p. 97-118). Routledge.  
Kavalieratos, D., Corbelli, J., Zhang, D., Dionne-Odom, J. N., Ernecoff, N. C., Hanmer, J., 
Hoydich, Z. P., Ikejiani, D. Z., Klein-Fedyshin, M., Zimmermann, C., Morton, S. C., 
Arnold, R. M., Heller, L., & Schenker, Y. (2016). Association between palliative care 
and patient and caregiver outcomes: A systematic review and meta-
analysis. JAMA, 316(20), 2104-2114. https://doi.org/10.1001/jama.2016.16840 
Kavalieratos, D., Gelfman, L. P., Tycon, L. E., Riegel, B., Bekelman, D. B., Ikejiani, D. Z., 
Goldstein, N., Kimmel, S. E., Bakitas, M. A., & Arnold, R. M. (2017). Palliative care in 
heart failure: Rationale, evidence, and future priorities. Journal of the American College 





Kavalieratos, D., Kamal, A. H., Abernethy, A. P., Biddle, A. K., Carey, T. S., Dev, S., Reeve, B. 
B., & Weinberger, M. (2014). Comparing unmet needs between community-based 
palliative care patients with heart failure and patients with cancer. Journal of Palliative 
Medicine, 17(4), 475-481. https://doi.org/10.1089/jpm.2013.0526 
Kavalieratos, D., Mitchell, E. M., Carey, T. S., Dev, S., Biddle, A. K., Reeve, B. B., Abernethy, 
A. P., & Weinberger, M. (2014). "Not the 'grim reaper service'": An assessment of 
provider knowledge, attitudes, and perceptions regarding palliative care referral barriers 
in heart failure. Journal of the American Heart Association, 3(1), e000544. 
https://doi.org/10.1161/JAHA.113.000544 
Kavalieratos, D., Rollman, B. L., & Arnold, R. M. (2016). Homeward bound, not hospital 
rebound: How transitional palliative care can reduce readmission. Heart, 102(14), 1079-
1080. https://doi.org/10.1136/heartjnl-2016-309385 
Khan, R. F., Feder, S., Goldstein, N. E., & Chaudhry, S. I. (2015). Symptom burden among 
patients who were hospitalized for heart failure. JAMA Intern Med, 175(10), 1713-1715. 
https://doi.org/10.1001/jamainternmed.2015.3871 
Khder, Y., Shi, V., McMurray, J. J. V., & Lefkowitz, M. P. (2017). Sacubitril/Valsartan 
(LCZ696) in heart failure. Handbook of Experimental Pharmacology, 243, 133-165. 
https://doi.org/10.1007/164_2016_77 
Khera, R., Dharmarajan, K., & Krumholz, H. M. (2018). Rising mortality in patients with heart 
failure in the united states: Facts versus fiction. JACC Heart Fail, 6(7), 610-612. 
https://doi.org/10.1016/j.jchf.2018.02.011 
Khera, R., Dharmarajan, K., Wang, Y., Lin, Z., Bernheim, S. M., Wang, Y., Normand, S. T., & 





with mortality during and after hospitalization for acute myocardial infarction, heart 
failure, and pneumonia. JAMA Network Open, 1(5), e182777. 
https://doi.org/10.1001/jamanetworkopen.2018.2777  
Kirkpatrick, J. N., Hauptman, P. J., Swetz, K. M., Blume, E. D., Gauvreau, K., Maurer, M., & 
Goodlin, S. J. (2016). Palliative care for patients with end-stage cardiovascular disease 
and devices: A report from the palliative care working group of the geriatrics section of 
the American College of Cardiology. JAMA Intern Med, 176(7), 1017-1019. 
https://doi.org/10.1001/jamainternmed.2016.2096 
Korda, R. J., Du, W., Day, C., Page, K., Macdonald, P. S., & Banks, E. (2017). Variation in 
readmission and mortality following hospitalisation with a diagnosis of heart failure: 
prospective cohort study using linked data. BMC Health Services Research, 17(1), 220. 
https://doi.org/10.1186/s12913-017-2152-0 
Krumholz, H. M., Chaudhry, S. I., Spertus, J. A., Mattera, J. A., Hodshon, B., & Herrin, J. 
(2016). Do non-clinical factors improve prediction of readmission risk?: Results from the 
Tele-HF Study. JACC Heart Fail, 4(1), 12-20. https://doi.org/10.1016/j.jchf.2015.07.017 
Krumholz, H. M., Lin, Z., Keenan, P. S., Chen, J., Ross, J. S., Drye, E. E., Bernheim, S. M., 
Wang, Y., Bradley, E. H., Han, L. F., & Normand, S. L. (2013). Relationship between 
hospital readmission and mortality rates for patients hospitalized with acute myocardial 
infarction, heart failure, or pneumonia. JAMA, 309(6), 587–593. 
https://doi.org/10.1001/jama.2013.333 
Krumholz, H. M., Merrill, A. R., Schone, E. M., Schreiner, G. C., Chen, J., Bradley, E. H., 
Wang, Y., Wang, Y., Lin, Z., Straube, B. M., Rapp, M. T., Normand, S. L., & Drye, E. E. 





30-day mortality and readmission. Circulation. Cardiovascular Quality and 
Outcomes, 2(5), 407-413. https://doi.org/10.1161/CIRCOUTCOMES.109.883256 
Leventhal, H., Brissette, I., & Leventhal, E. A. (2003). The common-sense model of self-
regulation of health and illness. In L. D. Cameron & H. Leventhal (Eds.), The self-
regulation of health and illness behaviour (p. 42-65). Routledge.  
Leventhal, H., Phillips, L. A., & Burns, E. (2016). The Common-Sense Model of Self-
Regulation (CSM): A dynamic framework for understanding illness self-management. 
Journal of Behavioral Medicine, 39(6), 935-946. https://doi.org/0.1007/s10865-016-
9782-2 
Levy, D., Kenchaiah, S., Larson, M. G., Benjamin, E. J., Kupka, M. J., Ho, K. K., Murabito, J. 
M., & Vasan, R. S. (2002). Long-term trends in the incidence of and survival with heart 
failure. The New England Journal of Medicine, 347(18), 1397–1402. 
https://doi.org/10.1056/NEJMoa020265  
Lewis, L. (1978). Three-ring circuit: A study of care of patients with congestive heart failure. 
QRB: Quality Review Bulletin, 4(10), 12-14. 
https://www.ncbi.nlm.nih.gov/pubmed/215954 
Lorenz, K. A., Lynn, J., Dy, S. M., Shugarman, L. R., Wilkinson, A., Mularski, R. A., Morton, S. 
C., Hughes, R. G., Hilton, L. K., Maglione, M., Rhodes, S. L., Rolon, C., Sun, V. C., & 
Shekelle, P. G. (2008). Evidence for improving palliative care at the end of life: A 






Lukas, L., Foltz, C., & Paxton, H. (2013). Hospital outcomes for a home-based palliative 
medicine consulting service. Journal of Palliative Medicine, 16(2), 179-184. 
https://doi.org/10.1089/jpm.2012.0414 
Maciver, J., & Ross, H. J. (2018). A palliative approach for heart failure end-of-life care. Current 
Opinion in Cardiology, 33(2), 202-207. https://doi.org/10.1097/HCO.0000000000000484 
Mandawat, A., Heidenreich, P. A., Mandawat, A., & Bhatt, D. L. (2016). Trends in palliative 
care use in veterans with severe heart failure using a large national cohort. JAMA 
Cardiol, 1(5), 617-619. https://doi.org/10.1001/jamacardio.2016.1687 
Martin, R., & Suls, J. (2003). How gender stereotypes influence self-regulation of cardiac health 
care-seeking and adaptation. In L. D. Cameron & H. Leventhal (Eds.), The self-
regulation of health and illness behaviour (p. 220-241). Routledge.  
May, P., Normand, C., Cassel, J. B., Del Fabbro, E., Fine, R. L., Menz, R., Morrison, C. A., 
Penrod, J. D., Robinson, C., & Morrison, R. S. (2018). Economics of Palliative Care for 
Hospitalized Adults With Serious Illness: A Meta-analysis. JAMA Internal 
Medicine, 178(6), 820-829. https://doi.org/10.1001/jamainternmed.2018.0750  
May, P., Normand, C., & Morrison, R. S. (2014). Economic impact of hospital inpatient 
palliative care consultation: Review of current evidence and directions for future 
research. Journal of Palliative Medicine, 17(9), 1054-1063. 
https://doi.org/10.1089/jpm.2013.0594 
McCullough, P. A., Philbin, E. F., Spertus, J. A., Kaatz, S., Sandberg, K. R., Weaver, W. D., & 
Resource Utilization Among Congestive Heart Failure (REACH) Study (2002). 





Congestive Heart Failure (REACH) study. Journal of the American College of 
Cardiology, 39(1), 60-69. https://doi.org/10.1016/s0735-1097(01)01700-4 
McIlvennan, C. K., & Allen, L. A. (2016). Palliative care in patients with heart failure. BMJ, 
353, i1010. https://doi.org/10.1136/bmj.i1010 
McIlvennan, C. K., Eapen, Z. J., & Allen, L. A. (2015). Hospital readmissions reduction 
program. Circulation, 131(20), 1796-1803. 
https://doi.org/10.1161/CIRCULATIONAHA.114.010270 
McKelvie, R. S., Moe, G. W., Cheung, A., Costigan, J., Ducharme, A., Estrella-Holder, E., 
Ezekowitz, J. A., Floras, J., Giannetti, N., Grzeslo, A., Harkness, K., Heckman, G. A., 
Howlett, J. G., Kouz, S., Leblanc, K., Mann, E., O'Meara, E., Rajda, M., Rao, V., Simon, 
J., … Ross, H. J. (2011). The 2011 Canadian Cardiovascular Society heart failure 
management guidelines update: Focus on sleep apnea, renal dysfunction, mechanical 
circulatory support, and palliative care. The Canadian Journal of Cardiology, 27(3), 319-
338. https://doi.org/10.1016/j.cjca.2011.03.011 
MedCalc Version 15.1. (2018). Logistic regression. 
https://www.medcalc.org/manual/logistic_regression.php 
Medicare. (2017). Hospital Readmissions Reduction Program. 
https://www.medicare.gov/hospitalcompare/readmission-reduction-program.html 
Meier, D. E. (2011). Increased access to palliative care and hospice services: Opportunities to 






Meier, D. E., Back, A. L., Berman, A., Block, S. D., Corrigan, J. M., & Morrison, R. S. (2017). 
A national strategy for palliative care. Health Affairs, 36(7), 1265-1273. 
https://doi.org/10.1377/hlthaff.2017.0164 
Meyers, D. E., & Goodlin, S. J. (2016). End-of-life decisions and palliative care in advanced 
heart failure. Canadian Journal of Cardiology, 32(9), 1148-1156. 
https://doi.org/10.1016/j.cjca.2016.04.015 
Mirkin, K. A., Enomoto, L. M., Caputo, G. M., & Hollenbeak, C. S. (2017). Risk factors for 30-
day readmission in patients with congestive heart failure. Heart and Lung, 46(5), 357-
362. https://doi.org/10.1016/j.hrtlng.2017.06.005 
Modified: Ventricular assist device destination therapy requirements. (2014). In Joint 
Commission Perspectives (2014/03/29 ed., Vol. 34, pp. 6-7). 
https://www.jointcommission.org 
Moore, B. J., White, S., Washington, R., Coenen, N., & Elixhauser, A. (2017). identifying 
increased risk of readmission and in-hospital mortality using hospital administrative data: 
The AHRQ elixhauser comorbidity index. Medical Care, 55(7), 698-705. 
https://doi.org/10.1097/MLR.0000000000000735 
Morrison, R. S., & Meier, D. E. (2004). Clinical practice. Palliative care. New England Journal 
of Medicine, 350(25), 2582-2590. https://doi.org/10.1056/NEJMcp035232 
Murray, S. A., & Sheikh, A. (2008). Palliative care beyond cancer: Care for all at the end of life. 
BMJ, 336(7650), 958-959. https://doi.org/10.1136/bmj.39535.491238.94 






National Quality Forum. (2016). Hospital 30-day, all-cause, risk-standardized readmission rate 
(RSRR) following heart failure (HF) hospitalization. 
http://www.qualityforum.org/QPS/0330 
Naylor, M. D., Kurtzman, E. T., Grabowski, D. C., Harrington, C., McClellan, M., & Reinhard, 
S. C. (2012). Unintended consequences of steps to cut readmissions and reform payment 
may threaten care of vulnerable older adults. Health Affairs, 31(7), 1623-1632. 
https://doi.org/10.1377/hlthaff.2012.0110 
Nelson, C., Chand, P., Sortais, J., Oloimooja, J., & Rembert, G. (2011). Inpatient palliative care 
consults and the probability of hospital readmission. The Permanente Journal, 15(2), 48-
51. https://doi.org/10.7812/tpp/10-142  
Ng, A. Y., Wong, F. K., & Lee, P. H. (2016). Effects of a transitional palliative care model on 
patients with end-stage heart failure: Study protocol for a randomized controlled trial. 
Trials, 17, 173. https://doi.org/10.1186/s13063-016-1303-7 
O'Connor, N. R., Moyer, M. E., Behta, M., & Casarett, D. J. (2015). The impact of inpatient 
palliative care consultations on 30-day hospital readmissions. Journal of Palliative 
Medicine, 18(11), 956-961. https://doi.org/10.1089/jpm.2015.0138 
O'Hearn, M., Liu, J., Cudhea, F., Micha, R., & Mozaffarian, D. (2021). Coronavirus disease 
2019 hospitalizations attributable to cardiometabolic conditions in the United States: A 
comparative risk assessment analysis. J Am Heart Assoc, 10(5), e019259. 
https://doi.org/10.1161/JAHA.120.019259 
Pandey, A., Golwala, H., Hall, H. M., Wang, T. Y., Lu, D., Xian, Y., Chiswell, K., Joynt, K. E., 
Goyal, A., Das, S. R., Kumbhani, D., Julien, H., Fonarow, G. C., & de Lemos, J. A. 





risk-standardized readmission metric with care quality and outcomes after acute 
myocardial infarction: Findings from the National Cardiovascular Data Registry/Acute 
Coronary Treatment and Intervention Outcomes Network Registry-Get with the 
guidelines. JAMA Cardiology, 2(7), 723–731. 
https://doi.org/10.1001/jamacardio.2017.1143 
Pantilat, S. Z., O'Riordan, D. L., Dibble, S. L., & Landefeld, C. S. (2010). Hospital-based 
palliative medicine consultation: a randomized controlled trial. Archives of Internal 
Medicine, 170(22), 2038-2040. https://doi.org/10.1001/archinternmed.2010.460 
Patel, A., Parikh, R., Howell, E. H., Hsich, E., Landers, S. H., & Gorodeski, E. Z. (2015). Mini-
cog performance: novel marker of post discharge risk among patients hospitalized for 
heart failure. Circulation: Heart Failure, 8(1), 8-16. 
https://doi.org/10.1161/CIRCHEARTFAILURE.114.001438 
Pattenden, J. F., Mason, A. R., & Lewin, R. J. (2013). Collaborative palliative care for advanced 
heart failure: outcomes and costs from the 'Better Together' pilot study. BMJ Support 
Palliat Care, 3(1), 69-76. https://doi.org/10.1136/bmjspcare-2012-000251 
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J. C., Saunders, L. D., 
Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005). Coding algorithms for defining 
comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care, 43(11), 
1130-1139. https://doi.org/10.1097/01.mlr.0000182534.19832.83  
Rabow, M. W., Dibble, S. L., Pantilat, S. Z., & McPhee, S. J. (2004). The comprehensive care 
team: a controlled trial of outpatient palliative medicine consultation. Archives of Internal 





Rayner-Hartley, E., Virani, S., & Toma, M. (2018). Update on the management of acute heart 
failure. Current Opinion in Cardiology, 33(2), 225-231. 
https://doi.org/10.1097/HCO.0000000000000485 
Riegel, B., Masterson Creber, R., Hill, J., Chittams, J., & Hoke, L. (2016). Effectiveness of 
motivational interviewing in decreasing hospital readmission in adults with heart failure 
and multimorbidity. Clinical Nursing Research, 25(4), 362-377. 
https://doi.org/10.1177/1054773815623252 
Rogers, J. G., Patel, C. B., Mentz, R. J., Granger, B. B., Steinhauser, K. E., Fiuzat, M., Adams, 
P. A., Speck, A., Johnson, K. S., Krishnamoorthy, A., Yang, H., Anstrom, K. J., Dodson, 
G. C., Taylor, D. H., Jr, Kirchner, J. L., Mark, D. B., O'Connor, C. M., & Tulsky, J. A. 
(2017). Palliative care in heart failure: The PAL-HF randomized, controlled clinical 
trial. Journal of the American College of Cardiology, 70(3), 331–341. 
https://doi.org/10.1016/j.jacc.2017.05.030 
Sahlen, K. G., Boman, K., & Brännström, M. (2016). A cost-effectiveness study of person-
centered integrated heart failure and palliative home care: Based on a randomized 
controlled trial. Palliative Medicine, 30(3), 296-302. 
https://doi.org/10.1177/0269216315618544 
Savovic, J., Turner, R. M., Mawdsley, D., Jones, H. E., Beynon, R., Higgins, J. P. T., & Sterne, 
J. A. C. (2018). Association between risk-of-bias assessments and results of randomized 
trials in Cochrane Reviews: The ROBES meta-epidemiologic study. American Journal of 





Scheier, M. F., & Carver, C. S. (2003). Goals and confidence as self-regulatory elements 
underlying health and illness behavior. In L. D. Cameron & H. Leventhal (Eds.), The self-
regulation of health and illness behaviour (p. 17-41). Routledge.  
Schellinger, S., Anderson, E. W., Frazer, M. S., & Cain, C. L. (2018). Patient self-defined goals: 
Essentials of person-centered care for serious illness. American Journal of Hospice and 
Palliative Care, 35(1), 159-165. https://doi.org/10.1177/1049909117699600 
Schellinger, S., Sidebottom, A., & Briggs, L. (2011). Disease specific advance care planning for 
heart failure patients: Implementation in a large health system. Journal of Palliative 
Medicine, 14(11), 1224-1230. https://doi.org/10.1089/jpm.2011.0105 
Schulz, K. F., Altman, D. G., & Moher, D. (2010). CONSORT 2010 Statement: Updated 
guidelines for reporting parallel group randomised trials. BMJ, 340, c332. 
https://doi.org/10.1136/bmj.c332 
Schwarz, E. R., Baraghoush, A., Morrissey, R. P., Shah, A. B., Shinde, A. M., Phan, A., & 
Bharadwaj, P. (2012). Pilot study of palliative care consultation in patients with advanced 
heart failure referred for cardiac transplantation. Journal of Palliative Medicine, 15(1), 
12-15. https://doi.org/10.1089/jpm.2011.0256 
Setoguchi, S., Glynn, R. J., Stedman, M., Flavell, C. M., Levin, R., & Stevenson, L. W. (2010). 
Hospice, opiates, and acute care service use among the elderly before death from heart 
failure or cancer. American Heart Journal, 160(1), 139-144. 
https://doi.org/10.1016/j.ahj.2010.03.038 
Sidebottom, A. C., Jorgenson, A., Richards, H., Kirven, J., & Sillah, A. (2015). Inpatient 
palliative care for patients with acute heart failure: outcomes from a randomized trial. 





Silberzahn, R., Uhlmann, E. L., Martin, D. P., Anselmi, P., Aust, F., Awtrey, E., Bahník, Š., Bai, 
F., Bannard, C., Bonnier, E., Carlsson, R., Cheung, F., Christensen, G., Clay, R., Craig, 
M. A., Dalla Rosa, A., Dam, L., Evans, M. H., Flores Cervantes, I., … Nosek, B. A. 
(2018). Many analysts, one data set: Making transparent how variations in analytic 
choices affect results. Advances in Methods and Practices in Psychological Science, 337-
356. https://doi.org/10.1177/2515245917747646  
Singer, A. E., Goebel, J. R., Kim, Y. S., Dy, S. M., Ahluwalia, S. C., Clifford, M., Dzeng, E., 
O'Hanlon, C. E., Motala, A., Walling, A. M., Goldberg, J., Meeker, D., Ochotorena, C., 
Shanman, R., Cui, M., & Lorenz, K. A. (2016). Populations and interventions for 
palliative and end-of-life care: A systematic review. Journal of palliative medicine, 19(9), 
995-1008. https://doi.org/10.1089/jpm.2015.0367 
Sperry, B. W., Ruiz, G., & Najjar, S. S. (2015). Hospital readmission in heart failure, a novel 
analysis of a longstanding problem. Heart Failure Reviews, 20(3), 251-258. 
https://doi.org/10.1007/s10741-014-9459-2 
Sukul, D., Sinha, S. S., Ryan, A. M., Sjoding, M. W., Hummel, S. L., & Nallamothu, B. K. 
(2017). Patterns of readmissions for three common conditions among younger US adults. 
American Journal of Medicine, 130(10), 1220 e1221-1220 e1216. 
https://doi.org/10.1016/j.amjmed.2017.05.025 
Szekendi, M. K., Vaughn, J., Lal, A., Ouchi, K., & Williams, M. V. (2016). The prevalence of 
inpatients at 33 U.S. hospitals appropriate for and receiving referral to palliative care. 





Taylor, R. A., Smith, C. B., Coats, H., Gelfman, L. P., & Dionne-Odom, J. N. (2017). Update in 
Hospice and Palliative Care. Journal of Palliative Medicine, 20(11), 1189-1194. 
https://doi.org/10.1089/jpm.2017.0435 
Teixeira, A., Arrigo, M., Tolppanen, H., Gayat, E., Laribi, S., Metra, M., Seronde, M. F., Cohen-
Solal, A., & Mebazaa, A. (2016). Management of acute heart failure in elderly 
patients. Archives of cardiovascular diseases, 109(6-7), 422-430. 
https://doi.org/10.1016/j.acvd.2016.02.002 
Thoemmes, F. (2012). Propensity score matching in SPSS. 
https://arxiv.org/ftp/arxiv/papers/1201/1201.6385.pdf 
Turrise, S. (2016). Illness representations, treatment beliefs, medication adherence, and 30-day 
hospital readmission in adults with chronic heart failure: A prospective correlational 
study. Journal of Cardiovascular Nursing, 31(3), 245-254. 
https://doi.org/10.1097/JCN.0000000000000249 
Twaddle, M. L., Maxwell, T. L., Cassel, J. B., Liao, S., Coyne, P. J., Usher, B. M., Amin, A., & 
Cuny, J. (2007). Palliative care benchmarks from academic medical centers. Journal of 
palliative medicine, 10(1), 86-98. https://doi.org/10.1089/jpm.2006.0048  
Unroe, K. T., Greiner, M. A., Johnson, K. S., Curtis, L. H., & Setoguchi, S. (2012). Racial 
differences in hospice use and patterns of care after enrollment in hospice among 
Medicare beneficiaries with heart failure. American Heart Journal, 163(6), 987-993 
e983. https://doi.org/10.1016/j.ahj.2012.03.006 
von Schwarz, E. R., He, M., & Bharadwaj, P. (2020). palliative care issues for patients with heart 






Wadhera, R. K., Joynt Maddox, K. E., Wang, Y., Shen, C., & Yeh, R. W. (2018). 30-Day 
episode payments and heart failure outcomes among medicare beneficiaries. JACC Heart 
Fail, 6(5), 379-387. https://doi.org/10.1016/j.jchf.2017.11.010 
Wadhera, R. K., Joynt Maddox, K. E., Wasfy, J. H., Haneuse, S., Shen, C., & Yeh, R. W. (2018). 
Association of the hospital readmissions reduction program with mortality among 
medicare beneficiaries hospitalized for heart failure, acute myocardial infarction, and 
pneumonia. JAMA, 320(24), 2542-2552. https://doi.org/10.1001/jama.2018.19232 
Wasfy, J. H., Zigler, C. M., Choirat, C., Wang, Y., Dominici, F., & Yeh, R. W. (2017). 
Readmission rates after passage of the hospital readmissions reduction program: A pre-
post analysis. Annals of Internal Medicine, 166(5), 324-331. 
https://doi.org/10.7326/M16-0185 
Wiebe, D. J., & Korbel, C. (2003). Defensive denial, affect, and the self-regulation of health 
threats. In L. D. Cameron & H. Leventhal (Eds.), The self-regulation of health and illness 
behaviour (p. 184–203). Routledge.  
Wiskar, K., Celi, L. A., Walley, K. R., Fruhstorfer, C., & Rush, B. (2017). Inpatient palliative 
care referral and 9-month hospital readmission in patients with congestive heart failure: A 
linked nationwide analysis. Journal of Internal Medicine, 282(5), 445-451. 
https://doi.org/10.1111/joim.12657 
Wong, F. K., Ng, A. Y., Lee, P. H., Lam, P. T., Ng, J. S., Ng, N. H., & Sham, M. M. (2016). 
Effects of a transitional palliative care model on patients with end-stage heart failure: A 






Woolhandler, S., & Himmelstein, D. U. (2016). The Hospital Readmissions Reduction Program. 
New England Journal of Medicine, 375(5), 493. 
https://doi.org/10.1056/NEJMc1606658#SA1 
Xie, K., Gelfman, L., Horton, J. R., & Goldstein, N. E. (2017). State of research on palliative 
care in heart failure as evidenced by published literature, conference proceedings, and 
NIH Funding. Journal of Cardiac Failure, 23(2), 197-200. 
https://doi.org/10.1016/j.cardfail.2016.10.013 
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Jr., Colvin, M. M., . . . Westlake, 
C. (2017). 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for 
the management of heart failure: A report of the American College of 
Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and 
the Heart Failure Society of America. Journal of Cardiac Failure, 23(8), 628-651. 
https://doi.org/10.1161/CIR.0000000000000509 
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Jr., Drazner, M. H., . . . 
American Heart Association Task Force on Practice, G. (2013). 2013 ACCF/AHA 
guideline for the management of heart failure: A report of the American College of 
Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
Journal of the American College of Cardiology, 62(16), e147-239. 
https://doi.org/10.1016/j.jacc.2013.05.019 
Young, K. A., Wordingham, S. E., Strand, J. J., Roger, V. L., & Dunlay, S. M. (2017). 
Discordance of patient-reported and clinician-ordered resuscitation status in patients 
hospitalized with acute decompensated heart failure. Journal of Pain and Symptom 





Ziaeian, B., & Fonarow, G. C. (2016). The prevention of hospital readmissions in heart failure. 
Progress in Cardiovascular Diseases, 58(4), 379-385. 
https://doi.org/10.1016/j.pcad.2015.09.004 
Zuckerman, R. B., Sheingold, S. H., Orav, E. J., Ruhter, J., & Epstein, A. M. (2016). 
Readmissions, observation, and the Hospital Readmissions Reduction Program. New 
England Journal of Medicine, 374(16), 1543-1551. 
https://doi.org/10.1056/NEJMsa1513024 
